PHILIPPINE BIDDING DOCUMENTS

(As Harmonized with Development Partners)

PROCUREMENT OF DRUGS AND MEDICINES

IB 2017-008A

Government of the Republic of the Philippines

Fifth Edition
August 2016

Preface

These Philippine Bidding Documents (PBDs) for the procurement of Goods through Competitive Bidding have been prepared by the Government of the Philippines (GOP) for use by all branches, agencies, departments, bureaus, offices, or instrumentalities of the government, including government-owned and/or -controlled corporations (GOCCs), government financial institutions (GFIs), state universities and colleges (SUCs), and local government units (LGUs) and autonomous regional government. The procedures and practices presented in this document have been developed through broad experience, and are for mandatory[1] use in projects that are financed in whole or in part by the GOP or any foreign government/foreign or international financing institution in accordance with the provisions of the 2016 Revised Implementing Rules and Regulations (IRR) of Republic Act (RA) 9184.

The Bidding Documents shall clearly and adequately define, among others: (a) the objectives, scope, and expected outputs and/or results of the proposed contract; (b) the eligibility requirements of bidders, such as track record to be determined by the Head of the Procuring Entity; (c) the expected contract duration, the estimated quantity in the case of procurement of goods, delivery schedule and/or time frame; and (d) the obligations, duties, and/or functions of the winning bidder.

In order to simplify the preparation of the Bidding Documents for each procurement, the PBDs groups the provisions that are intended to be used unchanged in Section II. Instructions to Bidders (ITB) and in Section IV. General Conditions of Contract (GCC). Data and provisions specific to each procurement and contract should be included in Section III. Bid Data Sheet (BDS); Section V. Special Conditions of Contract (SCC); Section VI. Schedule of Requirements; Section VII. Technical Specifications, and Section IX. Foreign-Assisted Projects. The forms to be used are provided in Section VIII. Bidding Forms.

Care should be taken to check the relevance of the provisions of the PBDs against the requirements of the specific Goods to be procured. In addition, each section is prepared with notes intended only as information for the Procuring Entity or the person drafting the Bidding Documents. They shall not be included in the final documents, except for the notes introducing Section VIII. Bidding Forms where the information is useful for the Bidder. The following general directions should be observed when using the documents:

(a) All the documents listed in the Table of Contents are normally required for the procurement of Goods. However, they should be adapted as necessary to the circumstances of the particular Project.

(b) Specific details, such as the "name of the Procuring Entity" and "address for bid submission," should be furnished in the ITB, BDS, and SCC. The final documents should contain neither blank spaces nor options.

(c) This Preface and the footnotes or notes in italics included in the Invitation to Bid, BDS, SCC, Schedule of Requirements, and Specifications are not part of

[1] Unless the Treaty or International or Executive Agreement expressly provides use of foreign government/foreign or international financing institution procurement guidelines.

the text of the final document, although they contain instructions that the Procuring Entity should strictly follow. The Bidding Documents should contain no footnotes except Section VIII. Bidding Forms since these provide important guidance to Bidders.

(d) The cover should be modified as required to identify the Bidding Documents as to the names of the Project, Contract, and Procuring Entity, in addition to date of issue.

(e) If modifications must be made to bidding requirements, they can be presented in the BDS. Modifications for specific Project or Contract details should be provided in the SCC as amendments to the Conditions of Contract. For easy completion, whenever reference has to be made to specific clauses in the BDS or SCC these terms shall be printed in bold type face on Section I. Instructions to Bidders and Section III. General Conditions of Contract, respectively.

TABLE OF CONTENTS

Section I. Invitation to Bid

Notes on the Invitation to Bid

The Invitation to Bid provides information that enables potential Bidders to decide whether to participate in the procurement at hand. The Invitation to Bid shall be:

(a) Posted continuously in the Philippine Government Electronic Procurement System (PhilGEPS) website, the website of the Procuring Entity concerned, if available, and the website prescribed by the foreign government/foreign or international financing institution, if applicable, for seven (7) calendar days starting on the date of advertisement;

(b) Posted at any conspicuous place reserved for this purpose in the premises of the Procuring Entity concerned for seven (7) calendar days, as certified by the head of the Bids and Awards Committee (BAC) Secretariat of the Procuring Entity concerned; and

(c) Advertised at least once in a newspaper of general nationwide circulation which has been regularly published for at least two (2) years before the date of issue of the advertisement, subject to Section 21.2.1(c) of the IRR of RA 9184[2].

Apart from the essential items listed in the Bidding Documents, the Invitation to Bid should also indicate the following:

(a) The date of availability of the Bidding Documents, which shall be from the time the Invitation to Bid is first advertised/posted until the deadline for the submission and receipt of bids;

(b) The place where the Bidding Documents may be acquired or the website where it may be downloaded;

(c) The deadline for the submission and receipt of bids from the last day of posting of the Invitation to Bid; and

(d) Any important bid evaluation criteria (*e.g.*, the application of a margin of preference in bid evaluation).

The Invitation to Bid should be incorporated in the Bidding Documents. The information contained in the Invitation to Bid must conform to the Bidding Documents and in particular to the relevant information in the BDS.

[2] Two years after the effectivity of the 2016 Revised IRR of R.A. No. 9184 on 28 October 2016, advertisement in a newspaper of general nationwide circulation shall no longer be required. However, a procuring entity that cannot post its opportunities in the PhilGEPS for justifiable reasons shall continue to publish its advertisements in a newspaper of general nationwide circulation.

For foreign-assisted projects, the Invitation to Bid to be used is provided in Section IX-Foreign-Assisted Projects.

INVITATION TO BID
IB 2017-008A

1. The Batangas Medical Center (BatMC) through the General Appropriations Act invites bid for the delivery of the following:

Project	ABC (PHP)	Bid Docs Fee (PHP)	Pre-bid Conference	Opening of Bids
Drugs and Medicines	90,606,249.00	50,000.00	Dec 8, 2017, 9:00 a.m	Dec 19, 2017, 9:00 a.m

Bids received in excess of the ABC shall be automatically rejected at the bid opening.

2. Bidders should have completed, within *two (2) years* from the date of submission and receipt of bids, a similar contract to the Project. The description of an eligible bidder is contained in the Bidding Documents, particularly, in Section II, Instructions to Bidders. Delivery of goods required, please refer to Section VI, Schedule of Requirement.

3. Bidding will be conducted through open competitive bidding procedures using a non-discretionary "pass/fail" criterion as specified in the 2016 Revised Implementing Rules and Regulations (IRR) of Republic Act (RA) 9184, otherwise known as the "Government Procurement Reform Act".

   Bidding is restricted to Filipino citizens/sole proprietorships, partnerships, or organizations with at least sixty percent (60%) interest or outstanding capital stock belonging to citizens of the Philippines, and to citizens or organizations of a country the laws or regulations of which grant similar rights or privileges to Filipino citizens, pursuant to RA 5183 and subject to Commonwealth Act 138.

4. Interested bidders may obtain further information from ***the BAC Secretariat, Procurement Section, Batangas Medical Center, Kumintang Ibaba, Batangas City*** and inspect the Bidding Documents at the address given below during weekdays, ***8:00 AM – 5:00 PM***.

5. A complete set of Bidding Documents may be acquired by interested Bidders on ***December 8, 2017 to December 19, 2017*** from the address below and upon payment of a non-refundable fee for the Bidding Documents, as stated above.

   It may also be downloaded free of charge from the website of the Procuring Entity, provided that Bidders who decided to participate shall pay the nonrefundable fee for the Bidding Documents not later than the submission of their bids.

6. The *BatMC* will hold a ***Pre-Bid Conference*** *on* ***December 8, 2017, 9:00 a.m***. *at* ***HBAC Conference Room, 2nd Floor, OPD Building, Batangas Medical Center*** *which* shall be opened to prospective bidders. At most, two (2) representatives shall be allowed to attend the Pre-bid Conference.

7. Bids must be duly received by the BAC Secretariat at the address below on the schedule stated above. All Bids must be accompanied by a bid security in any of the acceptable forms and in the amount stated in **ITB** Clause 18.

8. Bid opening shall be on ***December 19, 2017, 9:00 a.m***. at ***HBAC Conference Room, 2nd Floor, OPD Building***. Bids will be opened in the presence of the Bidders' representatives who choose to attend at the address below. Late bids shall not be accepted. Only one (1) representative shall be allowed to attend the Opening of Bid and must present an authorization letter approved by the duly authorized office of the company being represented. Attendance of the bidders shall not be mandatory in the Pre-Bid Conference.

9. The ***Batangas Medical Center*** reserves the right to reject any and all bids, declare a failure of bidding, or not award the contract at any time prior to contract award in accordance with Section 41 of RA 9184 and its IRR, without thereby incurring any liability to the affected bidder or bidders.

10. For further information, please refer to:

    HBAC Secretariat
    Batangas Medical Center
    Kumintang Ibaba
    Batangas City
    Tel. No. (043) 723-6176

_____

Sgd. ELIZABETH V. PALINES MD, FPNA
HBAC Chairman

Section II. Instructions to Bidders

Notes on the Instructions to Bidders

This Section of the Bidding Documents provides the information necessary for bidders to prepare responsive bids, in accordance with the requirements of the Procuring Entity. It also provides information on bid submission, eligibility check, opening and evaluation of bids, post-qualification and on the award of contract.

This Section also contains provisions that are to be used unchanged. Section III consists of provisions that supplement, amend, or specify in detail, information or requirements included in Section II which are specific to each procurement.

Matters governing performance of the Supplier, payments under the contract, or matters affecting the risks, rights, and obligations of the parties under the contract are not normally included in this Section, but rather under Section IV. General Conditions of Contract (GCC), and/or Section V. Special Conditions of Contract (SCC). If duplication of a subject is inevitable in other sections of the document prepared by the Procuring Entity, care must be exercised to avoid contradictions between clauses dealing with the same matter.

TABLE OF CONTENTS

A. General

1. Scope of Bid

1.1. The Procuring Entity named in the **BDS** invites bids for the supply and delivery of the Goods as described in Section VII. Technical Specifications.

1.2. The name, identification, and number of lots specific to this bidding are provided in the **BDS**. The contracting strategy and basis of evaluation of lots is described in **ITB** Clause 28.

2. Source of Funds

The Procuring Entity has a budget or has received funds from the Funding Source named in the **BDS**, and in the amount indicated in the **BDS**. It intends to apply part of the funds received for the Project, as defined in the **BDS**, to cover eligible payments under the contract.

3. Corrupt, Fraudulent, Collusive, and Coercive Practices

3.1. Unless otherwise specified in the **BDS**, the Procuring Entity as well as the bidders and suppliers shall observe the highest standard of ethics during the procurement and execution of the contract. In pursuance of this policy, the Procuring Entity:

(a) defines, for purposes of this provision, the terms set forth below as follows:

(i) "corrupt practice" means behavior on the part of officials in the public or private sectors by which they improperly and unlawfully enrich themselves, others, or induce others to do so, by misusing the position in which they are placed, and includes the offering, giving, receiving, or soliciting of anything of value to influence the action of any such official in the procurement process or in contract execution; entering, on behalf of the government, into any contract or transaction manifestly and grossly disadvantageous to the same, whether or not the public officer profited or will profit thereby, and similar acts as provided in RA 3019.

(ii) "fraudulent practice" means a misrepresentation of facts in order to influence a procurement process or the execution of a contract to the detriment of the Procuring Entity, and includes collusive practices among Bidders (prior to or after bid submission) designed to establish bid prices at artificial, non-competitive levels and to deprive the Procuring Entity of the benefits of free and open competition.

(iii) "collusive practices" means a scheme or arrangement between two or more Bidders, with or without the knowledge of the

Procuring Entity, designed to establish bid prices at artificial, non-competitive levels.

(iv) "coercive practices" means harming or threatening to harm, directly or indirectly, persons, or their property to influence their participation in a procurement process, or affect the execution of a contract;

(v) "obstructive practice" is

(aa) deliberately destroying, falsifying, altering or concealing of evidence material to an administrative proceedings or investigation or making false statements to investigators in order to materially impede an administrative proceedings or investigation of the Procuring Entity or any foreign government/foreign or international financing institution into allegations of a corrupt, fraudulent, coercive or collusive practice; and/or threatening, harassing or intimidating any party to prevent it from disclosing its knowledge of matters relevant to the administrative proceedings or investigation or from pursuing such proceedings or investigation; or

(bb) acts intended to materially impede the exercise of the inspection and audit rights of the Procuring Entity or any foreign government/foreign or international financing institution herein.

(b) will reject a proposal for award if it determines that the Bidder recommended for award has engaged in any of the practices mentioned in this Clause for purposes of competing for the contract.

3.2. Further, the Procuring Entity will seek to impose the maximum civil, administrative, and/or criminal penalties available under applicable laws on individuals and organizations deemed to be involved in any of the practices mentioned in **ITB** Clause 3.1(a).

3.3. Furthermore, the Funding Source and the Procuring Entity reserve the right to inspect and audit records and accounts of a bidder or supplier in the bidding for and performance of a contract themselves or through independent auditors as reflected in the **GCC** Clause 3.

4. Conflict of Interest

4.1. All Bidders found to have conflicting interests shall be disqualified to participate in the procurement at hand, without prejudice to the imposition of appropriate administrative, civil, and criminal sanctions. A Bidder may be considered to have conflicting interests with another Bidder in any of the events described in paragraphs (a) through (c) below and a general conflict of

interest in any of the circumstances set out in paragraphs (d) through (g) below:

(a) A Bidder has controlling shareholders in common with another Bidder;

(b) A Bidder receives or has received any direct or indirect subsidy from any other Bidder;

(c) A Bidder has the same legal representative as that of another Bidder for purposes of this bid;

(d) A Bidder has a relationship, directly or through third parties, that puts them in a position to have access to information about or influence on the bid of another Bidder or influence the decisions of the Procuring Entity regarding this bidding process;

(e) A Bidder submits more than one bid in this bidding process. However, this does not limit the participation of subcontractors in more than one bid;

(f) A Bidder who participated as a consultant in the preparation of the design or technical specifications of the Goods and related services that are the subject of the bid; or

(g) A Bidder who lends, or temporarily seconds, its personnel to firms or organizations which are engaged in consulting services for the preparation related to procurement for or implementation of the project, if the personnel would be involved in any capacity on the same project.

4.2. In accordance with Section 47 of the IRR of RA 9184, all Bidding Documents shall be accompanied by a sworn affidavit of the Bidder that it is not related to the Head of the Procuring Entity (HoPE), members of the Bids and Awards Committee (BAC), members of the Technical Working Group (TWG), members of the BAC Secretariat, the head of the Project Management Office (PMO) or the end-user unit, and the project consultants, by consanguinity or affinity up to the third civil degree. On the part of the Bidder, this Clause shall apply to the following persons:

(a) If the Bidder is an individual or a sole proprietorship, to the Bidder himself;

(b) If the Bidder is a partnership, to all its officers and members;

(c) If the Bidder is a corporation, to all its officers, directors, and controlling stockholders;

(d) If the Bidder is a cooperative, to all its officers, directors, and controlling shareholders or members; and

(e) If the Bidder is a joint venture (JV), the provisions of items (a), (b), (c), or (d) of this Clause shall correspondingly apply to each of the members of the said JV, as may be appropriate.

Relationship of the nature described above or failure to comply with this Clause will result in the automatic disqualification of a Bidder.

5. Eligible Bidders

5.1. Unless otherwise provided in the **BDS**, the following persons shall be eligible to participate in this bidding:

(a) Duly licensed Filipino citizens/sole proprietorships;

(b) Partnerships duly organized under the laws of the Philippines and of which at least sixty percent (60%) of the interest belongs to citizens of the Philippines;

(c) Corporations duly organized under the laws of the Philippines, and of which at least sixty percent (60%) of the outstanding capital stock belongs to citizens of the Philippines;

(d) Cooperatives duly organized under the laws of the Philippines; and

(e) Persons/entities forming themselves into a Joint Venture (JV), *i.e.*, a group of two (2) or more persons/entities that intend to be jointly and severally responsible or liable for a particular contract: Provided, however, that Filipino ownership or interest of the JV concerned shall be at least sixty percent (60%).

5.2. Foreign bidders may be eligible to participate when any of the following circumstances exist, as specified in the **BDS**:

(a) When a Treaty or International or Executive Agreement as provided in Section 4 of RA 9184 and its IRR allow foreign bidders to participate;

(b) Citizens, corporations, or associations of a country, the laws or regulations of which grant reciprocal rights or privileges to citizens, corporations, or associations of the Philippines;

(c) When the Goods sought to be procured are not available from local suppliers; or

(d) When there is a need to prevent situations that defeat competition or restrain trade.

5.3. Government owned or –controlled corporations (GOCCs) may be eligible to participate only if they can establish that they (a) are legally and financially autonomous, (b) operate under commercial law, and (c) are not attached agencies of the Procuring Entity.

5.4. Unless otherwise provided in the **BDS**, the Bidder must have completed a Single Largest Completed Contract (SLCC) similar to the Project and the value of which, adjusted, if necessary, by the Bidder to current prices using the Philippine Statistics Authority (PSA) consumer price index, must be at least equivalent to a percentage of the ABC stated in the **BDS**.

For this purpose, contracts similar to the Project shall be those described in the **BDS**, and completed within the relevant period stated in the Invitation to Bid and **ITB** Clause 12.1(a)(ii).

5.5. The Bidder must submit a computation of its Net Financial Contracting Capacity (NFCC), which must be at least equal to the ABC to be bid, calculated as follows:

> NFCC = [(Current assets minus current liabilities) (15)] minus the value of all outstanding or uncompleted portions of the projects under ongoing contracts, including awarded contracts yet to be started, coinciding with the contract to be bid.

The values of the domestic bidder's current assets and current liabilities shall be based on the latest Audited Financial Statements submitted to the BIR.

For purposes of computing the foreign bidders' NFCC, the value of the current assets and current liabilities shall be based on their audited financial statements prepared in accordance with international financial reporting standards.

If the prospective bidder opts to submit a committed Line of Credit, it must be at least equal to ten percent (10%) of the ABC to be bid. If issued by a foreign universal or commercial bank, it shall be confirmed or authenticated by a local universal or commercial bank.

6. Bidder's Responsibilities

6.1. The Bidder or its duly authorized representative shall submit a sworn statement in the form prescribed in Section VIII. Bidding Forms as required in **ITB** Clause 12.1(b)(iii).

6.2. The Bidder is responsible for the following:

(a) Having taken steps to carefully examine all of the Bidding Documents;

(b) Having acknowledged all conditions, local or otherwise, affecting the implementation of the contract;

(c) Having made an estimate of the facilities available and needed for the contract to be bid, if any;

(d) Having complied with its responsibility to inquire or secure Supplemental/Bid Bulletin(s) as provided under **ITB** Clause 10.4.

(e) Ensuring that it is not "blacklisted" or barred from bidding by the GOP or any of its agencies, offices, corporations, or LGUs, including foreign government/foreign or international financing institution whose blacklisting rules have been recognized by the GPPB;

(f) Ensuring that each of the documents submitted in satisfaction of the bidding requirements is an authentic copy of the original, complete, and all statements and information provided therein are true and correct;

(g) Authorizing the HoPE or its duly authorized representative/s to verify all the documents submitted;

(h) Ensuring that the signatory is the duly authorized representative of the Bidder, and granted full power and authority to do, execute and perform any and all acts necessary and/or to represent the Bidder in the bidding, with the duly notarized Secretary's Certificate attesting to such fact, if the Bidder is a corporation, partnership, cooperative, or joint venture;

(i) Complying with the disclosure provision under Section 47 of RA 9184 and its IRR in relation to other provisions of RA 3019;

(j) Complying with existing labor laws and standards, in the case of procurement of services; Moreover, bidder undertakes to:

(i) Ensure the entitlement of workers to wages, hours of work, safety and health and other prevailing conditions of work as established by national laws, rules and regulations; or collective bargaining agreement; or arbitration award, if and when applicable.

In case there is a finding by the Procuring Entity or the DOLE of underpayment or non-payment of workers' wage and wage-related benefits, bidder agrees that the performance security or portion of the contract amount shall be withheld in favor of the complaining workers pursuant to appropriate provisions of Republic Act No. 9184 without prejudice to the institution of appropriate actions under the Labor Code, as amended, and other social legislations.

(ii) Comply with occupational safety and health standards and to correct deficiencies, if any.

In case of imminent danger, injury or death of the worker, bidder undertakes to suspend contract implementation pending clearance to proceed from the DOLE Regional Office and to comply with Work Stoppage Order; and

(iii) Inform the workers of their conditions of work, labor clauses under the contract specifying wages, hours of work and other benefits under prevailing national laws, rules and regulations; or collective bargaining agreement; or arbitration award, if and when applicable, through posting in two (2) conspicuous places in the establishment's premises; and

(k) Ensuring that it did not give or pay, directly or indirectly, any commission, amount, fee, or any form of consideration, pecuniary or otherwise, to any person or official, personnel or representative of the government in relation to any procurement project or activity.

Failure to observe any of the above responsibilities shall be at the risk of the Bidder concerned.

6.3. The Bidder is expected to examine all instructions, forms, terms, and specifications in the Bidding Documents.

6.4. It shall be the sole responsibility of the Bidder to determine and to satisfy itself by such means as it considers necessary or desirable as to all matters pertaining to the contract to be bid, including: (a) the location and the nature of this Project; (b) climatic conditions; (c) transportation facilities; and (d) other factors that may affect the cost, duration, and execution or implementation of this Project.

6.5. The Procuring Entity shall not assume any responsibility regarding erroneous interpretations or conclusions by the prospective or eligible bidder out of the data furnished by the procuring entity. However, the Procuring Entity shall ensure that all information in the Bidding Documents, including bid/supplemental bid bulletin/s issued, are correct and consistent.

6.6. Before submitting their bids, the Bidder is deemed to have become familiar with all existing laws, decrees, ordinances, acts and regulations of the Philippines which may affect this Project in any way.

6.7. The Bidder shall bear all costs associated with the preparation and submission of his bid, and the Procuring Entity will in no case be responsible or liable for those costs, regardless of the conduct or outcome of the bidding process.

6.8. The Bidder should note that the Procuring Entity will accept bids only from those that have paid the applicable fee for the Bidding Documents at the office indicated in the Invitation to Bid.

7. Origin of Goods

Unless otherwise indicated in the **BDS**, there is no restriction on the origin of goods other than those prohibited by a decision of the United Nations Security Council taken under Chapter VII of the Charter of the United Nations, subject to **ITB** Clause 27.1.

8. Subcontracts

8.1. Unless otherwise specified in the **BDS**, the Bidder may subcontract portions of the Goods to an extent as may be approved by the Procuring Entity and stated in the **BDS**. However, subcontracting of any portion shall not relieve the Bidder from any liability or obligation that may arise from the contract for this Project.

8.2. Subcontractors must submit the documentary requirements under **ITB** Clause 12 and comply with the eligibility criteria specified in the **BDS.** In the event that any subcontractor is found by the Procuring Entity to be ineligible, the subcontracting of such portion of the Goods shall be disallowed.

8.3. The Bidder may identify the subcontractor to whom a portion of the Goods will be subcontracted at any stage of the bidding process or during contract implementation. If the Bidder opts to disclose the name of the subcontractor during bid submission, the Bidder shall include the required documents as part of the technical component of its bid.

B. Contents of Bidding Documents

9. Pre-Bid Conference

9.1. (a) If so specified in the **BDS**, a pre-bid conference shall be held at the venue and on the date indicated therein, to clarify and address the Bidders' questions on the technical and financial components of this Project.

(b) The pre-bid conference shall be held at least twelve (12) calendar days before the deadline for the submission and receipt of bids, but not earlier than seven (7) calendar days from the posting of the invitation to bid/bidding documents in the PhilGEPS website. If the Procuring Entity determines that, by reason of the method, nature, or complexity of the contract to be bid, or when international participation will be more advantageous to the GOP, a longer period for the preparation of bids is necessary, the pre-bid conference shall be held at least thirty (30) calendar days before the deadline for the submission and receipt of bids, as specified in the **BDS**.

9.2. Bidders are encouraged to attend the pre-bid conference to ensure that they fully understand the Procuring Entity's requirements. Non-attendance of the Bidder will in no way prejudice its bid; however, the Bidder is expected to know the changes and/or amendments to the Bidding Documents as recorded in the minutes of the pre-bid conference and the Supplemental/Bid Bulletin. The minutes of the pre-bid conference shall be recorded and prepared not later than five (5) calendar days after the pre-bid conference. The minutes shall be made available to prospective bidders not later than five (5) days upon written request.

9.3 Decisions of the BAC amending any provision of the bidding documents shall be issued in writing through a Supplemental/Bid Bulletin at least seven (7) calendar days before the deadline for the submission and receipt of bids.

10. Clarification and Amendment of Bidding Documents

10.1. Prospective bidders may request for clarification on and/or interpretation of any part of the Bidding Documents. Such request must be in writing and submitted to the Procuring Entity at the address indicated in the **BDS** at least ten (10) calendar days before the deadline set for the submission and receipt of Bids.

10.2. The BAC shall respond to the said request by issuing a Supplemental/Bid Bulletin, to be made available to all those who have properly secured the Bidding Documents, at least seven (7) calendar days before the deadline for the submission and receipt of Bids.

10.3. Supplemental/Bid Bulletins may also be issued upon the Procuring Entity's initiative for purposes of clarifying or modifying any provision of the Bidding Documents not later than seven (7) calendar days before the deadline for the submission and receipt of Bids. Any modification to the Bidding Documents shall be identified as an amendment.

10.4. Any Supplemental/Bid Bulletin issued by the BAC shall also be posted in the PhilGEPS and the website of the Procuring Entity concerned, if available, and at any conspicuous place in the premises of the Procuring Entity concerned. It shall be the responsibility of all Bidders who have properly secured the Bidding Documents to inquire and secure Supplemental/Bid Bulletins that may be issued by the BAC. However, Bidders who have submitted bids before the issuance of the Supplemental/Bid Bulletin must be informed and allowed to modify or withdraw their bids in accordance with **ITB** Clause 23.

C. Preparation of Bids

11. Language of Bids

The eligibility requirements or statements, the bids, and all other documents to be submitted to the BAC must be in English. If the eligibility requirements or statements, the bids, and all other documents submitted to the BAC are in foreign language other than English, it must be accompanied by a translation of the documents in English. The documents shall be translated by the relevant foreign government agency, the foreign government agency authorized to translate documents, or a registered translator in the foreign bidder's country; and shall be authenticated by the appropriate Philippine foreign service establishment/post or the equivalent office having jurisdiction over the foreign bidder's affairs in the Philippines. The English translation shall govern, for purposes of interpretation of the bid.

12. Documents Comprising the Bid: Eligibility and Technical Components

12.1. Unless otherwise indicated in the **BDS**, the first envelope shall contain the following eligibility and technical documents:

(a) Eligibility Documents –

Class "A" Documents:

(i) PhilGEPS Certificate of Registration and Membership in accordance with Section 8.5.2 of the IRR, except for foreign bidders participating in the procurement by a Philippine Foreign Service Office or Post, which shall submit their eligibility documents under Section 23.1 of the IRR, provided, that the winning bidder shall register with the PhilGEPS in accordance with section 37.1.4 of the IRR.

(ii) Statement of all its ongoing government and private contracts, including contracts awarded but not yet started, if any, whether similar or not similar in nature and complexity to the contract to be bid; and

Statement of the Bidder's SLCC similar to the contract to be bid, in accordance with ITB Clause 5.4, within the relevant period as provided in the **BDS.**

The two statements required shall indicate for each contract the following:

(ii.1) name of the contract;

(ii.2) date of the contract;

(ii.3) contract duration;

(ii.4) owner's name and address;

(ii.5) kinds of Goods;

(ii.6) For Statement of Ongoing Contracts - amount of contract and value of outstanding contracts;

(ii.7) For Statement of SLCC - amount of completed contracts, adjusted by the Bidder to current prices using PSA's consumer price index, if necessary for the purpose of meeting the SLCC requirement;

(ii.8) date of delivery; and

(ii.9) end user's acceptance or official receipt(s) or sales invoice issued for the contract, if completed, which shall be attached to the statements.

(iii) NFCC computation in accordance with ITB Clause 5.5 or a committed Line of Credit from a universal or commercial bank.

Class "B" Document:

(iv) If applicable, the Joint Venture Agreement (JVA) in case the joint venture is already in existence, or duly notarized

statements from all the potential joint venture partners in accordance with Section 23.1(b) of the IRR.

(b) Technical Documents –

(i) Bid security in accordance with **ITB** Clause 18. If the Bidder opts to submit the bid security in the form of:

(i.1) a bank draft/guarantee or an irrevocable letter of credit issued by a foreign bank, it shall be accompanied by a confirmation from a Universal or Commercial Bank; or

(i.2) a surety bond, it shall be accompanied by a certification by the Insurance Commission that the surety or insurance company is authorized to issue such instruments;

(ii) Conformity with technical specifications, as enumerated and specified in Sections VI and VII of the Bidding Documents; and

(iii) Sworn statement in accordance with Section 25.3 of the IRR of RA 9184 and using the form prescribed in Section VIII. Bidding Forms.

(iv) For foreign bidders claiming eligibility by reason of their country's extension of reciprocal rights to Filipinos, a certification from the relevant government office of their country stating that Filipinos are allowed to participate in their government procurement activities for the same item or product.

13. Documents Comprising the Bid: Financial Component

13.1. Unless otherwise stated in the **BDS**, the financial component of the bid shall contain the following:

(a) Financial Bid Form, which includes bid prices and the applicable Price Schedules, in accordance with **ITB** Clauses 15.1 and 15.4;

(b) If the Bidder claims preference as a Domestic Bidder, a certification from the DTI issued in accordance with **ITB** Clause 27, unless otherwise provided in the **BDS**; and

(c) Any other document related to the financial component of the bid as stated in the **BDS**.

13.2. (a) Unless otherwise stated in the **BDS,** all bids that exceed the ABC shall not be accepted.

(b) Unless otherwise indicated in the **BDS**, for foreign-funded procurement, a ceiling may be applied to bid prices provided the following conditions are met:

(i) Bidding Documents are obtainable free of charge on a freely accessible website. If payment of Bidding Documents is required by the procuring entity, payment could be made upon the submission of bids.

(ii) The procuring entity has procedures in place to ensure that the ABC is based on recent estimates made by the responsible unit of the procuring entity and that the estimates reflect the quality, supervision and risk and inflationary factors, as well as prevailing market prices, associated with the types of works or goods to be procured.

(iii) The procuring entity has trained cost estimators on estimating prices and analyzing bid variances.

(iv) The procuring entity has established a system to monitor and report bid prices relative to ABC and engineer's/procuring entity's estimate.

(v) The procuring entity has established a monitoring and evaluation system for contract implementation to provide a feedback on actual total costs of goods and works.

14. Alternative Bids

14.1 Alternative Bids shall be rejected. For this purpose, alternative bid is an offer made by a Bidder in addition or as a substitute to its original bid which may be included as part of its original bid or submitted separately therewith for purposes of bidding. A bid with options is considered an alternative bid regardless of whether said bid proposal is contained in a single envelope or submitted in two (2) or more separate bid envelopes.

14.2 Each Bidder shall submit only one Bid, either individually or as a partner in a JV. A Bidder who submits or participates in more than one bid (other than as a subcontractor if a subcontractor is permitted to participate in more than one bid) will cause all the proposals with the Bidder's participation to be disqualified. This shall be without prejudice to any applicable criminal, civil and administrative penalties that may be imposed upon the persons and entities concerned.

15. Bid Prices

15.1. The Bidder shall complete the appropriate Schedule of Prices included herein, stating the unit prices, total price per item, the total amount and the expected countries of origin of the Goods to be supplied under this Project.

15.2. The Bidder shall fill in rates and prices for all items of the Goods described in the Schedule of Prices. Bids not addressing or providing all of the required items in the Bidding Documents including, where applicable, Schedule of Prices, shall be considered non-responsive and, thus, automatically disqualified. In this regard, where a required item is provided, but no price is indicated, the same shall be considered as non-responsive, but specifying a zero (0) or a dash (-) for the said item would mean that it is being offered for free to the Government, except those required by law or regulations to be accomplished.

15.3. The terms Ex Works (EXW), Cost, Insurance and Freight (CIF), Cost and Insurance Paid to (CIP), Delivered Duty Paid (DDP), and other trade terms used to describe the obligations of the parties, shall be governed by the rules prescribed in the current edition of the International Commercial Terms (INCOTERMS) published by the International Chamber of Commerce, Paris.

15.4. Prices indicated on the Price Schedule shall be entered separately in the following manner:

(a) For Goods offered from within the Procuring Entity's country:

(i) The price of the Goods quoted EXW (ex works, ex factory, ex warehouse, ex showroom, or off-the-shelf, as applicable);

(ii) The cost of all customs duties and sales and other taxes already paid or payable;

(iii) The cost of transportation, insurance, and other costs incidental to delivery of the Goods to their final destination; and

(iv) The price of other (incidental) services, if any, listed in the **BDS**.

(b) For Goods offered from abroad:

(i) Unless otherwise stated in the **BDS**, the price of the Goods shall be quoted DDP with the place of destination in the Philippines as specified in the **BDS**. In quoting the price, the Bidder shall be free to use transportation through carriers registered in any eligible country. Similarly, the Bidder may obtain insurance services from any eligible source country.

(ii) The price of other (incidental) services, if any, listed in the **BDS**.

(c) For Services, based on the form which may be prescribed by the Procuring Entity, in accordance with existing laws, rules and regulations

15.5. Prices quoted by the Bidder shall be fixed during the Bidder's performance of the contract and not subject to variation or price escalation on any account. A

bid submitted with an adjustable price quotation shall be treated as non-responsive and shall be rejected, pursuant to **ITB** Clause 24.

All bid prices for the given scope of work in the contract as awarded shall be considered as fixed prices, and therefore not subject to price escalation during contract implementation, except under extraordinary circumstances. Upon the recommendation of the Procuring Entity, price escalation may be allowed in extraordinary circumstances as may be determined by the National Economic and Development Authority in accordance with the Civil Code of the Philippines, and upon approval by the GPPB. Nevertheless, in cases where the cost of the awarded contract is affected by any applicable new laws, ordinances, regulations, or other acts of the GOP, promulgated after the date of bid opening, a contract price adjustment shall be made or appropriate relief shall be applied on a no loss-no gain basis.

16. Bid Currencies

16.1. Prices shall be quoted in the following currencies:

(a) For Goods that the Bidder will supply from within the Philippines, the prices shall be quoted in Philippine Pesos.

(b) For Goods that the Bidder will supply from outside the Philippines, the prices may be quoted in the currency(ies) stated in the **BDS**. However, for purposes of bid evaluation, bids denominated in foreign currencies shall be converted to Philippine currency based on the exchange rate as published in the *Bangko Sentral ng Pilipinas* (BSP) reference rate bulletin on the day of the bid opening.

16.2. If so allowed in accordance with **ITB** Clause 16.1, the Procuring Entity for purposes of bid evaluation and comparing the bid prices will convert the amounts in various currencies in which the bid price is expressed to Philippine Pesos at the foregoing exchange rates.

16.3. Unless otherwise specified in the **BDS**, payment of the contract price shall be made in Philippine Pesos.

17. Bid Validity

17.1. Bids shall remain valid for the period specified in the **BDS** which shall not exceed one hundred twenty (120) calendar days from the date of the opening of bids.

17.2. In exceptional circumstances, prior to the expiration of the bid validity period, the Procuring Entity may request Bidders to extend the period of validity of their bids. The request and the responses shall be made in writing. The bid security described in **ITB** Clause 18 should also be extended corresponding to the extension of the bid validity period at the least. A Bidder may refuse the request without forfeiting its bid security, but his bid shall no longer be considered for further evaluation and award. A Bidder granting the request shall not be required or permitted to modify its bid.

18. Bid Security

18.1. The Bidder shall submit a Bid Securing Declaration or any form of Bid Security in the amount stated in the **BDS**, which shall be not less than the percentage of the ABC in accordance with the following schedule:

Form of Bid Security	Amount of Bid Security (Not Less than the Percentage of the ABC)
(a) Cash or cashier's/manager's check issued by a Universal or Commercial Bank. *For biddings conducted by LGUs, the Cashier's/Manager's Check may be issued by other banks certified by the BSP as authorized to issue such financial instrument.*	Two percent (2%)
(b) Bank draft/guarantee or irrevocable letter of credit issued by a Universal or Commercial Bank: Provided, however, that it shall be confirmed or authenticated by a Universal or Commercial Bank, if issued by a foreign bank. *For biddings conducted by LGUs, Bank Draft/Guarantee, or Irrevocable Letter of Credit may be issued by other banks certified by the BSP as authorized to issue such financial instrument.*	
(c) Surety bond callable upon demand issued by a surety or insurance company duly certified by the Insurance Commission as authorized to issue such security.	Five percent (5%)

The Bid Securing Declaration mentioned above is an undertaking which states, among others, that the Bidder shall enter into contract with the procuring entity and furnish the performance security required under ITB Clause 33.2, within ten (10) calendar days from receipt of the Notice of Award, and commits to pay the corresponding amount as fine, and be suspended for a period of time from being qualified to participate in any

government procurement activity in the event it violates any of the conditions stated therein as provided in the guidelines issued by the GPPB.

18.2. The bid security should be valid for the period specified in the **BDS**. Any bid not accompanied by an acceptable bid security shall be rejected by the Procuring Entity as non-responsive.

18.3. No bid securities shall be returned to Bidders after the opening of bids and before contract signing, except to those that failed or declared as post-disqualified, upon submission of a written waiver of their right to file a request for reconsideration and/or protest, or upon the lapse of the reglementary period to file a request for reconsideration or protest. Without prejudice on its forfeiture, bid securities shall be returned only after the Bidder with the Lowest Calculated Responsive Bid (LCRB) has signed the contract and furnished the performance security, but in no case later than the expiration of the bid security validity period indicated in **ITB** Clause 18.2.

18.4. Upon signing and execution of the contract pursuant to **ITB** Clause 32, and the posting of the performance security pursuant to **ITB** Clause 33, the successful Bidder's bid security will be discharged, but in no case later than the bid security validity period as indicated in the **ITB** Clause 18.2.

18.5. The bid security may be forfeited:

(a) if a Bidder:

(i) withdraws its bid during the period of bid validity specified in **ITB** Clause 17;

(ii) does not accept the correction of errors pursuant to **ITB** Clause 28.3(b);

(iii) has a finding against the veracity of any of the documents submitted as stated in **ITB** Clause 29.2;

(iv) submission of eligibility requirements containing false information or falsified documents;

(v) submission of bids that contain false information or falsified documents, or the concealment of such information in the bids in order to influence the outcome of eligibility screening or any other stage of the public bidding;

(vi) allowing the use of one's name, or using the name of another for purposes of public bidding;

(vii) withdrawal of a bid, or refusal to accept an award, or enter into contract with the Government without justifiable cause, after the Bidder had been adjudged as having submitted the LCRB;

(viii) refusal or failure to post the required performance security within the prescribed time;

(ix) refusal to clarify or validate in writing its bid during post-qualification within a period of seven (7) calendar days from receipt of the request for clarification;

(x) any documented attempt by a Bidder to unduly influence the outcome of the bidding in his favor;

(xi) failure of the potential joint venture partners to enter into the joint venture after the bid is declared successful; or

(xii) all other acts that tend to defeat the purpose of the competitive bidding, such as habitually withdrawing from bidding, submitting late Bids or patently insufficient bid, for at least three (3) times within a year, except for valid reasons.

(b) if the successful Bidder:

(i) fails to sign the contract in accordance with **ITB** Clause 32; or

(ii) fails to furnish performance security in accordance with **ITB** Clause 33.

19. Format and Signing of Bids

19.1. Bidders shall submit their bids through their duly authorized representative using the appropriate forms provided in Section VIII. Bidding Forms on or before the deadline specified in the **ITB** Clauses 21 in two (2) separate sealed bid envelopes, and which shall be submitted simultaneously. The first shall contain the technical component of the bid, including the eligibility requirements under **ITB** Clause 12.1, and the second shall contain the financial component of the bid. This shall also be observed for each lot in the case of lot procurement.

19.2. Forms as mentioned in **ITB** Clause 19.1 must be completed without any alterations to their format, and no substitute form shall be accepted. All blank spaces shall be filled in with the information requested.

19.3. The Bidder shall prepare and submit an original of the first and second envelopes as described in **ITB** Clauses 12 and 13. In addition, the Bidder shall submit copies of the first and second envelopes. In the event of any discrepancy between the original and the copies, the original shall prevail.

19.4. Each and every page of the Bid Form, including the Schedule of Prices, under Section VIII hereof, shall be signed by the duly authorized representative/s of the Bidder. Failure to do so shall be a ground for the rejection of the bid.

19.5. Any interlineations, erasures, or overwriting shall be valid only if they are signed or initialed by the duly authorized representative/s of the Bidder.

20. Sealing and Marking of Bids

20.1. Bidders shall enclose their original eligibility and technical documents described in **ITB** Clause 12 in one sealed envelope marked "ORIGINAL - TECHNICAL COMPONENT", and the original of their financial component in another sealed envelope marked "ORIGINAL - FINANCIAL COMPONENT", sealing them all in an outer envelope marked "ORIGINAL BID".

20.2. Each copy of the first and second envelopes shall be similarly sealed duly marking the inner envelopes as "COPY NO. ___ - TECHNICAL COMPONENT" and "COPY NO. ___ – FINANCIAL COMPONENT" and the outer envelope as "COPY NO. ___", respectively. These envelopes containing the original and the copies shall then be enclosed in one single envelope.

20.3. The original and the number of copies of the Bid as indicated in the **BDS** shall be typed or written in ink and shall be signed by the Bidder or its duly authorized representative/s.

20.4. All envelopes shall:

(a) contain the name of the contract to be bid in capital letters;

(b) bear the name and address of the Bidder in capital letters;

(c) be addressed to the Procuring Entity's BAC in accordance with **ITB** Clause 1.1;

(d) bear the specific identification of this bidding process indicated in the **ITB** Clause 1.2; and

(e) bear a warning "DO NOT OPEN BEFORE…" the date and time for the opening of bids, in accordance with **ITB** Clause 21.

20.5. Bid envelopes that are not properly sealed and marked, as required in the bidding documents, shall not be rejected, but the Bidder or its duly authorized representative shall acknowledge such condition of the bid as submitted. The BAC or the Procuring Entity shall assume no responsibility for the misplacement of the contents of the improperly sealed or marked bid, or for its premature opening.

D. Submission and Opening of Bids

21. Deadline for Submission of Bids

Bids must be received by the Procuring Entity's BAC at the address and on or before the date and time indicated in the **BDS**.

22. Late Bids

Any bid submitted after the deadline for submission and receipt of bids prescribed by the Procuring Entity, pursuant to **ITB** Clause 21, shall be declared "Late" and shall

not be accepted by the Procuring Entity. The BAC shall record in the minutes of bid submission and opening, the Bidder's name, its representative and the time the late bid was submitted.

23. Modification and Withdrawal of Bids

23.1. The Bidder may modify its bid after it has been submitted; provided that the modification is received by the Procuring Entity prior to the deadline prescribed for submission and receipt of bids. The Bidder shall not be allowed to retrieve its original bid, but shall be allowed to submit another bid equally sealed and properly identified in accordance with ITB Clause 20, linked to its original bid marked as "TECHNICAL MODIFICATION" or "FINANCIAL MODIFICATION" and stamped "received" by the BAC. Bid modifications received after the applicable deadline shall not be considered and shall be returned to the Bidder unopened.

23.2 A Bidder may, through a Letter of Withdrawal, withdraw its bid after it has been submitted, for valid and justifiable reason; provided that the Letter of Withdrawal is received by the Procuring Entity prior to the deadline prescribed for submission and receipt of bids. The Letter of Withdrawal must be executed by the duly authorized representative of the Bidder identified in the Omnibus Sworn Statement, a copy of which should be attached to the letter.

23.3. Bids requested to be withdrawn in accordance with **ITB** Clause 23.1 shall be returned unopened to the Bidders. A Bidder, who has acquired the bidding documents, may also express its intention not to participate in the bidding through a letter which should reach and be stamped by the BAC before the deadline for submission and receipt of bids. A Bidder that withdraws its bid shall not be permitted to submit another bid, directly or indirectly, for the same contract.

23.4. No bid may be modified after the deadline for submission of bids. No bid may be withdrawn in the interval between the deadline for submission of bids and the expiration of the period of bid validity specified by the Bidder on the Financial Bid Form. Withdrawal of a bid during this interval shall result in the forfeiture of the Bidder's bid security, pursuant to **ITB** Clause 18.5, and the imposition of administrative, civil and criminal sanctions as prescribed by RA 9184 and its IRR.

24. Opening and Preliminary Examination of Bids

24.1. The BAC shall open the bids in public, immediately after the deadline for the submission and receipt of bids, as specified in the **BDS**. In case the Bids cannot be opened as scheduled due to justifiable reasons, the BAC shall take custody of the Bids submitted and reschedule the opening of Bids on the next working day or at the soonest possible time through the issuance of a Notice of

Postponement to be posted in the PhilGEPS website and the website of the Procuring Entity concerned.

24.2. Unless otherwise specified in the **BDS**, the BAC shall open the first bid envelopes and determine each Bidder's compliance with the documents prescribed in **ITB** Clause 12, using a non-discretionary "pass/fail" criterion. If a Bidder submits the required document, it shall be rated "passed" for that particular requirement. In this regard, bids that fail to include any requirement or are incomplete or patently insufficient shall be considered as "failed". Otherwise, the BAC shall rate the said first bid envelope as "passed".

24.3. Unless otherwise specified in the **BDS**, immediately after determining compliance with the requirements in the first envelope, the BAC shall forthwith open the second bid envelope of each remaining eligible bidder whose first bid envelope was rated "passed". The second envelope of each complying bidder shall be opened within the same day. In case one or more of the requirements in the second envelope of a particular bid is missing, incomplete or patently insufficient, and/or if the submitted total bid price exceeds the ABC unless otherwise provided in **ITB** Clause 13.2, the BAC shall rate the bid concerned as "failed". Only bids that are determined to contain all the bid requirements for both components shall be rated "passed" and shall immediately be considered for evaluation and comparison.

24.4. Letters of Withdrawal shall be read out and recorded during bid opening, and the envelope containing the corresponding withdrawn bid shall be returned to the Bidder unopened.

24.5. All members of the BAC who are present during bid opening shall initial every page of the original copies of all bids received and opened.

24.6. In the case of an eligible foreign bidder as described in **ITB** Clause 5, the following Class "A" Documents may be substituted with the appropriate equivalent documents, if any, issued by the country of the foreign Bidder concerned, which shall likewise be uploaded and maintained in the PhilGEPS in accordance with Section 8.5.2 of the IRR:

(a) Registration certificate from the Securities and Exchange Commission (SEC), Department of Trade and Industry (DTI) for sole proprietorship, or CDA for cooperatives;

(b) Mayor's/Business permit issued by the local government where the principal place of business of the bidder is located; and

(c) Audited Financial Statements showing, among others, the prospective bidder's total and current assets and liabilities stamped "received" by the Bureau of Internal Revenue or its duly accredited and authorized institutions, for the preceding calendar year which should not be earlier than two years from the date of bid submission.

24.7. Each partner of a joint venture agreement shall likewise submit the requirements in **ITB** Clause 12.1(a)(i). Submission of documents required

under **ITB** Clauses 12.1(a)(ii) to 12.1(a)(iii) by any of the joint venture partners constitutes compliance.

24.8. The Procuring Entity shall prepare the minutes of the proceedings of the bid opening that shall include, as a minimum: (a) names of Bidders, their bid price (per lot, if applicable, and/or including discount, if any), bid security, findings of preliminary examination, and whether there is a withdrawal or modification; and (b) attendance sheet. The BAC members shall sign the abstract of bids as read.

24.8 The bidders or their duly authorized representatives may attend the opening of bids. The BAC shall ensure the integrity, security, and confidentiality of all submitted bids. The Abstract of Bids as read and the minutes of the bid opening shall be made available to the public upon written request and payment of a specified fee to recover cost of materials.

24.9 To ensure transparency and accurate representation of the bid submission, the BAC Secretariat shall notify in writing all bidders whose bids it has received through its PhilGEPS-registered physical address or official e-mail address. The notice shall be issued within seven (7) calendar days from the date of the bid opening.

E. Evaluation and Comparison of Bids

25. Process to be Confidential

25.1. Members of the BAC, including its staff and personnel, as well as its Secretariat and TWG, are prohibited from making or accepting any kind of communication with any bidder regarding the evaluation of their bids until the issuance of the Notice of Award, unless otherwise allowed in the case of **ITB** Clause 26.

25.2. Any effort by a bidder to influence the Procuring Entity in the Procuring Entity's decision in respect of bid evaluation, bid comparison or contract award will result in the rejection of the Bidder's bid.

26. Clarification of Bids

To assist in the evaluation, comparison, and post-qualification of the bids, the Procuring Entity may ask in writing any Bidder for a clarification of its bid. All responses to requests for clarification shall be in writing. Any clarification submitted by a Bidder in respect to its bid and that is not in response to a request by the Procuring Entity shall not be considered.

27. Domestic Preference

27.1. Unless otherwise stated in the **BDS**, the Procuring Entity will grant a margin of preference for the purpose of comparison of bids in accordance with the following:

(a) The preference shall be applied when the lowest Foreign Bid is lower than the lowest bid offered by a Domestic Bidder.

(b) For evaluation purposes, the lowest Foreign Bid shall be increased by fifteen percent (15%).

(c) In the event that the lowest bid offered by a Domestic Bidder does not exceed the lowest Foreign Bid as increased, then the Procuring Entity shall award the contract to the Domestic Bidder at the amount of the lowest Foreign Bid.

(d) If the Domestic Bidder refuses to accept the award of contract at the amount of the Foreign Bid within two (2) calendar days from receipt of written advice from the BAC, the Procuring Entity shall award to the bidder offering the Foreign Bid, subject to post-qualification and submission of all the documentary requirements under these Bidding Documents.

27.2. A Bidder may be granted preference as a Domestic Bidder subject to the certification from the DTI that the Bidder is offering unmanufactured articles, materials or supplies of the growth or production of the Philippines, or manufactured articles, materials, or supplies manufactured or to be manufactured in the Philippines substantially from articles, materials, or supplies of the growth, production, or manufacture, as the case may be, of the Philippines.

28. Detailed Evaluation and Comparison of Bids

28.1. The Procuring Entity will undertake the detailed evaluation and comparison of bids which have passed the opening and preliminary examination of bids, pursuant to **ITB** Clause 24, in order to determine the Lowest Calculated Bid.

28.2. The Lowest Calculated Bid shall be determined in two steps:

(a) The detailed evaluation of the financial component of the bids, to establish the correct calculated prices of the bids; and

(b) The ranking of the total bid prices as so calculated from the lowest to the highest. The bid with the lowest price shall be identified as the Lowest Calculated Bid.

28.3. The Procuring Entity's BAC shall immediately conduct a detailed evaluation of all bids rated "passed," using non-discretionary pass/fail criteria. The BAC shall consider the following in the evaluation of bids:

(a) Completeness of the bid. Unless the **BDS** allows partial bids, bids not addressing or providing all of the required items in the Schedule of Requirements including, where applicable, Schedule of Prices, shall be considered non-responsive and, thus, automatically disqualified. In this regard, where a required item is provided, but no price is indicated, the same shall be considered as non-responsive, but specifying a zero (0)

or a dash (-) for the said item would mean that it is being offered for free to the Procuring Entity, except those required by law or regulations to be provided for; and

(b) Arithmetical corrections. Consider computational errors and omissions to enable proper comparison of all eligible bids. It may also consider bid modifications. Any adjustment shall be calculated in monetary terms to determine the calculated prices.

28.4. Based on the detailed evaluation of bids, those that comply with the above-mentioned requirements shall be ranked in the ascending order of their total calculated bid prices, as evaluated and corrected for computational errors, discounts and other modifications, to identify the Lowest Calculated Bid. Total calculated bid prices, as evaluated and corrected for computational errors, discounts and other modifications, which exceed the ABC shall not be considered, unless otherwise indicated in the **BDS**.

28.5. The Procuring Entity's evaluation of bids shall be based on the bid price quoted in the Bid Form, which includes the Schedule of Prices.

28.6. Bids shall be evaluated on an equal footing to ensure fair competition. For this purpose, all bidders shall be required to include in their bids the cost of all taxes, such as, but not limited to, value added tax (VAT), income tax, local taxes, and other fiscal levies and duties which shall be itemized in the bid form and reflected in the detailed estimates. Such bids, including said taxes, shall be the basis for bid evaluation and comparison.

28.7. If so indicated pursuant to **ITB** Clause 1.2, Bids are being invited for individual lots or for any combination thereof, provided that all Bids and combinations of Bids shall be received by the same deadline and opened and evaluated simultaneously so as to determine the Bid or combination of Bids offering the lowest calculated cost to the Procuring Entity. Bid prices quoted shall correspond to all items specified for each lot and to all quantities specified for each item of a lot. Bid Security as required by **ITB** Clause 18 shall be submitted for each contract (lot) separately. The basis for evaluation of lots is specified in BDS Clause 28.3.

29. Post-Qualification

29.1. The BAC shall determine to its satisfaction whether the Bidder that is evaluated as having submitted the Lowest Calculated Bid complies with and is responsive to all the requirements and conditions specified in **ITB** Clauses 5, 12, and 13.

29.2. Within a non-extendible period of five (5) calendar days from receipt by the bidder of the notice from the BAC that it submitted the Lowest Calculated Bid, the Bidder shall submit its latest income and business tax returns filed and paid through the BIR Electronic Filing and Payment System (eFPS) and other appropriate licenses and permits required by law and stated in the **BDS**.

Failure to submit any of the post-qualification requirements on time, or a finding against the veracity thereof, shall disqualify the bidder for award. Provided in the event that a finding against the veracity of any of the documents submitted is made, it shall cause the forfeiture of the bid security in accordance with Section 69 of the IRR of RA 9184.

29.3. The determination shall be based upon an examination of the documentary evidence of the Bidder's qualifications submitted pursuant to **ITB** Clauses 12 and 13, as well as other information as the Procuring Entity deems necessary and appropriate, using a non-discretionary "pass/fail" criterion, which shall be completed within a period of twelve (12) calendar days.

29.4. If the BAC determines that the Bidder with the Lowest Calculated Bid passes all the criteria for post-qualification, it shall declare the said bid as the LCRB, and recommend to the HoPE the award of contract to the said Bidder at its submitted price or its calculated bid price, whichever is lower.

29.5. A negative determination shall result in rejection of the Bidder's Bid, in which event the Procuring Entity shall proceed to the next Lowest Calculated Bid with a fresh period to make a similar determination of that Bidder's capabilities to perform satisfactorily. If the second Bidder, however, fails the post qualification, the procedure for post qualification shall be repeated for the Bidder with the next Lowest Calculated Bid, and so on until the LCRB is determined for recommendation for contract award.

29.6. Within a period not exceeding fifteen (15) calendar days from the determination by the BAC of the LCRB and the recommendation to award the contract, the HoPE or his duly authorized representative shall approve or disapprove the said recommendation.

29.7. In the event of disapproval, which shall be based on valid, reasonable, and justifiable grounds as provided for under Section 41 of the IRR of RA 9184, the HoPE shall notify the BAC and the Bidder in writing of such decision and the grounds for it. When applicable, the BAC shall conduct a post-qualification of the Bidder with the next Lowest Calculated Bid. A request for reconsideration may be filed by the bidder with the HoPE in accordance with Section 37.1.3 of the IRR of RA 9184.

30. Reservation Clause

30.1. Notwithstanding the eligibility or post-qualification of a Bidder, the Procuring Entity concerned reserves the right to review its qualifications at any stage of the procurement process if it has reasonable grounds to believe that a misrepresentation has been made by the said Bidder, or that there has been a change in the Bidder's capability to undertake the project from the time it submitted its eligibility requirements. Should such review uncover any misrepresentation made in the eligibility and bidding requirements, statements or documents, or any changes in the situation of the Bidder which will affect its capability to undertake the project so that it fails the preset eligibility or bid evaluation criteria, the Procuring Entity shall consider the said Bidder as

ineligible and shall disqualify it from submitting a bid or from obtaining an award or contract.

30.2. Based on the following grounds, the Procuring Entity reserves the right to reject any and all bids, declare a Failure of Bidding at any time prior to the contract award, or not to award the contract, without thereby incurring any liability, and make no assurance that a contract shall be entered into as a result of the bidding:

(a) If there is *prima facie* evidence of collusion between appropriate public officers or employees of the Procuring Entity, or between the BAC and any of the Bidders, or if the collusion is between or among the bidders themselves, or between a Bidder and a third party, including any act which restricts, suppresses or nullifies or tends to restrict, suppress or nullify competition;

(b) If the Procuring Entity's BAC is found to have failed in following the prescribed bidding procedures; or

(c) For any justifiable and reasonable ground where the award of the contract will not redound to the benefit of the GOP as follows:

(i) If the physical and economic conditions have significantly changed so as to render the project no longer economically, financially or technically feasible as determined by the HoPE;

(ii) If the project is no longer necessary as determined by the HoPE; and

(iii) If the source of funds for the project has been withheld or reduced through no fault of the Procuring Entity.

30.3. In addition, the Procuring Entity may likewise declare a failure of bidding when:

(a) No bids are received;

(b) All prospective Bidders are declared ineligible;

(c) All bids fail to comply with all the bid requirements or fail post-qualification; or

(d) The bidder with the LCRB refuses, without justifiable cause to accept the award of contract, and no award is made in accordance with Section 40 of the IRR of RA 9184.

F. Award of Contract

31. Contract Award

31.1. Subject to **ITB** Clause 29, the HoPE or its duly authorized representative shall award the contract to the Bidder whose bid has been determined to be the LCRB.

31.2. Prior to the expiration of the period of bid validity, the Procuring Entity shall notify the successful Bidder in writing that its bid has been accepted, through a Notice of Award duly received by the Bidder or its representative personally or sent by registered mail or electronically, receipt of which must be confirmed in writing within two (2) days by the Bidder with the LCRB and submitted personally or sent by registered mail or electronically to the Procuring Entity.

31.3. Notwithstanding the issuance of the Notice of Award, award of contract shall be subject to the following conditions:

(a) Submission of the following documents within ten (10) calendar days from receipt of the Notice of Award:

(i) Valid JVA, if applicable; or

(ii) In the case of procurement by a Philippine Foreign Service Office or Post, the PhilGEPS Registration Number of the winning foreign Bidder;

(b) Posting of the performance security in accordance with **ITB** Clause 33;

(c) Signing of the contract as provided in **ITB** Clause 32; and

(d) Approval by higher authority, if required, as provided in Section 37.3 of the IRR of RA 9184.

31.4. At the time of contract award, the Procuring Entity shall not increase or decrease the quantity of goods originally specified in Section VI. Schedule of Requirements.

32. Signing of the Contract

32.1. At the same time as the Procuring Entity notifies the successful Bidder that its bid has been accepted, the Procuring Entity shall send the Contract Form to the Bidder, which contract has been provided in the Bidding Documents, incorporating therein all agreements between the parties.

32.2. Within ten (10) calendar days from receipt of the Notice of Award, the successful Bidder shall post the required performance security, sign and date the contract and return it to the Procuring Entity.

32.3. The Procuring Entity shall enter into contract with the successful Bidder within the same ten (10) calendar day period provided that all the documentary requirements are complied with.

32.4. The following documents shall form part of the contract:

(a) Contract Agreement;

(b) Bidding Documents;

(c) Winning bidder's bid, including the Technical and Financial Proposals, and all other documents/statements submitted (*e.g.,* bidder's response to request for clarifications on the bid), including corrections to the bid, if any, resulting from the Procuring Entity's bid evaluation;

(d) Performance Security;

(e) Notice of Award of Contract; and

(f) Other contract documents that may be required by existing laws and/or specified in the **BDS**.

33. Performance Security

33.1. To guarantee the faithful performance by the winning Bidder of its obligations under the contract, it shall post a performance security within a maximum period of ten (10) calendar days from the receipt of the Notice of Award from the Procuring Entity and in no case later than the signing of the contract.

33.2. The Performance Security shall be denominated in Philippine Pesos and posted in favor of the Procuring Entity in an amount not less than the percentage of the total contract price in accordance with the following schedule:

Form of Performance Security	Amount of Performance Security (Not less than the Percentage of the Total Contract Price)
(a) Cash or cashier's/manager's check issued by a Universal or Commercial Bank. *For biddings conducted by the LGUs, the Cashier's/Manager's Check may be issued by other banks certified by the BSP as authorized to issue such financial instrument.*	Five percent (5%)
(b) Bank draft/guarantee or irrevocable letter of credit issued by a Universal or Commercial Bank: Provided, however, that it shall be confirmed or authenticated by a Universal or Commercial Bank, if issued by a foreign bank.	

	For biddings conducted by the LGUs, the Bank Draft/ Guarantee or Irrevocable Letter of Credit may be issued by other banks certified by the BSP as authorized to issue such financial instrument.	
(c)	Surety bond callable upon demand issued by a surety or insurance company duly certified by the Insurance Commission as authorized to issue such security.	Thirty percent (30%)

33.3. Failure of the successful Bidder to comply with the above-mentioned requirement shall constitute sufficient ground for the annulment of the award and forfeiture of the bid security, in which event the Procuring Entity shall have a fresh period to initiate and complete the post qualification of the second Lowest Calculated Bid. The procedure shall be repeated until the LCRB is identified and selected for recommendation of contract award. However if no Bidder passed post-qualification, the BAC shall declare the bidding a failure and conduct a re-bidding with re-advertisement, if necessary.

34. Notice to Proceed

Within seven (7) calendar days from the date of approval of the contract by the appropriate government approving authority, the Procuring Entity shall issue the Notice to Proceed (NTP) together with a copy or copies of the approved contract to the successful Bidder. All notices called for by the terms of the contract shall be effective only at the time of receipt thereof by the successful Bidder.

35. Protest Mechanism

Decisions of the procuring entity at any stage of the procurement process may be questioned in accordance with Section 55 of the IRR of RA 9184.

Section III. Bid Data Sheet

Notes on the Bid Data Sheet

Section III is intended to assist the Procuring Entity in providing the specific information in relation to corresponding clauses in the ITB included in Section II, and has to be prepared for each specific procurement.

The Procuring Entity should specify in the BDS information and requirements specific to the circumstances of the Procuring Entity, the processing of the procurement, the applicable rules regarding bid price and currency, and the bid evaluation criteria that will apply to the bids. In preparing Section III, the following aspects should be checked:

(a) Information that specifies and complements provisions of Section II must be incorporated.

(b) Amendments and/or supplements, if any, to provisions of Section II as necessitated by the circumstances of the specific procurement, must also be incorporated.

For foreign-assisted projects, the Bid Data Sheet to be used is provided in Section IX-Foreign-Assisted Projects.

Bid Data Sheet

ITB Clause	
1.1	The Procuring Entity is ***BATANGAS MEDICAL CENTER*** The name of the Contract is ***PROCUREMENT OF DRUGS AND MEDICINES*** The identification number of the Contract is *IB 2017-008A*
1.2	The lot*(s)* and reference is/are: *[insert name]*
2	The Funding Source is: The Government of the Philippines (GOP) through the General Appropriations Act ***CY 2018*** in the amount ***NINETY MILLION SIX HUNDRED SIX THOUSAND TWO HUNDRED FORTY NINE PESOS ONLY. (Php 90,606,249.00)*** ***NOTE:*** *In the case of National Government Agencies, the General Appropriations Act and/or continuing appropriations; in the case of Government-Owned and/or –Controlled Corporations, Government Financial Institutions, and State Universities and Colleges, the Corporate Budget for the contract approved by the governing Boards; in the case of Local Government Units, the Budget for the contract approved by the respective Sanggunian.* The name of the Project is**:** ***PROCUREMENT OF DRUGS AND MEDICINES***
3.1	No further instructions.
5.1	No further instructions.
5.2	Foreign bidders may participate in this Project in view of the following circumstance*(s)*: *mentioned in the ITB Clause exists in the Project.*
5.4	*For procurement where the Procuring Entity has determined, after the conduct of market research, that imposition of the provisions of Section*

	23.4.1.3 of the IRR of RA 9184 will likely result to failure of bidding or monopoly that will defeat the purpose of public bidding: In view of the determination by the Procuring Entity that imposition of the provisions of Section 23.4.1.3 of the IRR of RA 9184 will likely result to *[State "*failure of bidding*" or "*monopoly that will defeat the purpose of public bidding*"]*, the Bidder should comply with the following requirements: a) Completed at least two (2) similar contracts, the aggregate amount of which should be equivalent to at least *[State "*fifty percent (50%)*" in the case of Non-expendable Supplies and Services or "*twenty-five percent (25%)*" in the case of Expendable Supplies]* of the ABC for this Project; and b) The largest of these similar contracts must be equivalent to at least half of the percentage of the ABC as required above.
7	No further instructions.
8.1	Subcontracting is allowed provided that the bidder shall principally undertake to do the substantial works or deliver substantial goods; provided further that the contracted works/goods shall not be more than 50% of the contractors own resources.
8.2	
9.1	The Procuring Entity will hold a pre-bid conference for this Project on ***8 DECEMBER 2017*** ***9:00 AM*** ***HBAC Conference Room*** ***2nd Floor OPD Building*** ***Batangas Medical Center***
10.1	The Procuring Entity's address is: ***Batangas Medical Center*** ***Kumintang Ibaba*** ***Batangas City***
12.1(a)	No further instructions.
12.1(a)(ii)	The bidder's SLCC similar to the contract to be bid should have been completed within *two(2) years* prior to the deadline for the submission and receipt of bids.
13.1	"No additional requirements."

13.1(b)	No further instructions.
13.1(c)	"No additional requirements."
13.2	The ABC is ***NINETY MILLION SIX HUNDRED SIX THOUSAND TWO HUNDRED FORTY NINE PESOS ONLY. (Php 90,606,249.00)*** Any bid with a financial component exceeding this amount shall not be accepted.
15.4(a)(iv)	"No incidental services are required."
15.4(b)	*"*Not applicable*",*
16.1(b)	The Bid prices for Goods supplied from outside of the Philippines shall be quoted in Philippine Pesos.
16.3	*"*Not applicable*"*
17.1	*"*Not applicable*"*
18.1	The bid security shall be in the form of a Bid Securing Declaration, or any of the following forms and amounts: ***1. 2% of ABC,*** if bid security is in cash, cashier's/manager's check, bank draft/guarantee or irrevocable letter of credit issued by a Universal Bank; ***2. 5% of ABC,*** if surety bond callable upon demand issued by a surety or insurance company duly certified by the Insurance Commission as authorized to issue such security;
18.2	The bid security shall be valid until *one hundred twenty (120) calendar days from opening of bids.*
20.3	Each Bidder shall submit **one*[1]* original and two *[2]* copies** of the first and second components of its bid.
21	The address for submission of bids is *[insert address]*. ***Batangas Medical Center*** ***Kumintang Ibaba*** ***Batangas City*** The deadline for submission of bids is ***DECEMBER 19, 2017 9:00 a.m.***

24.1	The place of bid opening is ***HBAC Conference Room*** ***2nd Floor, OPD Building*** ***Batangas Medical Center*** ***Kumintang Ibaba*** ***Batangas City*** The date and time of bid opening is ***DECEMBER 19, 2017 9:00 a.m.***
24.2	No further instructions.
24.3	No further instructions.
27.1	No further instructions.
28.3 (a)	**Grouping and Evaluation of Lots –** *Each item to be evaluated and compared with other Bids separately and recommended for contract award separately.* Partial bid is not allowed. The goods are grouped in a single lot and the lot shall not be divided into sub-lots for the purpose of bidding, evaluation, and contract award.
28.4	No further instructions.
29.2	*"No additional requirement."*
32.4(f)	*"No additional requirement."*

Section IV. General Conditions of Contract

Notes on the General Conditions of Contract

The GCC in Section IV, read in conjunction with the SCC in Section V and other documents listed therein, should be a complete document expressing all the rights and obligations of the parties.

The GCC herein shall not be altered. Any changes and complementary information, which may be needed, shall be introduced only through the SCC in Section V.

TABLE OF CONTENTS

1. Definitions

1.1. In this Contract, the following terms shall be interpreted as indicated:

(a) "The Contract" means the agreement entered into between the Procuring Entity and the Supplier, as recorded in the Contract Form signed by the parties, including all attachments and appendices thereto and all documents incorporated by reference therein.

(b) "The Contract Price" means the price payable to the Supplier under the Contract for the full and proper performance of its contractual obligations.

(c) "The Goods" means all of the supplies, equipment, machinery, spare parts, other materials and/or general support services which the Supplier is required to provide to the Procuring Entity under the Contract.

(d) "The Services" means those services ancillary to the supply of the Goods, such as transportation and insurance, and any other incidental services, such as installation, commissioning, provision of technical assistance, training, and other such obligations of the Supplier covered under the Contract.

(e) "GCC" means the General Conditions of Contract contained in this Section.

(f) "SCC" means the Special Conditions of Contract.

(g) "The Procuring Entity" means the organization purchasing the Goods, as named in the **SCC**.

(h) "The Procuring Entity's country" is the Philippines.

(i) "The Supplier" means the individual contractor, manufacturer distributor, or firm supplying/manufacturing the Goods and Services under this Contract and named in the **SCC**.

(j) The "Funding Source" means the organization named in the **SCC**.

(k) "The Project Site," where applicable, means the place or places named in the **SCC**.

(l) "Day" means calendar day.

(m) The "Effective Date" of the contract will be the date of signing the contract, however the Supplier shall commence performance of its obligations only upon receipt of the Notice to Proceed and copy of the approved contract.

(n) "Verified Report" refers to the report submitted by the Implementing Unit to the HoPE setting forth its findings as to the existence of grounds or causes for termination and explicitly stating its recommendation for the issuance of a Notice to Terminate.

2. Corrupt, Fraudulent, Collusive, and Coercive Practices

2.1. Unless otherwise provided in the **SCC**, the Procuring Entity as well as the bidders, contractors, or suppliers shall observe the highest standard of ethics during the procurement and execution of this Contract. In pursuance of this policy, the Procuring Entity:

(a) defines, for the purposes of this provision, the terms set forth below as follows:

(i) "corrupt practice" means behavior on the part of officials in the public or private sectors by which they improperly and unlawfully enrich themselves, others, or induce others to do so, by misusing the position in which they are placed, and it includes the offering, giving, receiving, or soliciting of anything of value to influence the action of any such official in the procurement process or in contract execution; entering, on behalf of the Government, into any contract or transaction manifestly and grossly disadvantageous to the same, whether or not the public officer profited or will profit thereby, and similar acts as provided in Republic Act 3019.

(ii) "fraudulent practice" means a misrepresentation of facts in order to influence a procurement process or the execution of a contract to the detriment of the Procuring Entity, and includes collusive practices among Bidders (prior to or after bid submission) designed to establish bid prices at artificial, non-competitive levels and to deprive the Procuring Entity of the benefits of free and open competition.

(iii) "collusive practices" means a scheme or arrangement between two or more Bidders, with or without the knowledge of the Procuring Entity, designed to establish bid prices at artificial, non-competitive levels.

(iv) "coercive practices" means harming or threatening to harm, directly or indirectly, persons, or their property to influence their participation in a procurement process, or affect the execution of a contract;

(v) "obstructive practice" is

(aa) deliberately destroying, falsifying, altering or concealing of evidence material to an administrative proceedings or investigation or making false statements to investigators in order to materially impede an

administrative proceedings or investigation of the Procuring Entity or any foreign government/foreign or international financing institution into allegations of a corrupt, fraudulent, coercive or collusive practice; and/or threatening, harassing or intimidating any party to prevent it from disclosing its knowledge of matters relevant to the administrative proceedings or investigation or from pursuing such proceedings or investigation; or

(bb) acts intended to materially impede the exercise of the inspection and audit rights of the Procuring Entity or any foreign government/foreign or international financing institution herein.

(b) will reject a proposal for award if it determines that the Bidder recommended for award has engaged in any of the practices mentioned in this Clause for purposes of competing for the contract.

2.2. Further the Funding Source, Borrower or Procuring Entity, as appropriate, will seek to impose the maximum civil, administrative and/or criminal penalties available under the applicable law on individuals and organizations deemed to be involved with any of the practices mentioned in **GCC** Clause 2.1(a).

3. Inspection and Audit by the Funding Source

The Supplier shall permit the Funding Source to inspect the Supplier's accounts and records relating to the performance of the Supplier and to have them audited by auditors appointed by the Funding Source, if so required by the Funding Source.

4. Governing Law and Language

4.1. This Contract shall be interpreted in accordance with the laws of the Republic of the Philippines.

4.2. This Contract has been executed in the English language, which shall be the binding and controlling language for all matters relating to the meaning or interpretation of this Contract. All correspondence and other documents pertaining to this Contract exchanged by the parties shall be written in English.

5. Notices

5.1. Any notice, request, or consent required or permitted to be given or made pursuant to this Contract shall be in writing. Any such notice, request, or consent shall be deemed to have been given or made when received by the concerned party, either in person or through an authorized representative of the Party to whom the communication is addressed, or when sent by registered mail, telex, telegram, or facsimile to such Party at the address specified in the

SCC, which shall be effective when delivered and duly received or on the notice's effective date, whichever is later.

5.2. A Party may change its address for notice hereunder by giving the other Party notice of such change pursuant to the provisions listed in the **SCC** for **GCC** Clause 5.1.

6. Scope of Contract

6.1. The Goods and Related Services to be provided shall be as specified in Section VI. Schedule of Requirements.

6.2. This Contract shall include all such items, although not specifically mentioned, that can be reasonably inferred as being required for its completion as if such items were expressly mentioned herein. Any additional requirements for the completion of this Contract shall be provided in the **SCC**.

7. Subcontracting

7.1. Subcontracting of any portion of the Goods, if allowed in the **BDS**, does not relieve the Supplier of any liability or obligation under this Contract. The Supplier will be responsible for the acts, defaults, and negligence of any subcontractor, its agents, servants or workmen as fully as if these were the Supplier's own acts, defaults, or negligence, or those of its agents, servants or workmen.

7.2. If subcontracting is allowed, the Supplier may identify its subcontractor during contract implementation. Subcontractors disclosed and identified during the bidding may be changed during the implementation of this Contract. In either case, subcontractors must submit the documentary requirements under **ITB** Clause 12 and comply with the eligibility criteria specified in the **BDS.** In the event that any subcontractor is found by the Procuring Entity to be ineligible, the subcontracting of such portion of the Goods shall be disallowed.

8. Procuring Entity's Responsibilities

8.1. Whenever the performance of the obligations in this Contract requires that the Supplier obtain permits, approvals, import, and other licenses from local public authorities, the Procuring Entity shall, if so needed by the Supplier, make its best effort to assist the Supplier in complying with such requirements in a timely and expeditious manner.

8.2. The Procuring Entity shall pay all costs involved in the performance of its responsibilities in accordance with **GCC** Clause 6.

9. Prices

9.1. For the given scope of work in this Contract as awarded, all bid prices are considered fixed prices, and therefore not subject to price escalation during contract implementation, except under extraordinary circumstances and upon

prior approval of the GPPB in accordance with Section 61 of R.A. 9184 and its IRR or except as provided in this Clause.

9.2. Prices charged by the Supplier for Goods delivered and/or services performed under this Contract shall not vary from the prices quoted by the Supplier in its bid, with the exception of any change in price resulting from a Change Order issued in accordance with **GCC** Clause 29.

10. Payment

10.1. Payments shall be made only upon a certification by the HoPE to the effect that the Goods have been rendered or delivered in accordance with the terms of this Contract and have been duly inspected and accepted**.** Except with the prior approval of the President no payment shall be made for services not yet rendered or for supplies and materials not yet delivered under this Contract. Ten percent (10%) of the amount of each payment shall be retained by the Procuring Entity to cover the Supplier's warranty obligations under this Contract as described in **GCC** Clause 17.

10.2. The Supplier's request(s) for payment shall be made to the Procuring Entity in writing, accompanied by an invoice describing, as appropriate, the Goods delivered and/or Services performed, and by documents submitted pursuant to the **SCC** provision for **GCC** Clause 6.2, and upon fulfillment of other obligations stipulated in this Contract.

10.3. Pursuant to **GCC** Clause 10.2, payments shall be made promptly by the Procuring Entity, but in no case later than sixty (60) days after submission of an invoice or claim by the Supplier. Payments shall be in accordance with the schedule stated in the **SCC**.

10.4. Unless otherwise provided in the **SCC**, the currency in which payment is made to the Supplier under this Contract shall be in Philippine Pesos.

10.5. Unless otherwise provided in the **SCC**, payments using Letter of Credit (LC), in accordance with the Guidelines issued by the GPPB, is allowed. For this purpose, the amount of provisional sum is indicated in the **SCC**. All charges for the opening of the LC and/or incidental expenses thereto shall be for the account of the Supplier.

11. Advance Payment and Terms of Payment

11.1. Advance payment shall be made only after prior approval of the President, and shall not exceed fifteen percent (15%) of the Contract amount, unless otherwise directed by the President or in cases allowed under Annex "D" of RA 9184.

11.2. All progress payments shall first be charged against the advance payment until the latter has been fully exhausted.

11.3. For Goods supplied from abroad, unless otherwise indicated in the **SCC**, the terms of payment shall be as follows:

(a) On Contract Signature: Fifteen Percent (15%) of the Contract Price shall be paid within sixty (60) days from signing of the Contract and upon submission of a claim and a bank guarantee for the equivalent amount valid until the Goods are delivered and in the form provided in Section VIII. Bidding Forms.

(b) On Delivery: Sixty-five percent (65%) of the Contract Price shall be paid to the Supplier within sixty (60) days after the date of receipt of the Goods and upon submission of the documents (i) through (vi) specified in the SCC provision on Delivery and Documents.

(c) On Acceptance: The remaining twenty percent (20%) of the Contract Price shall be paid to the Supplier within sixty (60) days after the date of submission of the acceptance and inspection certificate for the respective delivery issued by the Procuring Entity's authorized representative. In the event that no inspection or acceptance certificate is issued by the Procuring Entity's authorized representative within forty five (45) days of the date shown on the delivery receipt, the Supplier shall have the right to claim payment of the remaining twenty percent (20%) subject to the Procuring Entity's own verification of the reason(s) for the failure to issue documents (vii) and (viii) as described in the SCC provision on Delivery and Documents.

12. Taxes and Duties

The Supplier, whether local or foreign, shall be entirely responsible for all the necessary taxes, stamp duties, license fees, and other such levies imposed for the completion of this Contract.

13. Performance Security

13.1. Within ten (10) calendar days from receipt of the Notice of Award from the Procuring Entity but in no case later than the signing of the contract by both parties, the successful Bidder shall furnish the performance security in any the forms prescribed in the **ITB** Clause 33.2.

13.2. The performance security posted in favor of the Procuring Entity shall be forfeited in the event it is established that the winning bidder is in default in any of its obligations under the contract.

13.3. The performance security shall remain valid until issuance by the Procuring Entity of the Certificate of Final Acceptance.

13.4. The performance security may be released by the Procuring Entity and returned to the Supplier after the issuance of the Certificate of Final Acceptance subject to the following conditions:

(a) There are no pending claims against the Supplier or the surety company filed by the Procuring Entity;

(b) The Supplier has no pending claims for labor and materials filed against it; and

(c) Other terms specified in the **SCC**.

13.5. In case of a reduction of the contract value, the Procuring Entity shall allow a proportional reduction in the original performance security, provided that any such reduction is more than ten percent (10%) and that the aggregate of such reductions is not more than fifty percent (50%) of the original performance security.

14. Use of Contract Documents and Information

14.1. The Supplier shall not, except for purposes of performing the obligations in this Contract, without the Procuring Entity's prior written consent, disclose this Contract, or any provision thereof, or any specification, plan, drawing, pattern, sample, or information furnished by or on behalf of the Procuring Entity. Any such disclosure shall be made in confidence and shall extend only as far as may be necessary for purposes of such performance.

14.2. Any document, other than this Contract itself, enumerated in **GCC** Clause 14.1 shall remain the property of the Procuring Entity and shall be returned (all copies) to the Procuring Entity on completion of the Supplier's performance under this Contract if so required by the Procuring Entity.

15. Standards

The Goods provided under this Contract shall conform to the standards mentioned in the Section VII. Technical Specifications; and, when no applicable standard is mentioned, to the authoritative standards appropriate to the Goods' country of origin. Such standards shall be the latest issued by the institution concerned.

16. Inspection and Tests

16.1. The Procuring Entity or its representative shall have the right to inspect and/or to test the Goods to confirm their conformity to the Contract specifications at no extra cost to the Procuring Entity. The **SCC** and Section VII. Technical Specifications shall specify what inspections and/or tests the Procuring Entity requires and where they are to be conducted. The Procuring Entity shall notify the Supplier in writing, in a timely manner, of the identity of any representatives retained for these purposes.

16.2. If applicable, the inspections and tests may be conducted on the premises of the Supplier or its subcontractor(s), at point of delivery, and/or at the goods' final destination. If conducted on the premises of the Supplier or its subcontractor(s), all reasonable facilities and assistance, including access to drawings and production data, shall be furnished to the inspectors at no charge to the Procuring Entity. The Supplier shall provide the Procuring Entity with results of such inspections and tests.

16.3. The Procuring Entity or its designated representative shall be entitled to attend the tests and/or inspections referred to in this Clause provided that the Procuring Entity shall bear all of its own costs and expenses incurred in connection with such attendance including, but not limited to, all traveling and board and lodging expenses.

16.4. The Procuring Entity may reject any Goods or any part thereof that fail to pass any test and/or inspection or do not conform to the specifications. The Supplier shall either rectify or replace such rejected Goods or parts thereof or make alterations necessary to meet the specifications at no cost to the Procuring Entity, and shall repeat the test and/or inspection, at no cost to the Procuring Entity, upon giving a notice pursuant to **GCC** Clause 5.

16.5. The Supplier agrees that neither the execution of a test and/or inspection of the Goods or any part thereof, nor the attendance by the Procuring Entity or its representative, shall release the Supplier from any warranties or other obligations under this Contract.

17. Warranty

17.1. The Supplier warrants that the Goods supplied under the Contract are new, unused, of the most recent or current models, and that they incorporate all recent improvements in design and materials, except when the technical specifications required by the Procuring Entity provides otherwise.

17.2. The Supplier further warrants that all Goods supplied under this Contract shall have no defect, arising from design, materials, or workmanship or from any act or omission of the Supplier that may develop under normal use of the supplied Goods in the conditions prevailing in the country of final destination.

17.3. In order to assure that manufacturing defects shall be corrected by the Supplier, a warranty shall be required from the Supplier for a minimum period specified in the **SCC**. The obligation for the warranty shall be covered by, at the Supplier's option, either retention money in an amount equivalent to at least one percent (1%) of every progress payment, or a special bank guarantee equivalent to at least one percent (1%) of the total Contract Price or other such amount if so specified in the **SCC**. The said amounts shall only be released after the lapse of the warranty period specified in the **SCC**; provided, however, that the Supplies delivered are free from patent and latent defects and all the conditions imposed under this Contract have been fully met.

17.4. The Procuring Entity shall promptly notify the Supplier in writing of any claims arising under this warranty. Upon receipt of such notice, the Supplier shall, within the period specified in the **SCC** and with all reasonable speed, repair or replace the defective Goods or parts thereof, without cost to the Procuring Entity.

17.5. If the Supplier, having been notified, fails to remedy the defect(s) within the period specified in **GCC** Clause 17.4, the Procuring Entity may proceed to take such remedial action as may be necessary, at the Supplier's risk and expense and without prejudice to any other rights which the Procuring Entity

may have against the Supplier under the Contract and under the applicable law.

18. Delays in the Supplier's Performance

18.1. Delivery of the Goods and/or performance of Services shall be made by the Supplier in accordance with the time schedule prescribed by the Procuring Entity in Section VI. Schedule of Requirements.

18.2. If at any time during the performance of this Contract, the Supplier or its Subcontractor(s) should encounter conditions impeding timely delivery of the Goods and/or performance of Services, the Supplier shall promptly notify the Procuring Entity in writing of the fact of the delay, its likely duration and its cause(s). As soon as practicable after receipt of the Supplier's notice, and upon causes provided for under **GCC** Clause 22, the Procuring Entity shall evaluate the situation and may extend the Supplier's time for performance, in which case the extension shall be ratified by the parties by amendment of Contract.

18.3. Except as provided under **GCC** Clause 22, a delay by the Supplier in the performance of its obligations shall render the Supplier liable to the imposition of liquidated damages pursuant to **GCC** Clause 19, unless an extension of time is agreed upon pursuant to **GCC** Clause 29 without the application of liquidated damages.

19. Liquidated Damages

Subject to **GCC** Clauses 18 and 22, if the Supplier fails to satisfactorily deliver any or all of the Goods and/or to perform the Services within the period(s) specified in this Contract inclusive of duly granted time extensions if any, the Procuring Entity shall, without prejudice to its other remedies under this Contract and under the applicable law, deduct from the Contract Price, as liquidated damages, the applicable rate of one tenth (1/10) of one (1) percent of the cost of the unperformed portion for every day of delay until actual delivery or performance. The maximum deduction shall be ten percent (10%) of the amount of contract. Once the maximum is reached, the Procuring Entity may rescind or terminate the Contract pursuant to **GCC** Clause 23, without prejudice to other courses of action and remedies open to it.

20. Settlement of Disputes

20.1. If any dispute or difference of any kind whatsoever shall arise between the Procuring Entity and the Supplier in connection with or arising out of this Contract, the parties shall make every effort to resolve amicably such dispute or difference by mutual consultation.

20.2. If after thirty (30) days, the parties have failed to resolve their dispute or difference by such mutual consultation, then either the Procuring Entity or the Supplier may give notice to the other party of its intention to commence arbitration, as hereinafter provided, as to the matter in dispute, and no arbitration in respect of this matter may be commenced unless such notice is given.

20.3. Any dispute or difference in respect of which a notice of intention to commence arbitration has been given in accordance with this Clause shall be settled by arbitration. Arbitration may be commenced prior to or after delivery of the Goods under this Contract.

20.4. In the case of a dispute between the Procuring Entity and the Supplier, the dispute shall be resolved in accordance with Republic Act 9285 ("R.A. 9285"), otherwise known as the "Alternative Dispute Resolution Act of 2004."

20.5. Notwithstanding any reference to arbitration herein, the parties shall continue to perform their respective obligations under the Contract unless they otherwise agree; and the Procuring Entity shall pay the Supplier any monies due the Supplier.

21. Liability of the Supplier

21.1. The Supplier's liability under this Contract shall be as provided by the laws of the Republic of the Philippines, subject to additional provisions, if any, set forth in the **SCC**.

21.2. Except in cases of criminal negligence or willful misconduct, and in the case of infringement of patent rights, if applicable, the aggregate liability of the Supplier to the Procuring Entity shall not exceed the total Contract Price, provided that this limitation shall not apply to the cost of repairing or replacing defective equipment.

22. Force Majeure

22.1. The Supplier shall not be liable for forfeiture of its performance security, liquidated damages, or termination for default if and to the extent that the Supplier's delay in performance or other failure to perform its obligations under the Contract is the result of a *force majeure*.

22.2. For purposes of this Contract the terms "*force majeure*" and "fortuitous event" may be used interchangeably. In this regard, a fortuitous event or *force majeure* shall be interpreted to mean an event which the Supplier could not have foreseen, or which though foreseen, was inevitable. It shall not include ordinary unfavorable weather conditions; and any other cause the effects of which could have been avoided with the exercise of reasonable diligence by the Supplier. Such events may include, but not limited to, acts of the Procuring Entity in its sovereign capacity, wars or revolutions, fires, floods, epidemics, quarantine restrictions, and freight embargoes.

22.3. If a *force majeure* situation arises, the Supplier shall promptly notify the Procuring Entity in writing of such condition and the cause thereof. Unless otherwise directed by the Procuring Entity in writing, the Supplier shall continue to perform its obligations under the Contract as far as is reasonably practical, and shall seek all reasonable alternative means for performance not prevented by the *force majeure*.

23. Termination for Default

23.1. The Procuring Entity shall terminate this Contract for default when any of the following conditions attends its implementation:

(a) Outside of *force majeure*, the Supplier fails to deliver or perform any or all of the Goods within the period(s) specified in the contract, or within any extension thereof granted by the Procuring Entity pursuant to a request made by the Supplier prior to the delay, and such failure amounts to at least ten percent (10%) of the contact price;

(b) As a result of *force majeure*, the Supplier is unable to deliver or perform any or all of the Goods, amounting to at least ten percent (10%) of the contract price, for a period of not less than sixty (60) calendar days after receipt of the notice from the Procuring Entity stating that the circumstance of force majeure is deemed to have ceased; or

(c) The Supplier fails to perform any other obligation under the Contract.

23.2. In the event the Procuring Entity terminates this Contract in whole or in part, for any of the reasons provided under **GCC** Clauses 23 to 26, the Procuring Entity may procure, upon such terms and in such manner as it deems appropriate, Goods or Services similar to those undelivered, and the Supplier shall be liable to the Procuring Entity for any excess costs for such similar Goods or Services. However, the Supplier shall continue performance of this Contract to the extent not terminated.

23.3. In case the delay in the delivery of the Goods and/or performance of the Services exceeds a time duration equivalent to ten percent (10%) of the specified contract time plus any time extension duly granted to the Supplier, the Procuring Entity may terminate this Contract, forfeit the Supplier's performance security and award the same to a qualified Supplier.

24. Termination for Insolvency

The Procuring Entity shall terminate this Contract if the Supplier is declared bankrupt or insolvent as determined with finality by a court of competent jurisdiction. In this event, termination will be without compensation to the Supplier, provided that such termination will not prejudice or affect any right of action or remedy which has accrued or will accrue thereafter to the Procuring Entity and/or the Supplier.

25. Termination for Convenience

25.1. The Procuring Entity may terminate this Contract, in whole or in part, at any time for its convenience. The HoPE may terminate a contract for the convenience of the Government if he has determined the existence of conditions that make Project Implementation economically, financially or technically impractical and/or unnecessary, such as, but not limited to, fortuitous event(s) or changes in law and national government policies.

25.2. The Goods that have been delivered and/or performed or are ready for delivery or performance within thirty (30) calendar days after the Supplier’s receipt of

Notice to Terminate shall be accepted by the Procuring Entity at the contract terms and prices. For Goods not yet performed and/or ready for delivery, the Procuring Entity may elect:

(a) to have any portion delivered and/or performed and paid at the contract terms and prices; and/or

(b) to cancel the remainder and pay to the Supplier an agreed amount for partially completed and/or performed goods and for materials and parts previously procured by the Supplier.

25.3. If the Supplier suffers loss in its initial performance of the terminated contract, such as purchase of raw materials for goods specially manufactured for the Procuring Entity which cannot be sold in open market, it shall be allowed to recover partially from this Contract, on a *quantum meruit* basis. Before recovery may be made, the fact of loss must be established under oath by the Supplier to the satisfaction of the Procuring Entity before recovery may be made.

26. Termination for Unlawful Acts

26.1. The Procuring Entity may terminate this Contract in case it is determined *prima facie* that the Supplier has engaged, before or during the implementation of this Contract, in unlawful deeds and behaviors relative to contract acquisition and implementation. Unlawful acts include, but are not limited to, the following:

(a) Corrupt, fraudulent, and coercive practices as defined in **ITB** Clause 3.1(a);

(b) Drawing up or using forged documents;

(c) Using adulterated materials, means or methods, or engaging in production contrary to rules of science or the trade; and

(d) Any other act analogous to the foregoing.

27. Procedures for Termination of Contracts

27.1. The following provisions shall govern the procedures for termination of this Contract:

(a) Upon receipt of a written report of acts or causes which may constitute ground(s) for termination as aforementioned, or upon its own initiative, the Implementing Unit shall, within a period of seven (7) calendar days, verify the existence of such ground(s) and cause the execution of a Verified Report, with all relevant evidence attached;

(b) Upon recommendation by the Implementing Unit, the HoPE shall terminate this Contract only by a written notice to the Supplier conveying the termination of this Contract. The notice shall state:

(i) that this Contract is being terminated for any of the ground(s) afore-mentioned, and a statement of the acts that constitute the ground(s) constituting the same;

(ii) the extent of termination, whether in whole or in part;

(iii) an instruction to the Supplier to show cause as to why this Contract should not be terminated; and

(iv) special instructions of the Procuring Entity, if any.

(c) The Notice to Terminate shall be accompanied by a copy of the Verified Report;

(d) Within a period of seven (7) calendar days from receipt of the Notice of Termination, the Supplier shall submit to the HoPE a verified position paper stating why this Contract should not be terminated. If the Supplier fails to show cause after the lapse of the seven (7) day period, either by inaction or by default, the HoPE shall issue an order terminating this Contract;

(e) The Procuring Entity may, at any time before receipt of the Supplier's verified position paper described in item (d) above withdraw the Notice to Terminate if it is determined that certain items or works subject of the notice had been completed, delivered, or performed before the Supplier's receipt of the notice;

(f) Within a non-extendible period of ten (10) calendar days from receipt of the verified position paper, the HoPE shall decide whether or not to terminate this Contract. It shall serve a written notice to the Supplier of its decision and, unless otherwise provided, this Contract is deemed terminated from receipt of the Supplier of the notice of decision. The termination shall only be based on the ground(s) stated in the Notice to Terminate;

(g) The HoPE may create a Contract Termination Review Committee (CTRC) to assist him in the discharge of this function. All decisions recommended by the CTRC shall be subject to the approval of the HoPE; and

(h) The Supplier must serve a written notice to the Procuring Entity of its intention to terminate the contract at least thirty (30) calendar days before its intended termination. The Contract is deemed terminated if it is not resumed in thirty (30) calendar days after the receipt of such notice by the Procuring Entity.

28. Assignment of Rights

The Supplier shall not assign his rights or obligations under this Contract, in whole or in part, except with the Procuring Entity's prior written consent.

29. Contract Amendment

Subject to applicable laws, no variation in or modification of the terms of this Contract shall be made except by written amendment signed by the parties.

30. Application

These General Conditions shall apply to the extent that they are not superseded by provisions of other parts of this Contract.

Section V. Special Conditions of Contract

Notes on the Special Conditions of Contract

Similar to the BDS, the clauses in this Section are intended to assist the Procuring Entity in providing contract-specific information in relation to corresponding clauses in the GCC.

The provisions of this Section complement the GCC, specifying contractual requirements linked to the special circumstances of the Procuring Entity, the Procuring Entity's country, the sector, and the Goods purchased. In preparing this Section, the following aspects should be checked:

(a) Information that complements provisions of Section IV must be incorporated.

(b) Amendments and/or supplements to provisions of Section IV, as necessitated by the circumstances of the specific purchase, must also be incorporated.

However, no special condition which defeats or negates the general intent and purpose of the provisions of Section IV should be incorporated herein.

For foreign-assisted projects, the Special Conditions of Contract to be used is provided in Section IX-Foreign-Assisted Projects.

Special Conditions of Contract

GCC Clause	
1.1(g)	The Procuring Entity is ***BATANGAS MEDICAL CENTER***
1.1(i)	The Supplier is *[to be inserted at the time of contract award]*.
1.1(j)	The Funding Source is the Government of the Philippines (GOP) ***the General Appropriations Act CY 2018*** **in the amount** ***NINETY MILLION SIX HUNDRED SIX THOUSAND TWO HUNDRED FORTY NINE PESOS ONLY. (Php 90,606,249.00)*** ***NOTE:*** *In the case of National Government Agencies, the General Appropriations Act and/or continuing appropriations; in the case of Government-Owned and/or –Controlled Corporations, Government Financial Institutions, and State Universities and Colleges, the Corporate Budget for the contract approved by the governing Boards; in the case of Local Government Units, the Budget for the contract approved by the respective Sanggunian.*
1.1(k)	The Project sites are defined in Section VI. Schedule of Requirements
2.1	No further instructions.
5.1	The Procuring Entity's address for Notices is: ***HBAC Secretariat*** ***Batangas Medical Center*** ***Kumintang Ibaba, Batangas City*** The Supplier's address for Notices is: *[Insert address including, name of contact, fax and telephone number]*
6.2	*List here any additional requirements for the completion of this Contract. The following requirements and the corresponding provisions may be deleted, amended, or retained depending on its applicability to this Contract:* **Delivery and Documents –** For purposes of the Contract, "EXW," "FOB," "FCA," "CIF," "CIP," "DDP" and other trade terms used to describe the obligations of the parties shall have the meanings assigned to them by the current edition of INCOTERMS published by the International Chamber of Commerce, Paris. The Delivery terms of this Contract shall be as follows:

	*For Goods Supplied from Abroad, state "*The delivery terms applicable to the Contract are DDP delivered *[insert place of destination]*. In accordance with INCOTERMS." *For Goods Supplied from Within the Philippines, state "*The delivery terms applicable to this Contract are delivered *[insert place of destination]*. Risk and title will pass from the Supplier to the Procuring Entity upon receipt and final acceptance of the Goods at their final destination." Delivery of the Goods shall be made by the Supplier in accordance with the terms specified in Section VI. Schedule of Requirements. The details of shipping and/or other documents to be furnished by the Supplier are as follows: *For Goods supplied from within the Philippines:* Upon delivery of the Goods to the Project Site, the Supplier shall notify the Procuring Entity and present the following documents to the Procuring Entity: (i) Original and four copies of the Supplier's invoice showing Goods' description, quantity, unit price, and total amount; (ii) Original and four copies delivery receipt/note, railway receipt, or truck receipt; (iii) Original Supplier's factory inspection report; (iv) Original and four copies of the Manufacturer's and/or Supplier's warranty certificate; (v) Original and four copies of the certificate of origin (for imported Goods); (vi) Delivery receipt detailing number and description of items received signed by the authorized receiving personnel; (vii) Certificate of Acceptance/Inspection Report signed by the Procuring Entity's representative at the Project Site; and (viii) Four copies of the Invoice Receipt for Property signed by the Procuring Entity's representative at the Project Site. *For Goods supplied from abroad:* Upon shipment, the Supplier shall notify the Procuring Entity and the insurance company by cable the full details of the shipment, including Contract Number, description of the Goods, quantity, vessel, bill of lading number and date, port of loading, date of shipment, port of discharge etc. Upon delivery to the Project Site, the Supplier shall notify the Procuring Entity and present the following documents as applicable with the documentary requirements of any letter of credit

	issued taking precedence: (i) Original and four copies of the Supplier's invoice showing Goods' description, quantity, unit price, and total amount; (ii) Original and four copies of the negotiable, clean shipped on board bill of lading marked "freight pre-paid" and five copies of the non-negotiable bill of lading ; (iii) Original Supplier's factory inspection report; (iv) Original and four copies of the Manufacturer's and/or Supplier's warranty certificate; (v) Original and four copies of the certificate of origin (for imported Goods); (vi) Delivery receipt detailing number and description of items received signed by the Procuring Entity's representative at the Project Site; (vii) Certificate of Acceptance/Inspection Report signed by the Procuring Entity's representative at the Project Site; and (viii) Four copies of the Invoice Receipt for Property signed by the Procuring Entity's representative at the Project Site. For purposes of this Clause the Procuring Entity's Representative at the Project Site is ***the Head of Material Management Section.*** **Incidental Services –** The Supplier is required to provide all of the following services, including additional services, if any, specified in Section VI. Schedule of Requirements: *Select appropriate requirements and delete the rest.* (a) performance or supervision of on-site assembly and/or start-up of the supplied Goods; (b) furnishing of tools required for assembly and/or maintenance of the supplied Goods; (c) furnishing of a detailed operations and maintenance manual for each appropriate unit of the supplied Goods; (d) performance or supervision or maintenance and/or repair of the supplied Goods, for a period of time agreed by the parties, provided that this service shall not relieve the Supplier of any warranty obligations under this Contract; and (e) training of the Procuring Entity's personnel, at the Supplier's plant and/or on-site, in assembly, start-up, operation, maintenance, and/or repair of the supplied Goods.

	The Contract price for the Goods shall include the prices charged by the Supplier for incidental services and shall not exceed the prevailing rates charged to other parties by the Supplier for similar services. **Spare Parts –** The Supplier is required to provide all of the following materials, notifications, and information pertaining to spare parts manufactured or distributed by the Supplier: (a) such spare parts as the Procuring Entity may elect to purchase from the Supplier, provided that this election shall not relieve the Supplier of any warranty obligations under this Contract; and (b) in the event of termination of production of the spare parts: i. advance notification to the Procuring Entity of the pending termination, in sufficient time to permit the Procuring Entity to procure needed requirements; and ii. following such termination, furnishing at no cost to the Procuring Entity, the blueprints, drawings, and specifications of the spare parts, if requested. The spare parts required are listed in Section VI. Schedule of Requirements and the cost thereof are included in the Contract Price The Supplier shall carry sufficient inventories to assure ex-stock supply of consumable spares for the Goods for a period of *[insert here the time period specified. If not used insert time period of three times the warranty period]*. Other spare parts and components shall be supplied as promptly as possible, but in any case within *[insert appropriate time period]* months of placing the order. **Packaging –** The Supplier shall provide such packaging of the Goods as is required to prevent their damage or deterioration during transit to their final destination, as indicated in this Contract. The packaging shall be sufficient to withstand, without limitation, rough handling during transit and exposure to extreme temperatures, salt and precipitation during transit, and open storage. Packaging case size and weights shall take into consideration, where appropriate, the remoteness of the GOODS' final destination and the absence of heavy handling facilities at all points in transit. The packaging, marking, and documentation within and outside the

	packages shall comply strictly with such special requirements as shall be expressly provided for in the Contract, including additional requirements, if any, specified below, and in any subsequent instructions ordered by the Procuring Entity. The outer packaging must be clearly marked on at least four (4) sides as follows: Name of the Procuring Entity Name of the Supplier Contract Description Final Destination Gross weight Any special lifting instructions Any special handling instructions Any relevant HAZCHEM classifications A packaging list identifying the contents and quantities of the package is to be placed on an accessible point of the outer packaging if practical. If not practical the packaging list is to be placed inside the outer packaging but outside the secondary packaging. **Insurance –** The Goods supplied under this Contract shall be fully insured by the Supplier in a freely convertible currency against loss or damage incidental to manufacture or acquisition, transportation, storage, and delivery. The Goods remain at the risk and title of the Supplier until their final acceptance by the Procuring Entity. **Transportation –** Where the Supplier is required under Contract to deliver the Goods CIF, CIP or DDP, transport of the Goods to the port of destination or such other named place of destination in the Philippines, as shall be specified in this Contract, shall be arranged and paid for by the Supplier, and the cost thereof shall be included in the Contract Price. Where the Supplier is required under this Contract to transport the Goods to a specified place of destination within the Philippines, defined as the Project Site, transport to such place of destination in the Philippines, including insurance and storage, as shall be specified in this Contract, shall be arranged by the Supplier, and related costs shall be included in the Contract Price. Where the Supplier is required under Contract to deliver the Goods CIF, CIP or DDP, Goods are to be transported on carriers of

	Philippine registry. In the event that no carrier of Philippine registry is available, Goods may be shipped by a carrier which is not of Philippine registry provided that the Supplier obtains and presents to the Procuring Entity certification to this effect from the nearest Philippine consulate to the port of dispatch. In the event that carriers of Philippine registry are available but their schedule delays the Supplier in its performance of this Contract the period from when the Goods were first ready for shipment and the actual date of shipment the period of delay will be considered *force majeure* in accordance with **GCC** Clause 22. The Procuring Entity accepts no liability for the damage of Goods during transit other than those prescribed by INCOTERMS for DDP Deliveries. In the case of Goods supplied from within the Philippines or supplied by domestic Suppliers risk and title will not be deemed to have passed to the Procuring Entity until their receipt and final acceptance at the final destination. **Patent Rights –** The Supplier shall indemnify the Procuring Entity against all third-party claims of infringement of patent, trademark, or industrial design rights arising from use of the Goods or any part thereof.
10.4	*"*Not applicable*"*
10.5	"Payment using LC is not allowed."
11.3	"Maintain the GCC Clause."
13.4(c)	*"*No further instructions*"*.
16.1	The inspections and tests that will be conducted are: Ocular inspection of Goods upon delivery.
17.3	*If the Goods pertain to Expendable Supplies:* Three (3) months after acceptance by the Procuring Entity of the delivered Goods or after the Goods are consumed, whichever is earlier. *If the Goods pertain to Non-expendable Supplies:* One (1) year after acceptance by the Procuring Entity of the delivered Goods.
17.4	The period for correction of defects in the warranty period is three (3) days
21.1	*if the Supplier is a joint venture, "*All partners to the joint venture shall be jointly and severally liable to the Procuring Entity."

Section VI. Schedule of Requirements

The delivery schedule expressed as weeks/months stipulates hereafter a delivery date which is the date of delivery to the project site.

Item Number	Description	Quantity	Delivered, Weeks/Months
1	Procurement of Drugs and Medicines		The delivery of the item shall start within **ten (10) calendar days** from receipt of the Purchase Order.

Section VII. Technical Specifications

Notes for Preparing the Technical Specifications

A set of precise and clear specifications is a prerequisite for Bidders to respond realistically and competitively to the requirements of the Procuring Entity without qualifying their bids. In the context of Competitive Bidding, the specifications (*e.g.* production/delivery schedule, manpower requirements, and after-sales service/parts) must be prepared to permit the widest possible competition and, at the same time, present a clear statement of the required standards of workmanship, materials, and performance of the goods and services to be procured.. Only if this is done will the objectives of transparency, equity, efficiency, fairness and economy in procurement be realized, responsiveness of bids be ensured, and the subsequent task of bid evaluation and post-qualification facilitated. The specifications should require that all items, materials and accessories to be included or incorporated in the goods be new, unused, and of the most recent or current models, and that they include or incorporate all recent improvements in design and materials unless otherwise provided in the Contract.

Samples of specifications from previous similar procurements are useful in this respect. The use of metric units is encouraged. Depending on the complexity of the goods and the repetitiveness of the type of procurement, it may be advantageous to standardize the General Technical Specifications and incorporate them in a separate subsection. The General Technical Specifications should cover all classes of workmanship, materials, and equipment commonly involved in manufacturing similar goods. Deletions or addenda should then adapt the General Technical Specifications to the particular procurement.

Care must be taken in drafting specifications to ensure that they are not restrictive. In the specification of standards for equipment, materials, and workmanship, recognized Philippine and international standards should be used as much as possible. Where other particular standards are used, whether national standards or other standards, the specifications should state that equipment, materials, and workmanship that meet other authoritative standards, and which ensure at least a substantially equal quality than the standards mentioned, will also be acceptable. The following clause may be inserted in the Special Conditions of Contract or the Technical Specifications.

Sample Clause: Equivalency of Standards and Codes

Wherever reference is made in the Technical Specifications to specific standards and codes to be met by the goods and materials to be furnished or tested, the provisions of the latest edition or revision of the relevant standards and codes shall apply, unless otherwise expressly stated in the Contract. Where such standards and codes are national or relate to a particular country or region, other authoritative standards that ensure substantial equivalence to the standards and codes specified will be acceptable.

Reference to brand name and catalogue number should be avoided as far as possible; where unavoidable they should always be followed by the words “or at least equivalent.”

References to brand names cannot be used when the Funding Source is the GOP.

Where appropriate, drawings, including site plans as required, may be furnished by the Procuring Entity with the Bidding Documents. Similarly, the Supplier may be requested to provide drawings or samples either with its Bid or for prior review by the Procuring Entity during contract execution.

Bidders are also required, as part of the technical specifications, to complete their statement of compliance demonstrating how the items comply with the specification.

Technical Specifications

Item	Specification	Statement of Compliance Bidders must state here either "Comply" or "Not Comply" against each of the individual parameters of each Specification stating the corresponding performance parameter of the equipment offered. Statements of "Comply" or "Not Comply" must be supported by evidence in a Bidders Bid and cross-referenced to that evidence. Evidence shall be in the form of manufacturer's un-amended sales literature, unconditional statements of specification and compliance issued by the manufacturer, samples, independent test data etc., as appropriate. A statement that is not supported by evidence or is subsequently found to be contradicted by the evidence presented will render the Bid under evaluation liable for rejection. A statement either in the Bidders statement of compliance or the supporting evidence that is found to be false either during Bid evaluation, post-qualification or the execution of the Contract may be regarded as fraudulent and render the Bidder or supplier liable for prosecution subject to the provisions of **ITB** Clause 3.1(a)(ii) and/or **GCC** Clause 2.1(a)(ii).

TECHNICAL SPECIFICATIONS

PURCHASER'S SPECIFICATION							SUPPLIER'S SPECIFICATION
NO.	ARTICLES & DESCRIPTION		QTY	UNIT	UNIT COST PHP	ABC PHP	*(to include manufacturer's name , brand, dosage strength, country of origin & packaging)*
1	ACETAZOLAMIDE 250 MG TABLET	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	500	TABLET	26.00	13,000.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
2	ACETYLCYSTEINE 200 MG SACHET	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	8,000	SACHET	12.05	96,400.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
3	ACETYLCYSTEINE 200 MG/ML, 10 ML AMPULE	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	30	AMPULE	548.24	16,447.20	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
4	ACETYLCYSTEINE 200MG/ML, 25ML BOTTLE	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	20	BOTTLE	1,699.50	33,990.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
5	ACETYLCYSTEINE 600 MG EFFERVESCENT TABLET	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	5,000	TABLET	36.15	180,750.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
6	ACICLOVIR 400 MG TABLET	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	200	TABLET	20.07	4,014.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
7	ACTIVATED CHARCOAL	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	1,000	GRAMS	5.00	5,000.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
8	ADENOSINE 3MG/ML VIAL	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	20	VIAL	757.95	15,159.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____

PURCHASER'S SPECIFICATION							SUPPLIER'S SPECIFICATION
NO.	ARTICLES & DESCRIPTION		QTY	UNIT	UNIT COST PHP	ABC PHP	*(to include manufacturer's name , brand, dosage strength, country of origin & packaging)*
9	ALBENDAZOLE 200MG/5ML BOTTLE	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	20	BOTTLE	200.00	4,000.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
10	ALBENDAZOLE 400 MG CHEWABLE TABLET	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	200	TABLET	1.34	268.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
11	ALBUMIN, HUMAN 20%,50 ML BOTTLE	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	300	BOTTLE	2,775.85	832,755.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
12	ALBUMIN, HUMAN 20%, 100 ML BOTTLE	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	50	BOTTLE	3,700.00	185,000.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
13	ALLOPURINOL 100 MG TABLET	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	1,000	TABLET	0.90	900.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
14	ALLOPURINOL 300 MG TABLET	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	200	TABLET	2.11	422.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
15	AMIKACIN SULFATE 125MG/ML,2ML VIAL	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	6,000	VIAL	23.82	142,920.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
16	AMIKACIN SULFATE 250MG/ML,2ML VIAL	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	4,000	VIAL	29.81	119,240.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
17	AMIKACIN SULFATE 50MG/ML,2ML VIAL	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	3,000	VIAL	34.40	103,200.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____

PURCHASER'S SPECIFICATION							SUPPLIER'S SPECIFICATION
NO.	ARTICLES & DESCRIPTION		QTY	UNIT	UNIT COST PHP	ABC PHP	*(to include manufacturer's name , brand, dosage strength, country of origin & packaging)*
18	AMINOPHYLLINE 25MG/ML, 10ML AMPULE	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	1,500	AMPULE	23.15	34,725.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
19	AMINOSTERILE 6% VIAL	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	1,000	VIAL	385.00	385,000.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
20	AMIODARONE 200 MG TABLET	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	3,000	TABLET	24.87	74,610.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
21	AMIODARONE 50MG/ML,3ML AMPULE	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	500	AMPULE	307.97	153,985.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
22	AMOXICILLIN 100MG/ML, 15 ML DROPS	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	200	BOTTLE	36.99	7,398.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
23	AMOXICILLIN 250 MG/5ML BOTTLE,60 ML	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	200	BOTTLE	21.09	4,218.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
24	AMOXICILLIN 500 MG CAPSULE	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	8,000	CAPSULE	1.73	13,840.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
25	AMPHOTHERICIN B NON LIPID COMPLEX 50MG VIAL	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	100	VIAL	3,022.80	302,280.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
26	AMPICILLIN + SULBACTAM 1.5GM VIAL	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	6,000	VIAL	159.86	959,160.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____

PURCHASER'S SPECIFICATION							SUPPLIER'S SPECIFICATION
NO.	ARTICLES & DESCRIPTION		QTY	UNIT	UNIT COST PHP	ABC PHP	*(to include manufacturer's name , brand, dosage strength, country of origin & packaging)*
27	AMPICILLIN + SULBACTAM 750MG VIAL	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	6,000	VIAL	39.75	238,500.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
28	AMPICILLIN 1 GM (AS SODIUM SALT) VIAL	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	10,000	VIAL	14.04	140,400.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
29	AMPICILLIN 250 MG (AS SODIUM SALT) VIAL	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	20,000	VIAL	9.13	182,600.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
30	AMPICILLIN 500 MG (AS SODIUM SALT) VIAL	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	4,000	VIAL	8.45	33,800.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
31	ANTI RABIES SERUM(EQUINE) 200IU/ML,5ML IMMUNOGLOBULIN	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	1,000	VIAL	1,183.92	1,183,920.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
32	ANTI TETANUS SERUM (ATS)(EQUINE) 1,500 IU/ML, 1ML AMPULE	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	10,000	AMPULE	73.93	739,300.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
33	ASCORBIC ACID 500 MG TABLET	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	5,000	TABLET	0.87	4,350.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
34	ASCORBIC ACID 100 MG/5ML, 120 ML BOTTLE	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	200	BOTTLE	33.35	6,670.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
35	ASCORBIC ACID 100 MG/ML,15 ML BOTTLE	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	100	BOTTLE	18.38	1,838.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____

PURCHASER'S SPECIFICATION							SUPPLIER'S SPECIFICATION
NO.	ARTICLES & DESCRIPTION		QTY	UNIT	UNIT COST PHP	ABC PHP	*(to include manufacturer's name , brand, dosage strength, country of origin & packaging)*
36	ASCORBIC ACID 250MG/5ML,2 ML AMPULE	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	100	AMPULE	29.46	2,946.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
37	ASPIRIN 80MG TABLET	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	10,000	TABLET	1.20	12,000.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
38	ATENOLOL 100 MG TABLET	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	200	TABLET	7.12	1,424.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
39	ATENOLOL 50 MG TABLET	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	1,000	TABLET	2.65	2,650.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
40	ATRACURIUM 10MG/ML AMP	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	3,000	AMPULE	119.17	357,510.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
41	ATROPINE EYEDROP 1% 5 ML	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	200	BOTTLE	283.00	56,600.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
42	ATROPINE SULFATE 1MG/ML AMP	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	4,000	AMPULE	8.45	33,800.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
43	AZITHROMYCIN 200MG/5ML SYRUP, 30 ML	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	20	BOTTLE	215.63	4,312.60	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
44	AZITHROMYCIN 500 MG(DIHYDRATE) TABLET	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	10,000	TABLET	50.52	505,200.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____

PURCHASER'S SPECIFICATION							SUPPLIER'S SPECIFICATION
NO.	ARTICLES & DESCRIPTION		QTY	UNIT	UNIT COST PHP	ABC PHP	*(to include manufacturer's name , brand, dosage strength, country of origin & packaging)*
45	AZITHROMYCIN 500 MG(DIHYDRATE)(AS BAS/*DIHYDRATE) VIAL	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	700	VIAL	858.51	600,957.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
46	BACLOFEN 10 MG TABLET	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	2,000	TABLET	22.10	44,200.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
47	BARIUM SULFATE POWDER,USP GRADE SUSPENSION IN WATER 454 G, PACK	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	300	PACK	520.00	156,000.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
48	BERACTANT 25MG/ML, 4ML, SUSPENSION	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	10	VIAL	11,413.75	114,137.50	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
49	BETAHISTINE 16 MG TABLET	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	5,000	TABLET	32.50	162,500.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
50	BETAHISTINE 24 MG TABLET	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	4,000	TABLET	61.43	245,720.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
51	BETAHISTINE 8 MG TABLET	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	1,000	TABLET	18.75	18,750.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
52	BETAMETASONE DIPROPIONATE 0.05% CREAM 5 G TUBE	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	100	TUBE	51.64	5,164.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
53	BIPERIDEN 2 MG(AS HYDROCHLORIDE TABLET	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	1,000	TABLET	5.21	5,210.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____

PURCHASER'S SPECIFICATION							SUPPLIER'S SPECIFICATION
NO.	ARTICLES & DESCRIPTION		QTY	UNIT	UNIT COST PHP	ABC PHP	*(to include manufacturer's name , brand, dosage strength, country of origin & packaging)*
54	BIPHASIC ISOPAHNE HUMAN INSULIN 70/30, 10 ML VIAL	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	700	VIAL	229.65	160,755.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
55	BISACODYL 5 MG SUPPOSITORY	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	1,000	SUPPOSITORY	33.02	33,020.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
56	BISACODYL 10 MG SUPPOSITORY	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	2,000	SUPPOSITORY	28.34	56,680.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
57	BISACODYL 5 MG TABLET	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	3,000	TABLET	1.99	5,970.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
58	BLEOMYCIN 15MG,POWDER VIAL	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	50	VIAL	1,947.00	97,350.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
59	BUDESONIDE 250 MCG/ML,2ML NEBULE	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	7,000	NEBULE	24.39	170,730.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
60	BUDESONIDE+FORMETEROL 160MCG BUDESONIDE+4.5MCG FORMOTEROL DPI 120 DOSES	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	200	DPI	1,033.79	206,758.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
61	BUMETANIDE 1 MG TABLET	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	1,000	TABLET	28.85	28,850.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
62	BUMETANIDE 500 MCG/ML,1 ML AMPULE	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	100	AMPULE	531.96	53,196.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____

PURCHASER'S SPECIFICATION							SUPPLIER'S SPECIFICATION
NO.	ARTICLES & DESCRIPTION		QTY	UNIT	UNIT COST PHP	ABC PHP	*(to include manufacturer's name , brand, dosage strength, country of origin & packaging)*
63	BUPIVACAINE 0.5% ,5MG/ML,10 ML	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	4,000	AMPULE/VIAL	174.07	696,280.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
64	BUPIVACAINE HCL 0.5% ,4ML SPINAL WITH 8% DEXTROSE AS HCL	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	3,000	AMPULE	236.20	708,600.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
65	BUTAMIRATE 50 MG MR(CITRATE) TABLET	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	1,000	TABLET	17.94	17,940.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
66	BUTORPHANOL AS TARTRATE 2MG/ML, 1 ML VIAL	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	1,500	VIAL	567.07	850,605.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
67	CALAMINE,PLAIN 8%,60 ML LOTION BOTTLE	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	200	BOTTLE	38.83	7,766.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
68	CALCIUM CARBONATE 500 MG TABLET	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	5,000	TABLET	4.02	20,100.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
69	CALCIUM CARBONATE 600 MG TABLET	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	5,000	TABLET	5.20	26,000.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
70	CALCIUM GLUCONATE 10 %,10ML VIAL	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	4,000	VIAL	19.94	79,760.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
71	CALCIUM FOLINATE 50 MG POWDER VIAL	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	30	VIAL	7,163.75	214,912.50	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____

PURCHASER'S SPECIFICATION							SUPPLIER'S SPECIFICATION
NO.	ARTICLES & DESCRIPTION		QTY	UNIT	UNIT COST PHP	ABC PHP	*(to include manufacturer's name , brand, dosage strength, country of origin & packaging)*
72	CAPECITABINE 150 MG TABLET	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	2,000	TABLET	65.00	130,000.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
73	CAPECITABINE 500 MG TABLET	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	1,000	TABLET	118.37	118,370.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
74	CAPTOPRIL 25 MG TABLET	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	6,000	TABLET	0.78	4,680.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
75	CAPTOPRIL 50 MG TABLET	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	200	TABLET	3.64	728.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
76	CARBAMAZEPINE 100MG/5ML, 120 ML SYRUP	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	200	BOTTLE	564.59	112,918.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
77	CARBAMAZEPINE 200 MG TABLET	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	500	TABLET	2.26	1,130.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
78	CARBOPLATIN 150 MG,45ML VIAL	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	100	VIAL	1,220.01	122,001.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
79	CARBOPLATIN 450 MG,45 ML VIAL	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	200	VIAL	2,925.41	585,082.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
80	CARBOPROST 125MCG/0.5ML AMP	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	700	AMPULE	780.00	546,000.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____

PURCHASER'S SPECIFICATION							SUPPLIER'S SPECIFICATION
NO.	ARTICLES & DESCRIPTION		QTY	UNIT	UNIT COST PHP	ABC PHP	*(to include manufacturer's name , brand, dosage strength, country of origin & packaging)*
81	CARBOPROST 250 MCG/ML,	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	200	AMPULE	1,040.00	208,000.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
82	CARVEDILOL 25 MG TABLET	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	1,000	TABLET	6.19	6,190.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
83	CARVEDILOL 6.25 MG TABLET	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	6,000	TABLET	2.51	15,060.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
84	CASTOR OIL,USP GRADE BOTTLE	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	500	BOTTLE	45.50	22,750.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
85	CEFALEXIN 100MG/5ML BOTTLE,10 ML	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	50	BOTTLE	20.81	1,040.50	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
86	CEFALEXIN 125MG/5ML BOTTLE,30 ML	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	50	BOTTLE	19.99	999.50	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
87	CEFALEXIN 250 MG/5ML BOTTLE, 60ML	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	50	BOTTLE	29.91	1,495.50	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
88	CEFALEXIN 500 MG CAPSULE	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	6,000	CAPSULE	2.81	16,860.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
89	CEFAZOLIN 1G VIAL	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	3,000	VIAL	23.06	69,180.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____

PURCHASER'S SPECIFICATION							SUPPLIER'S SPECIFICATION
NO.	ARTICLES & DESCRIPTION		QTY	UNIT	UNIT COST PHP	ABC PHP	*(to include manufacturer's name , brand, dosage strength, country of origin & packaging)*
90	CEFEPIME 1 GM VIAL	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	2,000	VIAL	209.56	419,120.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
91	CEFEPIME 500 MG VIAL	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	2,000	VIAL	200.30	400,600.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
92	CEFIXIME 100MG/5ML BOTTLE, 60 ML SUSPENSION	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	20	BOTTLE	254.41	5,088.20	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
93	CEFIXIME 200 MG CAPSULE	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	3,000	CAPSULE	18.75	56,250.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
94	CEFIXIME 20MG/ML BOTTLE, 10 ML DROPS	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	50	BOTTLE	200.85	10,042.50	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
95	CEFOTAXIME 250MG+2ML DILUENT (IM/IV) VIAL	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	1,000	VIAL	64.66	64,660.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
96	CEFOTAXIME 500 MG+2ML DILUENT (IM/IV) VIAL	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	2,000	VIAL	46.14	92,280.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
97	CEFOXITIN 1G VIAL	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	12,000	VIAL	354.02	4,248,240.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
98	CEFTAZIDIME 500 MG (PENTAHYDRATE) VIAL	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	5,000	VIAL	74.24	371,200.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____

PURCHASER'S SPECIFICATION							SUPPLIER'S SPECIFICATION
NO.	ARTICLES & DESCRIPTION		QTY	UNIT	UNIT COST PHP	ABC PHP	*(to include manufacturer's name , brand, dosage strength, country of origin & packaging)*
99	CEFTAZIDIME 1 GM (AS PENTAHYDRATE) VIAL	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	10,000	VIAL	51.75	517,500.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
100	CEFTRIAXONE 1G VIAL+10 ML DILUENT SOLUTION	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	15,000	VIAL	26.30	394,500.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
101	CEFTRIAXONE 250 MG VIAL+5ML DILUENT	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	3,000	VIAL	26.00	78,000.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
102	CEFUROXIME 125MG/5ML BOTTLE, 70 ML	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	300	BOTTLE	230.98	69,294.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
103	CEFUROXIME 250MG/5ML BOTTLE, 70 ML	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	400	BOTTLE	300.27	120,108.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
104	CEFUROXIME 500MG TABLET	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	15,000	TABLET	12.00	180,000.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
105	CEFUROXIME 250 MG (IM/IV) VIAL	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	1,000	VIAL	73.65	73,650.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
106	CEFUROXIME 750 MG VIAL	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	10,000	VIAL	24.10	241,000.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
107	CELECOXIB 200 MG CAPSULE	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	10,000	CAPSULE	8.03	80,300.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____

PURCHASER'S SPECIFICATION							SUPPLIER'S SPECIFICATION
NO.	ARTICLES & DESCRIPTION		QTY	UNIT	UNIT COST PHP	ABC PHP	*(to include manufacturer's name , brand, dosage strength, country of origin & packaging)*
108	CELECOXIB 400 MG CAPSULE	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	5,000	CAPSULE	22.76	113,800.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
109	CETIRIZINE 10 MG TABLET	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	4,000	TABLET	0.64	2,560.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
110	CETIRIZINE 10MG/ML DROPS	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	100	BOTTLE	167.38	16,738.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
111	CETIRIZINE 5MG/5ML SYRUP, 60 ML	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	100	BOTTLE	100.43	10,043.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
112	CHLORAMPHENICOL 1 GM VIAL	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	200	VIAL	28.77	5,754.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
113	CHLORAMPHENICOL 500 MG CAPSULE	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	500	CAPSULE	2.68	1,340.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
114	CHLORHEXEDINE 0.12% SOLUTION, 120 ML BOTTLE	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	500	BOTTLE	110.00	55,000.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
115	CILOSTAZOL 100 MG TABLET	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	500	TABLET	12.86	6,430.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
116	CILOSTAZOL 50 MG TABLET	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	500	TABLET	9.28	4,640.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____

PURCHASER'S SPECIFICATION							SUPPLIER'S SPECIFICATION
NO.	ARTICLES & DESCRIPTION		QTY	UNIT	UNIT COST PHP	ABC PHP	*(to include manufacturer's name , brand, dosage strength, country of origin & packaging)*
117	CINNARIZINE 25 MG CAP	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	4,000	CAPSULE	1.50	6,000.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
118	CIPROFLOXACIN 2MG/ML,100 ML VIAL	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	5,000	VIAL	26.94	134,700.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
119	CIPROFLOXACIN 500 MG TABLET	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	10,000	TABLET	1.78	17,800.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
120	CISPLATIN 1MG/ML, 50MLVIAL	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	100	VIAL	588.50	58,850.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
121	CLARITHROMYCIN 125MG/5ML BOTTLE,50 ML GRANULES	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	200	BOTTLE	187.46	37,492.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
122	CLARITHROMYCIN 250MG/5ML BOTTLE, 70 ML	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	300	BOTTLE	649.42	194,826.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
123	CLARITHROMYCIN 500 MG TABLET	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	3,000	TABLET	14.44	43,320.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
124	CLINDAMYCIN 150MG/ML 4ML AMPULE	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	5,000	AMPULE	150.63	753,150.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
125	CLINDAMYCIN 150MG/ML, 2ML AMPULE	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	8,000	AMPULE	154.26	1,234,080.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____

PURCHASER'S SPECIFICATION							SUPPLIER'S SPECIFICATION
NO.	ARTICLES & DESCRIPTION		QTY	UNIT	UNIT COST PHP	ABC PHP	*(to include manufacturer's name , brand, dosage strength, country of origin & packaging)*
126	CLINDAMYCIN 300 MG (AS HYDROCCHLORIDE) CAPSULE	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	10,000	CAPSULE	3.61	36,100.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
127	CLINDAMYCIN 75MG/5ML 60ML	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	100	BOTTLE	266.97	26,697.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
128	CLOBETASOL 0.05% 10 GMS(AS PROPIONATE(CREAM) 15 GM	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	100	OINTMENT/CREAM	156.00	15,600.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
129	CLONAZEPAM 2 MG TABLET	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	1,000	TABLET	10.31	10,310.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
130	CLONIDINE 150 MCG TABLET	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	100	TABLET	20.09	2,009.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
131	CLONIDINE 150 MCG/ML, 2 ML AMPULE	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	100	AMPULE	142.64	14,264.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
132	CLONIDINE 75 MCG TABLET	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	10,000	TABLET	19.68	196,800.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
133	CLOPIDOGREL 75 MG TABLET	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	15,000	TABLET	3.73	55,950.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
134	CLOXACILLIN 125MG/5ML BOTTLE, 60ML	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	200	BOTTLE	26.78	5,356.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____

PURCHASER'S SPECIFICATION							SUPPLIER'S SPECIFICATION
NO.	ARTICLES & DESCRIPTION		QTY	UNIT	UNIT COST PHP	ABC PHP	*(to include manufacturer's name , brand, dosage strength, country of origin & packaging)*
135	CLOXACILLIN 250MG/5ML BOTTLE, 60 ML SUSPENSION	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	200	BOTTLE	46.87	9,374.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
136	CLOXACILLIN 500 MG CAPSULE	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	15,000	CAPSULE	3.52	52,800.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
137	CO TRIMOXAZOLE 400 MG SMX +80MG TRIMETHORPIN,5ML AMPULE	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	50	AMPULE	221.00	11,050.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
138	CO TRIMOXAZOLE 400 MG SMX+80 MG TRIMETHORPIN PER TABLET	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	1,000	TABLET	1.03	1,030.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
139	CO TRIMOXAZOLE 800 MG SMX+160 MG TRIMETHORPIN PER TABLET	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	1,000	TABLET	1.55	1,550.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
140	CO AMOXICLAV 1 GM TABLET	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	3,000	TABLET	24.75	74,250.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
141	CO-AMOXICLAV 200MG+28.5MG/5ML BOTTLE, 70 ML	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	200	BOTTLE	208.23	41,646.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
142	CO-AMOXICLAV 4000MG+57MG/5ML BOTTLE,70 ML	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	200	BOTTLE	314.39	62,878.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
143	CO-AMOXICLAV 625MG TAB	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	20,000	TABLET	11.83	236,600.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____

PURCHASER'S SPECIFICATION							SUPPLIER'S SPECIFICATION
NO.	ARTICLES & DESCRIPTION		QTY	UNIT	UNIT COST PHP	ABC PHP	*(to include manufacturer's name , brand, dosage strength, country of origin & packaging)*
144	COBRA ANTIVENIN 800 MU/4.8ML,1ML AMPULE	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	10	AMPULE	2,750.00	27,500.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
145	COLCHICINE 500 MCG TABLET	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	5,000	TABLET	3.48	17,400.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
146	COLISTIN 2,000,000 IU LYOPHILIZED POWDER FOR INJECTION VIAL	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	50	VIAL	2,100.00	105,000.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
147	COMBINED AMINO ACIDS+SORBITOL 500 ML BOTTLE	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	300	BOTTLE	939.98	281,994.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
148	COMBINED GLUCOSE+AMINO ACIDS SOLUTION 500 ML BOTTLE	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	100	BOTTLE	900.00	90,000.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
149	CYCLOPHOSPHAMIDE 500 MG VIAL	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	500	VIAL	301.28	150,640.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
150	CYTARABINE 100MG VIAL	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	100	VIAL	136.45	13,645.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
151	DACTINOMYCIN 500 MCG VIAL	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	100	VIAL	455.00	45,500.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
152	DANTROLENE SODIUM 20MG(W/ MANNITOL 3G)/ VIAL (FOR RECONSTITUTION 60ML STERILE WATER FOR INJECTION)	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	5	VIAL	20,000.00	100,000.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____

PURCHASER'S SPECIFICATION							SUPPLIER'S SPECIFICATION
NO.	ARTICLES & DESCRIPTION		QTY	UNIT	UNIT COST PHP	ABC PHP	*(to include manufacturer's name , brand, dosage strength, country of origin & packaging)*
153	DEXAMETHASONE 4 MG TABLET	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	5,000	TABLET	22.92	114,600.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
154	DEXAMETHASONE 4MG/ML,1 ML(IM,IV) AMPULE	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	5,000	AMPULE	73.65	368,250.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
155	DEXTROSE 50 % 50 cc VIAL	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	5,000	VIAL	34.15	170,750.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
156	DIAZEPAM 5 MG TABLET	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	200	TABLET	9.36	1,872.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
157	DIAZEPAM 5MG/ML, 2 ML AMPULE	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	10,000	AMPULE	83.01	830,100.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
158	DICLOFENAC 25MG/ML, 3 ML AMPULE	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	100	AMPULE	40.57	4,057.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
159	DICLOFENAC 50 MG TABLET	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	200	TABLET	1.05	210.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
160	DIGOXIN 250MCG TABLET	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	6,000	TABLET	5.90	35,400.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
161	DIGOXIN 250MCG/ML , 2ML AMPULE	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	3,000	AMPULE	191.48	574,440.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____

PURCHASER'S SPECIFICATION							SUPPLIER'S SPECIFICATION
NO.	ARTICLES & DESCRIPTION		QTY	UNIT	UNIT COST PHP	ABC PHP	*(to include manufacturer's name , brand, dosage strength, country of origin & packaging)*
162	DILTIAZEM HCL 60 MG TABLET	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	100	TABLET	41.28	4,128.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
163	DIPHENHYDRAMINE 12.5MG/5ML SYRUP, 60 ML	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	100	BOTTLE	23.50	2,350.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
164	DIPHENHYDRAMINE 50 MG CAPSULE	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	5,000	CAPSULE	1.21	6,050.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
165	DIPHENHYDRAMINE 50MG/ML,1ML AMPULE	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	5,000	AMPULE	51.53	257,650.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
166	DOBUTAMINE 2MG/ML,250ML D5WATER PREMIXED	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	200	BOTTLE	976.13	195,226.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
167	DOBUTAMINE 50 MG/ML,5 ML AMPULE	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	2,000	AMPULE	253.92	507,840.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
168	DOCETAXEL 20MG/0.5ML, 0.5ML VIAL	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	200	VIAL	2,130.04	426,008.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
169	DOCETAXEL 40MG/ML,2ML VIAL	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	200	VIAL	8,928.04	1,785,608.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
170	DOMPERIDONE 10 MG TABLET	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	1,500	TABLET	4.00	6,000.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____

PURCHASER'S SPECIFICATION							SUPPLIER'S SPECIFICATION
NO.	ARTICLES & DESCRIPTION		QTY	UNIT	UNIT COST PHP	ABC PHP	*(to include manufacturer's name , brand, dosage strength, country of origin & packaging)*
171	DOMPERIDONE 1MG/ML, 60 ML SUSPENSION	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	100	BOTTLE	194.16	19,416.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
172	DOPAMINE 40MG/ML,5ML	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	4,000	AMPULE/VIAL	60.01	240,040.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
173	DOPAMINE 800MCG/ML, 250ML D5W(PRE MIXEd) (IV)	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	1,000	BOTTLE	320.48	320,480.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
174	DOXORUBICIN 50 MG VIAL	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	200	VIAL	921.23	184,246.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
175	DOXORUBICN 10 MG VIAL	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	200	VIAL	211.90	42,380.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
176	DOXYCYCLINE 100 MG CAP	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	2,000	CAPSULE	1.27	2,540.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
177	DYDROGESTERONE 10MG TAB	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	1,000	TABLET	56.24	56,240.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
178	ENALAPRIL 20 MG TABLET	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	2,000	TABLET	12.56	25,120.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
179	ENALAPRIL 5MG TABLET	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	3,000	TABLET	5.02	15,060.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____

PURCHASER'S SPECIFICATION							SUPPLIER'S SPECIFICATION
NO.	ARTICLES & DESCRIPTION		QTY	UNIT	UNIT COST PHP	ABC PHP	*(to include manufacturer's name , brand, dosage strength, country of origin & packaging)*
180	ENOXAPARIN 100MG/ML, 0.4 cc PREFILLED SYRINGE	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	3,000	PREFILLED SYRINGE	317.34	952,020.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
181	EPHEDRINE SULFATE 50MG/ML, 1ML AMP	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	6,000	AMPULE	80.34	482,040.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
182	EPINEPHRINE 1 MG/ML, 1ML AMP	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	25,000	AMPULE	54.50	1,362,500.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
183	EPOETIN ALFA 4000 IU/ 1ML SOLUTION FOR INJECTION(IV/SC) PREFILLED SYRINGE GLASS	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	8,000	PREFILLED SYRINGE	633.35	5,066,800.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
184	EPOETIN BETA 5000 IU/0.3ML, PRE FILLED SYRINGE WITH NEEDLE (IV,SC)	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	200	PREFILLED SYRINGE	1,272.18	254,436.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
185	ERTAPENEM (AS SODIUM) 1 GM VIAL	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	30	VIAL	2,562.87	76,886.10	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
186	ERYTHROMYCIN 200MG/5ML GRANULES/POWDER SUSPENSION,50ML	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	50	BOTTLE	57.24	2,862.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
187	ERYTHROMYCIN 400MG/5ML GRANULE/POWDER/DROPS,60ML	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	50	BOTTLE	74.41	3,720.50	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
188	ERYTHROMYCIN 0.5% EYE OINTMENT 5 GM TUBE	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	1,000	TUBE	206.21	206,210.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____

PURCHASER'S SPECIFICATION							SUPPLIER'S SPECIFICATION
NO.	ARTICLES & DESCRIPTION		QTY	UNIT	UNIT COST PHP	ABC PHP	*(to include manufacturer's name , brand, dosage strength, country of origin & packaging)*
189	ESMOLOL 100 mg/mL, 10 mL vial (IV)	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	50	VIAL	800.00	40,000.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
190	ETHAMBUTOL 400 MG TABLET	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	1,000	TABLET	9.56	9,560.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
191	ETOPOSIDE 20MG/ML,5ML AMPULE/VIAL	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	50	AMPULE/VIAL	429.00	21,450.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
192	FAMOTIDINE 10 MG/ML,2ML AMPULE	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	4,000	AMPULE	131.11	524,440.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
193	FAMOTIDINE 20 MG TABLET	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	2,000	TABLET	32.08	64,160.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
194	FELODIPINE 10MG TABLET	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	1,000	TABLET	19.15	19,150.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
195	FELODIPINE 5 MG TABLET	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	500	TABLET	10.05	5,025.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
196	FENOFIBRATE 160 MG TABLET	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	4,000	TABLET	34.81	139,240.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
197	FENOFIBRATE 200 MG CAPSULE	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	5,000	CAPSULE	18.51	92,550.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____

PURCHASER'S SPECIFICATION							SUPPLIER'S SPECIFICATION
NO.	ARTICLES & DESCRIPTION		QTY	UNIT	UNIT COST PHP	ABC PHP	*(to include manufacturer's name , brand, dosage strength, country of origin & packaging)*
198	FENTANYL 50MCG/2ML AMPULE	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	5,000	AMPULE	91.05	455,250.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
199	FERROUS SALT+FOLIC ACID(60 MG ELEMENTAL IRON+400 MICROGRAM FOLIC ACID) TABLET	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	6,000	TABLET	0.96	5,760.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
200	FERROUS SULFATE 60 MG ELEMENTAL IRON TABLET	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	5,000	TABLET	4.02	20,100.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
201	FERROUS SULFATE 15MG/0.6ML,15 ML DROPS	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	200	BOTTLE	24.10	4,820.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
202	FERROUS SULFATE 30MG/5ML,60 ML SYRUP	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	200	BOTTLE	28.08	5,616.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
203	FILGRASTIM 300MG/ML VIAL	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	100	VIAL	1,642.85	164,285.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
204	FLUCONAZOLE 150MG TABLET	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	1,500	TABLET	122.60	183,900.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
205	FLUCONAZOLE 50 MG TABLET	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	1,000	TABLET	115.65	115,650.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
206	FLUCONAZOLE 2MG/ML,100 ML VIAL	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	500	VIAL	522.20	261,100.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____

PURCHASER'S SPECIFICATION							SUPPLIER'S SPECIFICATION
NO.	ARTICLES & DESCRIPTION		QTY	UNIT	UNIT COST PHP	ABC PHP	*(to include manufacturer's name , brand, dosage strength, country of origin & packaging)*
207	FLUOROURACIL 50MG/ML , 10 ML VIAL	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	1,000	VIAL	107.12	107,120.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
208	FLUTICASONE 125+ SALMETEROL 25MCG 120 DOSES MDI	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	200	MDI	366.42	73,284.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
209	FLUTICASONE 250+SALMETEROL 25MCG 120 DOSES MDI	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	300	MDI	534.26	160,278.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
210	FLUTICASONE 50 MCG+SALMETEROL 25MCG 120 DOSES MDI	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	100	MDI	261.11	26,111.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
211	FLUTICASONE+SALMETEROL 250MCG+50MCG 60 DOSES DPI	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	300	DPI	851.07	255,321.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
212	FLUTICASONE+SALMETEROL 500MCG+50MCG 60 DOSES DPI	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	300	DPI	1,272.50	381,750.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
213	FOLIC ACID 5 MG TABLET	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	1,000	TABLET	3.08	3,080.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
214	FUROSEMIDE 10 MG/ML , 2ML AMPULE	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	30,000	AMPULE	6.70	201,000.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
215	FUROSEMIDE 20 MG TABLET	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	5,000	TABLET	1.40	7,000.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____

PURCHASER'S SPECIFICATION							SUPPLIER'S SPECIFICATION
NO.	ARTICLES & DESCRIPTION		QTY	UNIT	UNIT COST PHP	ABC PHP	*(to include manufacturer's name , brand, dosage strength, country of origin & packaging)*
216	FUROSEMIDE 40 MG TABLET	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	5,000	TABLET	2.08	10,400.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
217	FUSIDATE SODIUM/FUSIDIC ACID 2%,15 G OINTMENT TUBE	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	500	TUBE	143.27	71,635.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
218	GABAPENTIN 100 MG CAPSULE	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	100	CAPSULE	13.39	1,339.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
219	GABAPENTIN 300 MG CAPSULE	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	100	CAPSULE	15.41	1,541.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
220	GADOBUTROL 1.0 MMOL/ML PREFILLED SYRINGE	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	200	PREFILLED SYRINGE	2,000.00	400,000.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
221	GENTAMICIN 40 MG/ML ,2 ML (IM/IV)	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	20,000	AMPULE	4.41	88,200.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
222	GLICLAZIDE 30MG/MR TABLET	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	500	TABLET	3.61	1,805.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
223	GLICLAZIDE 80 MG TABLET	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	2,000	TABLET	4.02	8,040.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
224	GLYCEROL 2 GM SUPPOSITORY(RECTAL) SUPPOSITORY	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	500	SUPPOSITOR Y	10.00	5,000.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____

PURCHASER'S SPECIFICATION							SUPPLIER'S SPECIFICATION
NO.	ARTICLES & DESCRIPTION		QTY	UNIT	UNIT COST PHP	ABC PHP	*(to include manufacturer's name , brand, dosage strength, country of origin & packaging)*
225	GLYCERYL TRINITRATE(NITROGLYCERIN) 1MG/ML,10 ML AMPULE	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	200	AMPULE	507.00	101,400.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
226	HALOPERIDOL 5 MG TABLET	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	100	TABLET	3.78	378.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
227	HALOPERIDOL 5 MG/ML ,1 ML AMPULE	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	50	AMPULE	158.27	7,913.50	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
228	HEPATITIS B 10 MCG/0.5 ML VACCINE VIAL	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	100	VIAL	227.63	22,763.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
229	HEPATITIS B 20 MCG/ ML,1 ML VACCINE VIAL	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	100	VIAL	286.55	28,655.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
230	HYDRALAZINE 20 MG/ML , 1ML AMP	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	1,500	AMPULE	219.93	329,895.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
231	HYDRALAZINE 25 MG TABLET	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	500	TABLET	25.20	12,600.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
232	HYDROCORTISONE 100 MG (AS SODIUM SUCCINATE) VIAL	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	6,000	VIAL	29.32	175,920.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
233	HYDROCORTISONE 250 MG (AS SODIUM SUCCINATE) VIAL	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	2,500	VIAL	86.75	216,875.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____

PURCHASER'S SPECIFICATION							SUPPLIER'S SPECIFICATION
NO.	ARTICLES & DESCRIPTION		QTY	UNIT	UNIT COST PHP	ABC PHP	*(to include manufacturer's name , brand, dosage strength, country of origin & packaging)*
234	HYDROXYETHYL STARCH 6 % , 500 ML BOTTLE	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	500	BOTTLE	642.06	321,030.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
235	HYOSCINE 10 MG (AS N-BUTYL BROMIDE) TABLET	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	5,000	TABLET	2.47	12,350.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
236	HYOSCINE 20 MG/ML , 1 ML (AS N-BUTYL BROMIDE) AMPULE	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	10,000	AMPULE	15.11	151,100.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
237	IBUPROFEN 100 MG/5ML SYRUP ,60ML	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	200	BOTTLE	45.50	9,100.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
238	IBUPROFEN 400 MG	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	2,000	TABLET	1.25	2,500.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
239	IFOSFAMIDE 2 GM VIAL	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	50	VIAL	2,634.23	131,711.50	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
240	IMMUNOGLOBULIN NORMAL,HUMAN 50 MG /ML,10 ML(IGIV) VIAL	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	50	VIAL	2,145.00	107,250.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
241	IMMUNOGLOBULIN NORMAL,HUMAN 50 MG /ML,50 ML(IGIV) VIAL	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	50	VIAL	7,804.10	390,205.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
242	INFLUENZA POLYVALENT VACCINE 0.5 ML+PREFILLED SYRINGE	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	500	AMPULE	468.65	234,325.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____

PURCHASER'S SPECIFICATION							SUPPLIER'S SPECIFICATION
NO.	ARTICLES & DESCRIPTION		QTY	UNIT	UNIT COST PHP	ABC PHP	*(to include manufacturer's name , brand, dosage strength, country of origin & packaging)*
243	INSULIN,REGULAR 100IU,10 ML VIAL	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	1,000	VIAL	281.19	281,190.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
244	INTRAOCULAR IRRIGATING SOLUTION 500 ML(BALANCED SALT SOLN	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	1,000	BOTTLE	508.82	508,820.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
245	IOPAMIDOL 612MG/ML EQUIV TO 300 MG IODINE,50ML	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	1,000	VIAL	935.96	935,960.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
246	IPRATROPIUM 500MCCG+SALBUTAMOL 2.5MG, 2.5ML	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	50,000	NEBULE	14.08	704,000.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
247	IRON SUCROSE 20MG/ML, 5 ML	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	300	AMPULE	181.35	54,405.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
248	ISOFLURANE 100ML BOTTLE	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	100	BOTTLE	2,877.82	287,782.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
249	ISONIAZID 200MG/ML BOTTLE,120 ml SYRUP	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	200	BOTTLE	96.34	19,268.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
250	ISONIAZID 400 MG TABLET	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	1,000	TABLET	3.00	3,000.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
251	ISOPHANE HUMAN INSULIN 100 IU/ML , 10 ML VIAL	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	1,000	VIAL	233.90	233,900.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____

PURCHASER'S SPECIFICATION							SUPPLIER'S SPECIFICATION
NO.	ARTICLES & DESCRIPTION		QTY	UNIT	UNIT COST PHP	ABC PHP	*(to include manufacturer's name , brand, dosage strength, country of origin & packaging)*
252	ISOSORBIDE 5 MONONITRATE 40 MG TABLET	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	3,000	TABLET	13.00	39,000.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
253	ISOSORBIDE 5 MONONITRATE 60 MG TABLET MR	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	2,000	TABLET	8.71	17,420.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
254	ISOSORBIDE DINITRATE 1 MG/ML,10 ML AMPULE	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	1,500	AMPULE	533.99	800,985.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
255	ISOSORBIDE DINITRATE 10 MG TABLET	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	3,000	TABLET	13.68	41,040.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
256	ISOSORBIDE DINITRATE 20 MG TABLET	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	4,000	TABLET	15.95	63,800.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
257	ISOSORBIDE DINITRATE 5 MG SUBLINGUAL TABLET	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	6,000	TABLET	11.31	67,860.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
258	ISOXSUPRINE HCL 5MG/ML,2 ML AMPULE	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	2,000	AMPULE	148.43	296,860.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
259	KETAMINE 50MG/ML,10 ML VIAL	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	300	VIAL	1,033.70	310,110.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
260	KETOROLAC 30 MG/ML, 1 ML AMPULE	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	15,000	AMPULE	31.19	467,850.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____

PURCHASER'S SPECIFICATION							SUPPLIER'S SPECIFICATION
NO.	ARTICLES & DESCRIPTION		QTY	UNIT	UNIT COST PHP	ABC PHP	*(to include manufacturer's name , brand, dosage strength, country of origin & packaging)*
261	LACTULOSE 3.3 G/5ML SYRUP, 120 ML BOTTLE	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	1,000	BOTTLE	86.89	86,890.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
262	LAGUNDI 300MG/5ML SYRUP, 60 ML BOTTLE	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	100	BOTTLE	80.34	8,034.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
263	LAGUNDI 600 MG TABLET	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	500	TABLET	4.02	2,010.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
264	LETROZOLE 2.5 MG TABLET	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	500	TABLET	137.80	68,900.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
265	LEVODOPA+CARBIDOPA 250 MG+25 MG TABLET	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	200	TABLET	59.71	11,942.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
266	LEVOFLOXACIN 500 MG TABLET	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	1,000	TABLET	10.63	10,630.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
267	LEVOFLOXACIN 5MG/ML, 100 ML VIAL	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	500	VIAL	334.75	167,375.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
268	LEVOFLOXACIN 750 MG TABLET	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	1,000	TABLET	23.95	23,950.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
269	LEVOTHYROXINE 100 MCG TABLET	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	1,000	TABLET	11.45	11,450.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____

PURCHASER'S SPECIFICATION							SUPPLIER'S SPECIFICATION
NO.	ARTICLES & DESCRIPTION		QTY	UNIT	UNIT COST PHP	ABC PHP	*(to include manufacturer's name , brand, dosage strength, country of origin & packaging)*
270	LEVOTHYROXINE 150 MCG TABLET	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	1,000	TABLET	14.07	14,070.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
271	LEVOTHYROXINE 50 MCG TABLET	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	1,000	TABLET	5.02	5,020.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
272	LIDOCAINE 10%, 50ML SPRAY BOTTLE	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	10	BOTTLE	2,210.20	22,102.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
273	LIDOCAINE 2% WITH EPINEPHRINE,1.8ML CAPSULE	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	10,000	CAPSULE	24.10	241,000.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
274	LIDOCAINE 2% 5 ML POLYAMPULE	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	20,000	POLYAMPULE	11.39	227,800.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
275	LIPIDS 10% 500 ML BOTTLE	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	300	BOTTLE	1,044.42	313,326.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
276	LOPERAMIDE 2 MG CAPSULE	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	2,000	CAPSULE	0.57	1,140.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
277	LORATADINE 10 MG TABLET	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	2,000	TABLET	2.95	5,900.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
278	LORATADINE 5MG/5ML SYRUP, 30 ML BOTTLE	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	100	BOTTLE	52.22	5,222.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____

PURCHASER'S SPECIFICATION							SUPPLIER'S SPECIFICATION
NO.	ARTICLES & DESCRIPTION		QTY	UNIT	UNIT COST PHP	ABC PHP	*(to include manufacturer's name , brand, dosage strength, country of origin & packaging)*
279	LOSARTAN 100 MG TABLET	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	2,000	TABLET	3.77	7,540.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
280	LOSARTAN+HYDROCHLOROTHIAZIDE 50MG+12.5 MG TABLET	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	2,000	TABLET	2.50	5,000.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
281	MAGNESIUM SULFATE 250 MG/ML, 10 ML AMPULE	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	4,000	AMPULE	19.79	79,160.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
282	MANNITOL 20% 500 ML BOTTLE	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	2,000	BOTTLE	119.82	239,640.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
283	MEBENDAZOLE 100MG/5ML SUSPENSION,60 ML	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	100	BOTTLE	19.02	1,902.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
284	MEBENDAZOLE 500 MG TABLET	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	1,000	TABLET	2.56	2,560.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
285	MEDROXYPROGESTERONE 150MG/ML,1 ML VIAL	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	100	VIAL	65.42	6,542.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
286	MEFENAMIC ACID 250 MG TABLET	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	2,000	TABLET	0.62	1,240.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
287	MEFENAMIC ACID 500 MG TABLET	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	10,000	TABLET	0.61	6,100.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____

PURCHASER'S SPECIFICATION							SUPPLIER'S SPECIFICATION
NO.	ARTICLES & DESCRIPTION		QTY	UNIT	UNIT COST PHP	ABC PHP	*(to include manufacturer's name , brand, dosage strength, country of origin & packaging)*
288	MERCAPTOPURINE 50 MG TABLET	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	1,000	TABLET	26.78	26,780.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
289	MEROPENEM 1 GM VIAL	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	5,000	VIAL	372.68	1,863,400.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
290	MEROPENEM 500 MG VIAL	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	5,000	VIAL	233.65	1,168,250.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
291	MESNA 100MG/ML, 4 ML AMPULE	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	100	AMPULE	214.24	21,424.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
292	METFORMIN HYDROCHLORIDE 850 MG TABLET	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	2,000	TABLET	9.32	18,640.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
293	METHOTREXATE 2.5 MG TABLET	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	1,000	TABLET	14.30	14,300.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
294	METHOTREXATE 25MG/ML, 2 ML VIAL	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	200	VIAL	173.56	34,712.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
295	METHYLDOPA 250 MG TABLET	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	5,000	TABLET	16.07	80,350.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
296	METHYLPREDNISOLONE 16 MG TABLET	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	2,000	TABLET	21.91	43,820.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____

PURCHASER'S SPECIFICATION							SUPPLIER'S SPECIFICATION
NO.	ARTICLES & DESCRIPTION		QTY	UNIT	UNIT COST PHP	ABC PHP	*(to include manufacturer's name , brand, dosage strength, country of origin & packaging)*
297	METHYLPREDNISOLONE 1GM/16ML+DILUENT POV	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	50	VIAL	3,152.72	157,636.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
298	METHYLPREDNISOLONE 4 MG TABLET	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	500	TABLET	8.63	4,315.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
299	METOCLOPRAMIDE 10 MG TABLET	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	2,000	TABLET	2.22	4,440.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
300	METOCLOPRAMIDE 5MG/ML,2 ML AMPULE	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	5,000	AMPULE	4.00	20,000.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
301	METOPROLOL 100 MG TABLET	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	1,000	TABLET	2.03	2,030.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
302	METOPROLOL 50 MG TABLET	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	1,000	TABLET	2.02	2,020.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
303	METRONIDAZOLE 125MG/5MLSUSPENSION, 60 ML BOTTLE	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	200	BOTTLE	19.75	3,950.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
304	METRONIDAZOLE 500 MG TABLET	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	5,000	TABLET	1.29	6,450.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
305	METRONIDAZOLE 5MG/ML, 100 ML VIAL	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	5,000	VIAL	16.20	81,000.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____

PURCHASER'S SPECIFICATION							SUPPLIER'S SPECIFICATION
NO.	ARTICLES & DESCRIPTION		QTY	UNIT	UNIT COST PHP	ABC PHP	*(to include manufacturer's name , brand, dosage strength, country of origin & packaging)*
306	MIDAZOLAM 15 MG TABLET	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	100	TABLET	31.47	3,147.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
307	MIDAZOLAM 5MG/ML, 1 ML AMPULE	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	5,000	AMPULE	104.16	520,800.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
308	MODIFIED FLUID GELATIN 4 % SOLUTION 500 ML BOTTLE	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	500	BOTTLE	669.50	334,750.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
309	MONOBASIC/DIBASIC SODIUM PHOSPATE 19G/7G/133ML, RECTAL	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	500	BOTTLE	241.02	120,510.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
310	MONOBASIC/DIBASIC SODIUM PHOSPATE 48G/18G/100ML SOLN,45ML, ORAL	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	500	BOTTLE	241.02	120,510.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
311	MONTELUKAST 10 MG TAB	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	4,000	TABLET	13.39	53,560.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
312	MONTELUKAST 4 MG ,CHEWABLE	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	2,000	TABLET	9.27	18,540.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
313	MONTELUKAST 5 MG ,CHEWABLE	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	2,000	TABLET	10.54	21,080.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
314	MORPHINE SULFATE 10 MG	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	3,000	TABLET	27.31	81,930.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____

PURCHASER'S SPECIFICATION							SUPPLIER'S SPECIFICATION
NO.	ARTICLES & DESCRIPTION		QTY	UNIT	UNIT COST PHP	ABC PHP	*(to include manufacturer's name , brand, dosage strength, country of origin & packaging)*
315	MORPHINE SULFATE 10MG/ML AMPULE(IM/IV/SC),1ML (HYDROCHLORIDE)	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	5,000	AMPULE	66.95	334,750.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
316	MORPHINE SULFATE 30 MG TAB	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	1,000	TABLET	66.95	66,950.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
317	MULTIVITAMINS FOR ADULTS CAPSULE	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	10,000	CAPSULE	1.34	13,400.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
318	MULTIVITAMINS PER 1ML, 15ML DROPS BOTTLE	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	500	BOTTLE	29.33	14,665.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
319	MULTIVITAMINS PER 5ML, 60 ML SYRUP BOTTLE	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	500	BOTTLE	24.10	12,050.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
320	MUPIROCIN 2%, 5 GM OINTMENT	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	1,000	TUBE	78.18	78,180.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
321	NALBUPHINE 10 MG/ML, 1ML (IM/IV/SC)(AS HYDROCHLORIDE) AMPULE	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	5,000	AMPULE	83.85	419,250.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
322	NALOXONE HCL 400MCG/ML,1ML AMPULE	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	20	AMPULE	509.60	10,192.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
323	NAPROXEN SODIUM 550 MG TABLET	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	2,000	TABLET	3.37	6,740.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____

PURCHASER'S SPECIFICATION							SUPPLIER'S SPECIFICATION
NO.	ARTICLES & DESCRIPTION		QTY	UNIT	UNIT COST PHP	ABC PHP	*(to include manufacturer's name , brand, dosage strength, country of origin & packaging)*
324	NEOSTIGMINE 500 MCG/ML (IM/IV/SC) AMPULE	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	10	AMPULE	121.84	1,218.40	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
325	NICARDIPINE 1MG/ML , 10ML AMPULE	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	2,000	AMPULE	816.79	1,633,580.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
326	NICARDIPINE 1MG/ML , 2 ML AMPULE	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	100	AMPULE	195.49	19,549.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
327	NIFEDIPINE 10 MG CAPSULE	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	5,000	CAPSULE	4.55	22,750.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
328	NIFEDIPINE 30 MG MR TABLET	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	2,000	TABLET	45.24	90,480.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
329	NITROFURANTOIN 100 MG CAPSULE	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	1,000	CAPSULE	5.20	5,200.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
330	NOREPINEPHRINE 1MG/ML, 2ML AMPULE	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	3,000	AMPULE	245.56	736,680.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
331	NOREPINEPHRINE 1MG/ML, 4ML AMPULE	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	1,000	AMPULE	707.82	707,820.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
332	NYSTATIN 100,000 U/ML SUSPENSION,30ML	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	50	BOTTLE	257.76	12,888.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____

PURCHASER'S SPECIFICATION							SUPPLIER'S SPECIFICATION
NO.	ARTICLES & DESCRIPTION		QTY	UNIT	UNIT COST PHP	ABC PHP	*(to include manufacturer's name , brand, dosage strength, country of origin & packaging)*
333	OFLOXACIN 200 MG TABLET	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	500	TABLET	5.36	2,680.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
334	OMEPRAZOLE 20 MG CAPSULE	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	4,000	CAPSULE	1.31	5,240.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
335	OMEPRAZOLE 40 MG CAPSULE	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	6,000	CAPSULE	13.39	80,340.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
336	OMEPRAZOLE 40 MG POWDER+10ML SOLVENT VIAL	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	15,000	VIAL	50.87	763,050.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
337	ONDANSETRON 2MG/ML,4ML AMPULE	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	600	AMPULE	293.24	175,944.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
338	ONDANSETRON 8 MG TABLET	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	200	TABLET	20.00	4,000.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
339	ORAL REHYDRATION SALTS SACHET(ORS 75 REPLACEMENT) 5.125 GM	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	5,000	SACHET	3.48	17,400.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
340	OXACILLIN 500 MG VIAL	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	10,000	VIAL	27.42	274,200.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
341	OXALIPLATIN 50 MG VIAL	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	100	VIAL	4,950.00	495,000.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____

PURCHASER'S SPECIFICATION							SUPPLIER'S SPECIFICATION
NO.	ARTICLES & DESCRIPTION		QTY	UNIT	UNIT COST PHP	ABC PHP	*(to include manufacturer's name , brand, dosage strength, country of origin & packaging)*
342	OXALIPLATIN 5MG/ML,20 ML VIAL	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	50	VIAL	10,342.00	517,100.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
343	OXYCODONE 10 MG TABLET	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	28	TABLET	165.31	4,628.68	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
344	OXYMETAZOLINE 0.025%,15ML,NASAL DROPS(AS HYDROCHLORIDE) BOTTLE	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	100	BOTTLE	237.00	23,700.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
345	OXYMETAZOLINE 0.05%,10ML,NASAL SPRAY(AS HYDROCHLORIDE) BOTTLE	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	100	BOTTLE	276.12	27,612.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
346	OXYTOCIN 10 IU /ML, 1 ML AMPULE	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	2,000	AMPULE	12.86	25,720.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
347	PACLITAXEL 6MG/ML,17ML	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	200	VIAL	2,379.30	475,860.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
348	PACLITAXEL 6MG/ML,25	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	100	VIAL	6,900.00	690,000.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
349	PARACETAMOL 500 MG TABLET	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	20,000	TABLET	0.30	6,000.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
350	PARACETAMOL 100MG/ML DROPS,15ML(ALCOHOL FREE)	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	500	BOTTLE	15.73	7,865.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____

PURCHASER'S SPECIFICATION							SUPPLIER'S SPECIFICATION
NO.	ARTICLES & DESCRIPTION		QTY	UNIT	UNIT COST PHP	ABC PHP	*(to include manufacturer's name , brand, dosage strength, country of origin & packaging)*
351	PARACETAMOL 10MG/ML,100 ML VIAL	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	2,000	VIAL	398.01	796,020.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
352	PARACETAMOL 125 MG SUPPOSITORY	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	1,000	SUPPOSITORY	25.77	25,770.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
353	PARACETAMOL 125MG/ML SYRUP,60ML(125MG/ML)(ALCOHOL FREE)	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	300	BOTTLE	15.73	4,719.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
354	PARACETAMOL 150MG/2ML,AMPULE	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	30,000	AMPULE	7.37	221,100.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
355	PARACETAMOL 250MG/ML SYRUP, 60ML	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	300	BOTTLE	16.74	5,022.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
356	PENICILLIN G BENZATHINE 1,200,000 UNITS VIAL	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	1,000	VIAL	71.77	71,770.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
357	PENICILLIN G CRYSTALLINE 1 MILLION UNITS (AS SODIUM SALT) VIAL	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	20,000	VIAL	6.85	137,000.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
358	PENICILLIN G CRYSTALLINE 5 MILLION UNITS VIAL	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	3,000	VIAL	19.98	59,940.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
359	PETHIDINE 50MG/ML AMPULE(IM/IV/SC),2 ML AMPULE	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	30	AMPULE	246.81	7,404.30	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____

PURCHASER'S SPECIFICATION							SUPPLIER'S SPECIFICATION
NO.	ARTICLES & DESCRIPTION		QTY	UNIT	UNIT COST PHP	ABC PHP	*(to include manufacturer's name , brand, dosage strength, country of origin & packaging)*
360	PETROLEUM JELLY USP GRADE 25 GM JAR	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	500	JAR	30.00	15,000.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
361	PHENOBARBITAL 130MG/ML (IM/IV),1ML	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	500	AMPULE	636.73	318,365.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
362	PHENOBARBITAL 15 MG TABLET	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	1,000	TABLET	2.56	2,560.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
363	PHENOBARBITAL 30 MG TABLET	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	1,000	TABLET	3.13	3,130.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
364	PHENOBARBITAL 60 MG TABLET	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	1,000	TABLET	4.55	4,550.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
365	PHENOBARBITAL 90 MG TABLET	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	1,000	TABLET	4.00	4,000.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
366	PHENYTOIN 100 MG CAPSULE	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	10,000	CAPSULE	14.87	148,700.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
367	PHENYTOIN 30MG/5ML SUSPENSION,120 ML	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	100	BOTTLE	205.74	20,574.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
368	PHENYTOIN 50MG/ML ,2ML(IM/IV),2ML AMPULE	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	3,000		274.50	823,500.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____

PURCHASER'S SPECIFICATION							SUPPLIER'S SPECIFICATION
NO.	ARTICLES & DESCRIPTION		QTY	UNIT	UNIT COST PHP	ABC PHP	*(to include manufacturer's name , brand, dosage strength, country of origin & packaging)*
369	PHENYTOIN 50MG/ML,5 ML AMPULE	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	100	AMPULE	361.53	36,153.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
370	PHYTOMENADIONE 10 MG/ML (IM/IV/SC),1 ML AMPULE	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	8,000	AMPULE	23.95	191,600.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
371	PIPERACILLIN TAZOBACTAM 2.25 GM VIAL	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	7,000	VIAL	97.23	680,610.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
372	PIPERACILLIN TAZOBACTAM 4.5 GM VIAL	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	6,000	VIAL	136.29	817,740.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
373	PNEUMOCCOCAL POLYVALENT VACCINE,25MCG/0.5ML PREFILLED	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	50	VIAL	696.28	34,814.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
374	POTASSIUM CHLORDE 2 MEQ/ML , 20 ML VIAL	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	6,000	VIAL	26.78	160,680.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
375	POTASSIUM CHLORIDE 750 MG DURULES TABLET	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	6,000	TABLET	31.21	187,260.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
376	POTASSIUM CITRATE 10 MEQ TABLET	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	1,000	TABLET	15.41	15,410.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
377	POVIDONE IODINE 1% ORAL ANTISEPTIC, 60 ML BOTTLE	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	300	BOTTLE	100.43	30,129.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____

PURCHASER'S SPECIFICATION							SUPPLIER'S SPECIFICATION
NO.	ARTICLES & DESCRIPTION		QTY	UNIT	UNIT COST PHP	ABC PHP	*(to include manufacturer's name , brand, dosage strength, country of origin & packaging)*
378	POVIDONE IODINE 7.5% SURGICAL CLEANSER, 60 ML BOTTLE	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	500	BOTTLE	133.10	66,550.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
379	PREDNISOLONE 0.5%, 5ML EYE DROPS	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	300	BOTTLE	210.22	63,066.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
380	PREDNISONE 10 MG TABLET	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	1,000	TABLET	5.36	5,360.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
381	PREDNISONE 10 MG/5ML SUSPENSION, 60 ML	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	100	BOTTLE	120.51	12,051.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
382	PREDNISONE 5 MG TABLET	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	1,000	TABLET	1.05	1,050.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
383	PROPANOLOL 10 MG TABLET	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	3,000	TABLET	12.99	38,970.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
384	PROPANOLOL 40 MG TABLET	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	4,000	TABLET	18.16	72,640.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
385	PROPOFOL 10MG/ML, 20ML VIAL	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	1,500	VIAL	144.27	216,405.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
386	PROPOFOL 10MG/ML, 50ML PREFILLED SYRINGE	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	10	PREFILLED SYRINGE	1,356.03	13,560.30	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____

PURCHASER'S SPECIFICATION							SUPPLIER'S SPECIFICATION
NO.	ARTICLES & DESCRIPTION		QTY	UNIT	UNIT COST PHP	ABC PHP	*(to include manufacturer's name , brand, dosage strength, country of origin & packaging)*
387	PROPYLTHIOURACIL 50 MG TABLET	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	5,000	TABLET	11.62	58,100.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
388	PYRAZINAMIDE 250MG/ML SYRUP,120 ML	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	200	BOTTLE	100.43	20,086.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
389	RANITIDINE 150 MG TABLET	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	500	TABLET	1.21	605.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
390	RANITIDINE 25 MG/ML , 2 ML AMPULE	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	15,000	AMPULE	4.45	66,750.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
391	RIFAMPICIN 200 MG/5ML , 120 ML SUSPENSION	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	200	BOTTLE	210.90	42,180.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
392	ROCURONIUM 10MG/ML VIAL,5ML	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	50	VIAL	328.06	16,403.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
393	ROPIVACAINE 10MG/ML,10 ML	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	50	AMPULE	456.65	22,832.50	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
394	ROSUVASTATIN 10 MG (CALCIUM)	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	5,000	TABLET	10.95	54,750.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
395	ROSUVASTATIN 20 MG (CALCIUM)	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	5,000	TABLET	15.30	76,500.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____

PURCHASER'S SPECIFICATION							SUPPLIER'S SPECIFICATION
NO.	ARTICLES & DESCRIPTION		QTY	UNIT	UNIT COST PHP	ABC PHP	*(to include manufacturer's name , brand, dosage strength, country of origin & packaging)*
396	SALBUTAMOL 2MG/5ML, 60 ML SYRUP	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	100	BOTTLE	15.20	1,520.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
397	SALBUTAMOL 2MG/ML,2.5 ML (AS SULFATE) NEBULE	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	7,000	NEBULE	8.31	58,170.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
398	SAMBONG 500 MG TABLET	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	500	TABLET	7.90	3,950.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
399	SEVOFLURANE 250 MG BOTTLE	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	200	BOTTLE	8,344.55	1,668,910.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
400	SILVER SULFADIAZINE CREAM,25 GMS TUBE	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	500	TUBE	112.27	56,135.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
401	SIMVASTATIN 20 MG TABLET	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	6,000	TABLET	1.07	6,420.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
402	SIMVASTATIN 40 MG TABLET	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	5,000	TABLET	5.06	25,300.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
403	SODIUM BICARBONATE 1 MEQ/ML ,20 ML VIAL	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	3,000	VIAL	125.00	375,000.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
404	SODIUM BICARBONATE 1 MEQ/ML ,50 ML VIAL	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	4,000	VIAL	85.70	342,800.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____

PURCHASER'S SPECIFICATION							SUPPLIER'S SPECIFICATION
NO.	ARTICLES & DESCRIPTION		QTY	UNIT	UNIT COST PHP	ABC PHP	*(to include manufacturer's name , brand, dosage strength, country of origin & packaging)*
405	SODIUM BICARBONATE 650 MG TABLET	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	6,000	TABLET	6.50	39,000.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
406	SODIUM CHLORIDE 2.5 MEQ/ML , 20ML	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	3,000	VIAL	38.83	116,490.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
407	SODIUM SULFATE POWDER USP GRADE	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	1,000	GRAMS	3.00	3,000.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
408	SOMATOSTATIN 250 MCG	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	300	AMPULE/VIAL	1,581.80	474,540.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
409	SOMATOSTATIN 3MG VIAL	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	50	VIAL	4,830.21	241,510.50	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
410	SPIRONOLACTONE 100 MG TAB	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	3,000	TABLET	31.28	93,840.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
411	SPIRONOLACTONE 25 MG TAB	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	3,000	TABLET	12.95	38,850.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
412	SPIRONOLACTONE 50 MG TAB	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	3,000	TABLET	33.15	99,450.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
413	STERILE WATER FOR INJECTION 20 ML	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	8,000	AMPULE	32.81	262,480.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____

PURCHASER'S SPECIFICATION							SUPPLIER'S SPECIFICATION
NO.	ARTICLES & DESCRIPTION		QTY	UNIT	UNIT COST PHP	ABC PHP	*(to include manufacturer's name , brand, dosage strength, country of origin & packaging)*
414	STREPTOKINASE 1,500,000 VIAL	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	50	VIAL	4,305.40	215,270.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
415	SUXAMETHONIUM (SUCCINYLCHOLINE) 20MG/ML,10 ML VIAL	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	1,500	VIAL	241.02	361,530.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
416	TAMOXIFEN 20 MG TABLET	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	5,000	TABLET	13.12	65,600.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
417	TAMSOLUSIN 200 MCG CAPSULE	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	2,000	CAPSULE	67.51	135,020.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
418	TELMISARTAN 40 MG TABLET	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	200	TABLET	26.81	5,362.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
419	TELMISARTAN 80 MG TABLET	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	200	TABLET	40.04	8,008.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
420	TERBUTALINE SO4 2.5 MG/ML, 5 ML NEBULE	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	500	NEBULE	13.00	6,500.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
421	TETANUS TOXOID 0.5ML AMPULE	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	7,000	AMPULE	60.26	421,820.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
422	TETANUS TOXOID IMMUNOGLOBULIN(HUMAN)250IU/ML,1 ML AMPULE	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	100	AMPULE	977.47	97,747.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____

PURCHASER'S SPECIFICATION							SUPPLIER'S SPECIFICATION
NO.	ARTICLES & DESCRIPTION		QTY	UNIT	UNIT COST PHP	ABC PHP	*(to include manufacturer's name , brand, dosage strength, country of origin & packaging)*
423	TETRACYCLINE 250 MG CAPSULE	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	200	CAPSULE	1.95	390.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
424	TETRACYCLINE 500 MG CAPSULE	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	200	CAPSULE	2.47	494.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
425	THEOPHYLLINE 200 MG TABLET	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	500	TABLET	140.00	70,000.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
426	TIOTROPIUM 18MCG/DOSE DRY POWDER HANDIHALER	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	300	DPI	360.00	108,000.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
427	TOBRAMYCIN 0.3%, 5ML EYEDROPS	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	300	BOTTLE	411.65	123,495.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
428	TOBRAMYCIN DEXAMETHASONE 0.3%+0.1%, 5ML EYE DROPS	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	100	BOTTLE	307.97	30,797.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
429	TRAMADOL 100 MG MR (AS HYDROCHLORIDE) TABLET	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	1,000	TABLET	94.48	94,480.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
430	TRAMADOL 50 MG (AS HYDROCHLORIDE) CAPSULE	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	5,000	CAPSULE	2.64	13,200.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
431	TRAMADOL 50 MG/ML, 2ML (IM/IVLSC) AMPULE	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	5,000	AMPULE	6.55	32,750.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____

PURCHASER'S SPECIFICATION							SUPPLIER'S SPECIFICATION
NO.	ARTICLES & DESCRIPTION		QTY	UNIT	UNIT COST PHP	ABC PHP	*(to include manufacturer's name , brand, dosage strength, country of origin & packaging)*
432	TRAMADOL 50MG/ML ,1 ML(IM,IV,SC) AMPULE	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	20,000	AMPULE	11.99	239,800.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
433	TRANEXAMIC ACID 100 MG/ML ,5ML AMPULE	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	10,000	AMPULE	16.45	164,500.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
434	TRANEXAMIC ACID 500 MG CAPSULE	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	6,000	CAPSULE	6.70	40,200.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
435	TRIMETAZIDINE 35 MG TAB	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	1,000	TABLET	12.03	12,030.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
436	TROPICAMIDE 0.5%, 5 ML EYE DROPS SOLUTION	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	200	BOTTLE	457.34	91,468.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
437	URSODEOXYCHOLIC ACID 250 MG CAPSULE	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	1,000	CAPSULE	45.71	45,710.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
438	VALPROATE SODIUM 250 MG (AS SODIUM SALT)	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	200	TABLET	31.03	6,206.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
439	VALPROIC ACID 250MG/5ML,120 ML SYRUP	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	100	BOTTLE	669.50	66,950.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
440	VALPROIC ACID 500MG/5ML, 5 ML VIAL	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	100	VIAL	1,927.38	192,738.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____

PURCHASER'S SPECIFICATION							SUPPLIER'S SPECIFICATION
NO.	ARTICLES & DESCRIPTION		QTY	UNIT	UNIT COST PHP	ABC PHP	*(to include manufacturer's name , brand, dosage strength, country of origin & packaging)*
441	VANCOMYCIN 1 GM VIAL	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	500	VIAL	1,250.00	625,000.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
442	VANCOMYCIN 500 MG VIAL	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	5,000	VIAL	211.56	1,057,800.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
443	VERAPAMIL 2.5MG/ML,2ML AMPULE	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	100	AMPULE	169.25	16,925.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
444	VERAPAMIL 80 MG TABLET	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	500	TABLET	57.79	28,895.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
445	VINCRISTINE1MG/ML,2ML VIAL	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	200	VIAL	461.82	92,364.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
446	VITAMIN B1B6B12(100MG+5MG+1MG),3ML AMPULE	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	1,000	AMPULE	82.82	82,820.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
447	VITAMIN B1B6B12(100MG+5MG+50MCG) TABLET	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	6,000	TABLET	1.68	10,080.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
448	WARFARIN 1 MG TABLET	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	2,000	TABLET	12.52	25,040.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
449	WARFARIN 2.5 MG TABLET	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	2,000	TABLET	13.92	27,840.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____

PURCHASER'S SPECIFICATION							SUPPLIER'S SPECIFICATION
NO.	ARTICLES & DESCRIPTION		QTY	UNIT	UNIT COST PHP	ABC PHP	*(to include manufacturer's name , brand, dosage strength, country of origin & packaging)*
450	WARFARIN 5 MG TABLET	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	2,000	TABLET	19.28	38,560.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
451	ZINC 27.5MG/ML,15ML DROPS BOTTLE	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	200	BOTTLE	50.88	10,176.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
452	ZINC 55MG/5ML, 60ML SYRUP BOTTLE	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	200	BOTTLE	54.90	10,980.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
453	ZOLPIDEM 10 MG TABLET	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	200	TABLET	65.00	13,000.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
454	DEXTROSE 10% WATER 500 ML PLASTIC BOTTLE	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	1,000	BOTTLE	58.50	58,500.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
455	DEXTROSE 5% BALANCE MULTIPLE MAINTENANCE SOLUTION 500 ML PLASTIC BOTTLE	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	7,000	BOTTLE	58.50	409,500.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
456	DEXTROSE 5% LACTATED RINGERS SOLUTION 1 LITER PLASTIC BOTTLE	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	30,000	BOTTLE	58.50	1,755,000.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
457	DEXTROSE 5% LACTATED RINGERS SOLUTION 500 ML PLASTIC BOTTLE	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	3,000	BOTTLE	58.50	175,500.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
458	DEXTROSE 5%0.3 SODIUM CHLORIDE 1 LITER PLASTIC BOTTLE	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	5,000	BOTTLE	58.50	292,500.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____

PURCHASER'S SPECIFICATION							SUPPLIER'S SPECIFICATION
NO.	ARTICLES & DESCRIPTION		QTY	UNIT	UNIT COST PHP	ABC PHP	*(to include manufacturer's name , brand, dosage strength, country of origin & packaging)*
459	DEXTROSE 5% 0.9% SODIUM CHLORIDE 1 LITER PLASTIC BOTTLE	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	7,000	BOTTLE	58.50	409,500.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
460	DEXTROSE 5% 0.9% SODIUM CHLORIDE 500 ML PLASTIC BOTTLE	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	5,000	BOTTLE	58.50	292,500.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
461	DEXTROSE 5% BALANCE MULTIPLE MAINTENANCE SOLUTION 1 LITER PLASTIC BOTTLE	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	6,000	BOTTLE	58.50	351,000.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
462	0.9% SODIUM CHLORIDE 1 LITER PLASTIC BOTTLE	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	75,000	BOTTLE	58.50	4,387,500.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
463	0.9% SODIUM CHLORIDE 500 ML PLASTIC BOTTLE	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	4,000	BOTTLE	58.50	234,000.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
464	0.9% SODIUM CHLORIDE IRRIGATION SOLUTION 1 LITER PLASTIC BOTTLE	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	6,000	BOTTLE	58.50	351,000.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
465	DEXTROSE 5% NORMOSOL RINGERS 1 LITER	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	300	BOTTLE	58.50	17,550.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
466	DEXTROSE 5% WATER 1 LITER PLASTIC BOTTLE	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	3,000	BOTTLE	58.50	175,500.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
467	DEXTROSE 5% WATER 250 ML GLASS BOTTLE	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	1,000	BOTTLE	80.00	80,000.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____

PURCHASER'S SPECIFICATION							SUPPLIER'S SPECIFICATION
NO.	ARTICLES & DESCRIPTION		QTY	UNIT	UNIT COST PHP	ABC PHP	*(to include manufacturer's name , brand, dosage strength, country of origin & packaging)*
468	LACTATED RINGERS SOLUTION 1 LITER PLASTIC BOTTLE	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	5,000	BOTTLE	58.50	292,500.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
469	LACTATED RINGERS SOLUTION 500 ML PLASTIC BOTTLE	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	5,000	BOTTLE	58.50	292,500.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
470	CHLORPRAZAMINE 100 MG TABLET	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	2,000	TABLET	1.51	3,020.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
471	CLOZAPINE 100 MG TABLET	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	1,000	TABLET	17.06	17,060.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
472	OLANZEPINE 5 MG TABLET	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	500	TABLET	75.00	37,500.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
473	OLANZEPINE 10 MG TABLET	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	500	TABLET	36.15	18,075.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
474	RESPERIDONE 1 MG TABLET	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	2,000	TABLET	20.28	40,560.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
475	RESPERIDONE 2 MG TABLET	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	2,000	TABLET	19.28	38,560.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
476	RESPERIDONE 3 MG TABLET	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	2,000	TABLET	45.00	90,000.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____

PURCHASER'S SPECIFICATION							SUPPLIER'S SPECIFICATION
NO.	ARTICLES & DESCRIPTION		QTY	UNIT	UNIT COST PHP	ABC PHP	*(to include manufacturer's name , brand, dosage strength, country of origin & packaging)*
477	ESCITALOPRAM 10 MG TABLET	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	500	TABLET	196.40	98,200.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
478	QUETIAPINE 100 MG TABLET	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	500	TABLET	32.27	16,135.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
479	QUETIAPINE 300 MG TABLET	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	500	TABLET	86.76	43,380.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
480	SERTRALINE 50 MG TABLET	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	300	TABLET	160.60	48,180.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
481	ALPRAZOLAM 250 MCG TABLET	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	1,000	TABLET	82.40	82,400.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
482	ALPRAZOLAM 500 MCG TABLET	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	1,000	TABLET	195.80	195,800.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
483	FLUPHENAZINE 25 MG/ML,10ML	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	50	VIAL	520.87	26,043.50	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____
484	LITHIUM CARBONATE 450 MG TABLET MR	Shelf life: Drugs must be fresh commercial stock with a total shelf life of twenty four(24) months from the date of manufacture but not less than sixteen (16) months from the date of delivery.	500	TABLET	216.50	108,250.00	Brand: _____ Dosage Strength: _____ Manufacturer's Name: _____ Country of Origin: _____ Packaging: _____

NAME OF COMPANY _____ **ADDRESS** _____

SIGNATURE OVER PRINTED NAME _____ **TELEPHONE / FAX NO** _____

Section VIII. Bidding Forms

Notes on the Bidding Forms

The Bidder shall complete and submit with its Bid the **Bid Form** and **Price Schedules** in accordance with **ITB** Clause 15 with the requirements of the Bidding Documents and the format set out in this Section.

When requested in the BDS, the Bidder should provide the **Bid Security**, either in the form included hereafter or in another form acceptable to the Entity, pursuant to **ITB** Clause 18.1.

The **Contract Agreement Form**, when it is finalized at the time of contract award, should incorporate any corrections or modifications to the accepted Bid resulting from price corrections. The Price Schedule and Schedule of Requirements deemed to form part of the contract should be modified accordingly.

The **Performance Security Form** and **Bank Guarantee Form for Advance Payment** should not be completed by the Bidders at the time of their Bid preparation. Only the successful Bidder will be required to provide performance security and bank guarantee for advance payment in accordance with one of the forms indicated herein or in another form acceptable to the Procuring Entity and pursuant to **GCC** Clause 13 and its corresponding SCC provision.

The sworn affidavit must be completed by all Bidders in accordance with **ITB** Clause 4.2. Failure to do so and submit it with the bid shall result in the rejection of the bid and the Bidder's disqualification.

TABLE OF CONTENTS

						BIDDER'S OFFER	
NO.	ARTICLES & DESCRIPTION	QTY	UNIT	UNIT COST PHP	ABC (php)	UNIT COST	TOTAL COST
1	ACETAZOLAMIDE 250 MG TABLET	500	TABLET	26.00	13,000.00		
2	ACETYLCYSTEINE 200 MG SACHET	8,000	SACHET	12.05	96,400.00		
3	ACETYLCYSTEINE 200 MG/ML, 10 ML AMPULE	30	AMPULE	548.24	16,447.20		
4	ACETYLCYSTEINE 200MG/ML, 25ML BOTTLE	20	BOTTLE	1,699.50	33,990.00		
5	ACETYLCYSTEINE 600 MG EFFERVESCENT TABLET	5,000	TABLET	36.15	180,750.00		
6	ACICLOVIR 400 MG TABLET	200	TABLET	20.07	4,014.00		
7	ACTIVATED CHARCOAL	1,000	GRAMS	5.00	5,000.00		
8	ADENOSINE 3MG/ML VIAL	20	VIAL	757.95	15,159.00		
9	ALBENDAZOLE 200MG/5ML BOTTLE	20	BOTTLE	200.00	4,000.00		
10	ALBENDAZOLE 400 MG CHEWABLE TABLET	200	TABLET	1.34	268.00		
11	ALBUMIN, HUMAN 20%,50 ML BOTTLE	300	BOTTLE	2,775.85	832,755.00		
12	ALBUMIN, HUMAN 20%, 100 ML BOTTLE	50	BOTTLE	3,700.00	185,000.00		
13	ALLOPURINOL 100 MG TABLET	1,000	TABLET	0.90	900.00		
14	ALLOPURINOL 300 MG TABLET	200	TABLET	2.11	422.00		
15	AMIKACIN SULFATE 125MG/ML,2ML VIAL	6,000	VIAL	23.82	142,920.00		
16	AMIKACIN SULFATE 250MG/ML,2ML VIAL	4,000	VIAL	29.81	119,240.00		

						BIDDER'S OFFER	
NO.	ARTICLES & DESCRIPTION	QTY	UNIT	UNIT COST PHP	ABC (php)	UNIT COST	TOTAL COST
17	AMIKACIN SULFATE 50MG/ML,2ML VIAL	3,000	VIAL	34.40	103,200.00		
18	AMINOPHYLLINE 25MG/ML, 10ML AMPULE	1,500	AMPULE	23.15	34,725.00		
19	AMINOSTERILE 6% VIAL	1,000	VIAL	385.00	385,000.00		
20	AMIODARONE 200 MG TABLET	3,000	TABLET	24.87	74,610.00		
21	AMIODARONE 50MG/ML,3ML AMPULE	500	AMPULE	307.97	153,985.00		
22	AMOXICILLIN 100MG/ML, 15 ML DROPS	200	BOTTLE	36.99	7,398.00		
23	AMOXICILLIN 250 MG/5ML BOTTLE,60 ML	200	BOTTLE	21.09	4,218.00		
24	AMOXICILLIN 500 MG CAPSULE	8,000	CAPSULE	1.73	13,840.00		
25	AMPHOTHERICIN B NON LIPID COMPLEX 50MG VIAL	100	VIAL	3,022.80	302,280.00		
26	AMPICILLIN + SULBACTAM 1.5GM VIAL	6,000	VIAL	159.86	959,160.00		
27	AMPICILLIN + SULBACTAM 750MG VIAL	6,000	VIAL	39.75	238,500.00		
28	AMPICILLIN 1 GM (AS SODIUM SALT) VIAL	10,000	VIAL	14.04	140,400.00		
29	AMPICILLIN 250 MG (AS SODIUM SALT) VIAL	20,000	VIAL	9.13	182,600.00		
30	AMPICILLIN 500 MG (AS SODIUM SALT) VIAL	4,000	VIAL	8.45	33,800.00		
31	ANTI RABIES SERUM(EQUINE) 200IU/ML,5ML IMMUNOGLOBULIN	1,000	VIAL	1,183.92	1,183,920.00		
32	ANTI TETANUS SERUM (ATS)(EQUINE) 1,500 IU/ML, 1ML AMPULE	10,000	AMPULE	73.93	739,300.00		

						BIDDER'S OFFER	
NO.	ARTICLES & DESCRIPTION	QTY	UNIT	UNIT COST PHP	ABC (php)	UNIT COST	TOTAL COST
33	ASCORBIC ACID 500 MG TABLET	5,000	TABLET	0.87	4,350.00		
34	ASCORBIC ACID 100 MG/5ML, 120 ML BOTTLE	200	BOTTLE	33.35	6,670.00		
35	ASCORBIC ACID 100 MG/ML,15 ML BOTTLE	100	BOTTLE	18.38	1,838.00		
36	ASCORBIC ACID 250MG/5ML,2 ML AMPULE	100	AMPULE	29.46	2,946.00		
37	ASPIRIN 80MG TABLET	10,000	TABLET	1.20	12,000.00		
38	ATENOLOL 100 MG TABLET	200	TABLET	7.12	1,424.00		
39	ATENOLOL 50 MG TABLET	1,000	TABLET	2.65	2,650.00		
40	ATRACURIUM 10MG/ML AMP	3,000	AMPULE	119.17	357,510.00		
41	ATROPINE EYEDROP 1% 5 ML	200	BOTTLE	283.00	56,600.00		
42	ATROPINE SULFATE 1MG/ML AMP	4,000	AMPULE	8.45	33,800.00		
43	AZITHROMYCIN 200MG/5ML SYRUP, 30 ML	20	BOTTLE	215.63	4,312.60		
44	AZITHROMYCIN 500 MG(DIHYDRATE) TABLET	10,000	TABLET	50.52	505,200.00		
45	AZITHROMYCIN 500 MG(DIHYDRATE)(AS BAS/*DIHYDRATE) VIAL	700	VIAL	858.51	600,957.00		
46	BACLOFEN 10 MG TABLET	2,000	TABLET	22.10	44,200.00		
47	BARIUM SULFATE POWDER,USP GRADE SUSPENSION IN WATER 454 G, PACK	300	PACK	520.00	156,000.00		
48	BERACTANT 25MG/ML, 4ML, SUSPENSION	10	VIAL	11,413.75	114,137.50		

						BIDDER'S OFFER	
NO.	ARTICLES & DESCRIPTION	QTY	UNIT	UNIT COST PHP	ABC (php)	UNIT COST	TOTAL COST
49	BETAHISTINE 16 MG TABLET	5,000	TABLET	32.50	162,500.00		
50	BETAHISTINE 24 MG TABLET	4,000	TABLET	61.43	245,720.00		
51	BETAHISTINE 8 MG TABLET	1,000	TABLET	18.75	18,750.00		
52	BETAMETASONE DIPROPIONATE 0.05% CREAM 5 G TUBE	100	TUBE	51.64	5,164.00		
53	BIPERIDEN 2 MG(AS HYDROCHLORIDE TABLET	1,000	TABLET	5.21	5,210.00		
54	BIPHASIC ISOPAHNE HUMAN INSULIN 70/30, 10 ML VIAL	700	VIAL	229.65	160,755.00		
55	BISACODYL 5 MG SUPPOSITORY	1,000	SUPPOSITORY	33.02	33,020.00		
56	BISACODYL 10 MG SUPPOSITORY	2,000	SUPPOSITORY	28.34	56,680.00		
57	BISACODYL 5 MG TABLET	3,000	TABLET	1.99	5,970.00		
58	BLEOMYCIN 15MG,POWDER VIAL	50	VIAL	1,947.00	97,350.00		
59	BUDESONIDE 250 MCG/ML,2ML NEBULE	7,000	NEBULE	24.39	170,730.00		
60	BUDESONIDE+FORMETEROL 160MCG BUDESONIDE+4.5MCG FORMOTEROL DPI 120 DOSES	200	DPI	1,033.79	206,758.00		
61	BUMETANIDE 1 MG TABLET	1,000	TABLET	28.85	28,850.00		
62	BUMETANIDE 500 MCG/ML,1 ML AMPULE	100	AMPULE	531.96	53,196.00		
63	BUPIVACAINE 0.5% ,5MG/ML,10 ML	4,000	AMPULE/VIAL	174.07	696,280.00		
64	BUPIVACAINE HCL 0.5% ,4ML SPINAL WITH 8% DEXTROSE AS HCL	3,000	AMPULE	236.20	708,600.00		

						BIDDER'S OFFER	
NO.	ARTICLES & DESCRIPTION	QTY	UNIT	UNIT COST PHP	ABC (php)	UNIT COST	TOTAL COST
65	BUTAMIRATE 50 MG MR(CITRATE) TABLET	1,000	TABLET	17.94	17,940.00		
66	BUTORPHANOL AS TARTRATE 2MG/ML, 1 ML VIAL	1,500	VIAL	567.07	850,605.00		
67	CALAMINE,PLAIN 8%,60 ML LOTION BOTTLE	200	BOTTLE	38.83	7,766.00		
68	CALCIUM CARBONATE 500 MG TABLET	5,000	TABLET	4.02	20,100.00		
69	CALCIUM CARBONATE 600 MG TABLET	5,000	TABLET	5.20	26,000.00		
70	CALCIUM GLUCONATE 10 %,10ML VIAL	4,000	VIAL	19.94	79,760.00		
71	CALCIUM FOLINATE 50 MG POWDER VIAL	30	VIAL	7,163.75	214,912.50		
72	CAPECITABINE 150 MG TABLET	2,000	TABLET	65.00	130,000.00		
73	CAPECITABINE 500 MG TABLET	1,000	TABLET	118.37	118,370.00		
74	CAPTOPRIL 25 MG TABLET	6,000	TABLET	0.78	4,680.00		
75	CAPTOPRIL 50 MG TABLET	200	TABLET	3.64	728.00		
76	CARBAMAZEPINE 100MG/5ML, 120 ML SYRUP	200	BOTTLE	564.59	112,918.00		
77	CARBAMAZEPINE 200 MG TABLET	500	TABLET	2.26	1,130.00		
78	CARBOPLATIN 150 MG,45ML VIAL	100	VIAL	1,220.01	122,001.00		
79	CARBOPLATIN 450 MG,45 ML VIAL	200	VIAL	2,925.41	585,082.00		
80	CARBOPROST 125MCG/0.5ML AMP	700	AMPULE	780.00	546,000.00		

						BIDDER'S OFFER	
NO.	ARTICLES & DESCRIPTION	QTY	UNIT	UNIT COST PHP	ABC (php)	UNIT COST	TOTAL COST
81	CARBOPROST 250 MCG/ML,	200	AMPULE	1,040.00	208,000.00		
82	CARVEDILOL 25 MG TABLET	1,000	TABLET	6.19	6,190.00		
83	CARVEDILOL 6.25 MG TABLET	6,000	TABLET	2.51	15,060.00		
84	CASTOR OIL,USP GRADE BOTTLE	500	BOTTLE	45.50	22,750.00		
85	CEFALEXIN 100MG/5ML BOTTLE,10 ML	50	BOTTLE	20.81	1,040.50		
86	CEFALEXIN 125MG/5ML BOTTLE,30 ML	50	BOTTLE	19.99	999.50		
87	CEFALEXIN 250 MG/5ML BOTTLE, 60ML	50	BOTTLE	29.91	1,495.50		
88	CEFALEXIN 500 MG CAPSULE	6,000	CAPSULE	2.81	16,860.00		
89	CEFAZOLIN 1G VIAL	3,000	VIAL	23.06	69,180.00		
90	CEFEPIME 1 GM VIAL	2,000	VIAL	209.56	419,120.00		
91	CEFEPIME 500 MG VIAL	2,000	VIAL	200.30	400,600.00		
92	CEFIXIME 100MG/5ML BOTTLE, 60 ML SUSPENSION	20	BOTTLE	254.41	5,088.20		
93	CEFIXIME 200 MG CAPSULE	3,000	CAPSULE	18.75	56,250.00		
94	CEFIXIME 20MG/ML BOTTLE, 10 ML DROPS	50	BOTTLE	200.85	10,042.50		
95	CEFOTAXIME 250MG+2ML DILUENT (IM/IV) VIAL	1,000	VIAL	64.66	64,660.00		
96	CEFOTAXIME 500 MG+2ML DILUENT (IM/IV) VIAL	2,000	VIAL	46.14	92,280.00		

						BIDDER'S OFFER	
NO.	ARTICLES & DESCRIPTION	QTY	UNIT	UNIT COST PHP	ABC (php)	UNIT COST	TOTAL COST
97	CEFOXITIN 1G VIAL	12,000	VIAL	354.02	4,248,240.00		
98	CEFTAZIDIME 500 MG (PENTAHYDRATE) VIAL	5,000	VIAL	74.24	371,200.00		
99	CEFTAZIDIME 1 GM (AS PENTAHYDRATE) VIAL	10,000	VIAL	51.75	517,500.00		
100	CEFTRIAXONE 1G VIAL+10 ML DILUENT SOLUTION	15,000	VIAL	26.30	394,500.00		
101	CEFTRIAXONE 250 MG VIAL+5ML DILUENT	3,000	VIAL	26.00	78,000.00		
102	CEFUROXIME 125MG/5ML BOTTLE, 70 ML	300	BOTTLE	230.98	69,294.00		
103	CEFUROXIME 250MG/5ML BOTTLE, 70 ML	400	BOTTLE	300.27	120,108.00		
104	CEFUROXIME 500MG TABLET	15,000	TABLET	12.00	180,000.00		
105	CEFUROXIME 250 MG (IM/IV) VIAL	1,000	VIAL	73.65	73,650.00		
106	CEFUROXIME 750 MG VIAL	10,000	VIAL	24.10	241,000.00		
107	CELECOXIB 200 MG CAPSULE	10,000	CAPSULE	8.03	80,300.00		
108	CELECOXIB 400 MG CAPSULE	5,000	CAPSULE	22.76	113,800.00		
109	CETIRIZINE 10 MG TABLET	4,000	TABLET	0.64	2,560.00		
110	CETIRIZINE 10MG/ML DROPS	100	BOTTLE	167.38	16,738.00		
111	CETIRIZINE 5MG/5ML SYRUP, 60 ML	100	BOTTLE	100.43	10,043.00		
112	CHLORAMPHENICOL 1 GM VIAL	200	VIAL	28.77	5,754.00		

						BIDDER'S OFFER	
NO.	ARTICLES & DESCRIPTION	QTY	UNIT	UNIT COST PHP	ABC (php)	UNIT COST	TOTAL COST
113	CHLORAMPHENICOL 500 MG CAPSULE	500	CAPSULE	2.68	1,340.00		
114	CHLORHEXEDINE 0.12% SOLUTION, 120 ML BOTTLE	500	BOTTLE	110.00	55,000.00		
115	CILOSTAZOL 100 MG TABLET	500	TABLET	12.86	6,430.00		
116	CILOSTAZOL 50 MG TABLET	500	TABLET	9.28	4,640.00		
117	CINNARIZINE 25 MG CAP	4,000	CAPSULE	1.50	6,000.00		
118	CIPROFLOXACIN 2MG/ML,100 ML VIAL	5,000	VIAL	26.94	134,700.00		
119	CIPROFLOXACIN 500 MG TABLET	10,000	TABLET	1.78	17,800.00		
120	CISPLATIN 1MG/ML, 50MLVIAL	100	VIAL	588.50	58,850.00		
121	CLARITHROMYCIN 125MG/5ML BOTTLE,50 ML GRANULES	200	BOTTLE	187.46	37,492.00		
122	CLARITHROMYCIN 250MG/5ML BOTTLE, 70 ML	300	BOTTLE	649.42	194,826.00		
123	CLARITHROMYCIN 500 MG TABLET	3,000	TABLET	14.44	43,320.00		
124	CLINDAMYCIN 150MG/ML 4ML AMPULE	5,000	AMPULE	150.63	753,150.00		
125	CLINDAMYCIN 150MG/ML, 2ML AMPULE	8,000	AMPULE	154.26	1,234,080.00		
126	CLINDAMYCIN 300 MG (AS HYDROCCHLORIDE) CAPSULE	10,000	CAPSULE	3.61	36,100.00		
127	CLINDAMYCIN 75MG/5ML 60ML	100	BOTTLE	266.97	26,697.00		
128	CLOBETASOL 0.05% 10 GMS(AS PROPIONATE(CREAM) 15 GM	100	OINTMENT/CREAM	156.00	15,600.00		

						BIDDER'S OFFER	
NO.	ARTICLES & DESCRIPTION	QTY	UNIT	UNIT COST PHP	ABC (php)	UNIT COST	TOTAL COST
129	CLONAZEPAM 2 MG TABLET	1,000	TABLET	10.31	10,310.00		
130	CLONIDINE 150 MCG TABLET	100	TABLET	20.09	2,009.00		
131	CLONIDINE 150 MCG/ML, 2 ML AMPULE	100	AMPULE	142.64	14,264.00		
132	CLONIDINE 75 MCG TABLET	10,000	TABLET	19.68	196,800.00		
133	CLOPIDOGREL 75 MG TABLET	15,000	TABLET	3.73	55,950.00		
134	CLOXACILLIN 125MG/5ML BOTTLE, 60ML	200	BOTTLE	26.78	5,356.00		
135	CLOXACILLIN 250MG/5ML BOTTLE, 60 ML SUSPENSION	200	BOTTLE	46.87	9,374.00		
136	CLOXACILLIN 500 MG CAPSULE	15,000	CAPSULE	3.52	52,800.00		
137	CO TRIMOXAZOLE 400 MG SMX +80MG TRIMETHORPIN,5ML AMPULE	50	AMPULE	221.00	11,050.00		
138	CO TRIMOXAZOLE 400 MG SMX+80 MG TRIMETHORPIN PER TABLET	1,000	TABLET	1.03	1,030.00		
139	CO TRIMOXAZOLE 800 MG SMX+160 MG TRIMETHORPIN PER TABLET	1,000	TABLET	1.55	1,550.00		
140	CO AMOXICLAV 1 GM TABLET	3,000	TABLET	24.75	74,250.00		
141	CO-AMOXICLAV 200MG+28.5MG/5ML BOTTLE, 70 ML	200	BOTTLE	208.23	41,646.00		
142	CO-AMOXICLAV 4000MG+57MG/5ML BOTTLE,70 ML	200	BOTTLE	314.39	62,878.00		
143	CO-AMOXICLAV 625MG TAB	20,000	TABLET	11.83	236,600.00		
144	COBRA ANTIVENIN 800 MU/4.8ML,1ML AMPULE	10	AMPULE	2,750.00	27,500.00		

						BIDDER'S OFFER	
NO.	ARTICLES & DESCRIPTION	QTY	UNIT	UNIT COST PHP	ABC (php)	UNIT COST	TOTAL COST
145	COLCHICINE 500 MCG TABLET	5,000	TABLET	3.48	17,400.00		
146	COLISTIN 2,000,000 IU LYOPHILIZED POWDER FOR INJECTION VIAL	50	VIAL	2,100.00	105,000.00		
147	COMBINED AMINO ACIDS+SORBITOL 500 ML BOTTLE	300	BOTTLE	939.98	281,994.00		
148	COMBINED GLUCOSE+AMINO ACIDS SOLUTION 500 ML BOTTLE	100	BOTTLE	900.00	90,000.00		
149	CYCLOPHOSPHAMIDE 500 MG VIAL	500	VIAL	301.28	150,640.00		
150	CYTARABINE 100MG VIAL	100	VIAL	136.45	13,645.00		
151	DACTINOMYCIN 500 MCG VIAL	100	VIAL	455.00	45,500.00		
152	DANTROLENE SODIUM 20MG(W/ MANNITOL 3G)/ VIAL (FOR RECONSTITUTION 60ML STERILE WATER FOR INJECTION)	5	VIAL	20,000.00	100,000.00		
153	DEXAMETHASONE 4 MG TABLET	5,000	TABLET	22.92	114,600.00		
154	DEXAMETHASONE 4MG/ML,1 ML(IM,IV) AMPULE	5,000	AMPULE	73.65	368,250.00		
155	DEXTROSE 50 % 50 cc VIAL	5,000	VIAL	34.15	170,750.00		
156	DIAZEPAM 5 MG TABLET	200	TABLET	9.36	1,872.00		
157	DIAZEPAM 5MG/ML, 2 ML AMPULE	10,000	AMPULE	83.01	830,100.00		
158	DICLOFENAC 25MG/ML, 3 ML AMPULE	100	AMPULE	40.57	4,057.00		
159	DICLOFENAC 50 MG TABLET	200	TABLET	1.05	210.00		
160	DIGOXIN 250MCG TABLET	6,000	TABLET	5.90	35,400.00		

						BIDDER'S OFFER	
NO.	ARTICLES & DESCRIPTION	QTY	UNIT	UNIT COST PHP	ABC (php)	UNIT COST	TOTAL COST
161	DIGOXIN 250MCG/ML , 2ML AMPULE	3,000	AMPULE	191.48	574,440.00		
162	DILTIAZEM HCL 60 MG TABLET	100	TABLET	41.28	4,128.00		
163	DIPHENHYDRAMINE 12.5MG/5ML SYRUP, 60 ML	100	BOTTLE	23.50	2,350.00		
164	DIPHENHYDRAMINE 50 MG CAPSULE	5,000	CAPSULE	1.21	6,050.00		
165	DIPHENHYDRAMINE 50MG/ML,1ML AMPULE	5,000	AMPULE	51.53	257,650.00		
166	DOBUTAMINE 2MG/ML,250ML D5WATER PREMIXED	200	BOTTLE	976.13	195,226.00		
167	DOBUTAMINE 50 MG/ML,5 ML AMPULE	2,000	AMPULE	253.92	507,840.00		
168	DOCETAXEL 20MG/0.5ML, 0.5ML VIAL	200	VIAL	2,130.04	426,008.00		
169	DOCETAXEL 40MG/ML,2ML VIAL	200	VIAL	8,928.04	1,785,608.00		
170	DOMPERIDONE 10 MG TABLET	1,500	TABLET	4.00	6,000.00		
171	DOMPERIDONE 1MG/ML, 60 ML SUSPENSION	100	BOTTLE	194.16	19,416.00		
172	DOPAMINE 40MG/ML,5ML	4,000	AMPULE/VIAL	60.01	240,040.00		
173	DOPAMINE 800MCG/ML, 250ML D5W(PRE MIXEd) (IV)	1,000	BOTTLE	320.48	320,480.00		
174	DOXORUBICIN 50 MG VIAL	200	VIAL	921.23	184,246.00		
175	DOXORUBICN 10 MG VIAL	200	VIAL	211.90	42,380.00		
176	DOXYCYCLINE 100 MG CAP	2,000	CAPSULE	1.27	2,540.00		

						BIDDER'S OFFER	
NO.	ARTICLES & DESCRIPTION	QTY	UNIT	UNIT COST PHP	ABC (php)	UNIT COST	TOTAL COST
177	DYDROGESTERONE 10MG TAB	1,000	TABLET	56.24	56,240.00		
178	ENALAPRIL 20 MG TABLET	2,000	TABLET	12.56	25,120.00		
179	ENALAPRIL 5MG TABLET	3,000	TABLET	5.02	15,060.00		
180	ENOXAPARIN 100MG/ML, 0.4 cc PREFILLED SYRINGE	3,000	PREFILLED SYRINGE	317.34	952,020.00		
181	EPHEDRINE SULFATE 50MG/ML, 1ML AMP	6,000	AMPULE	80.34	482,040.00		
182	EPINEPHRINE 1 MG/ML, 1ML AMP	25,000	AMPULE	54.50	1,362,500.00		
183	EPOETIN ALFA 4000 IU/ 1ML SOLUTION FOR INJECTION(IV/SC) PREFILLED SYRINGE GLASS	8,000	PREFILLED SYRINGE	633.35	5,066,800.00		
184	EPOETIN BETA 5000 IU/0.3ML, PRE FILLED SYRINGE WITH NEEDLE (IV,SC)	200	PREFILLED SYRINGE	1,272.18	254,436.00		
185	ERTAPENEM (AS SODIUM) 1 GM VIAL	30	VIAL	2,562.87	76,886.10		
186	ERYTHROMYCIN 200MG/5ML GRANULES/POWDER SUSPENSION,50ML	50	BOTTLE	57.24	2,862.00		
187	ERYTHROMYCIN 400MG/5ML GRANULE/POWDER/DROPS,60ML	50	BOTTLE	74.41	3,720.50		
188	ERYTHROMYCIN 0.5% EYE OINTMENT 5 GM TUBE	1,000	TUBE	206.21	206,210.00		
189	ESMOLOL 100 mg/mL, 10 mL vial (IV)	50	VIAL	800.00	40,000.00		
190	ETHAMBUTOL 400 MG TABLET	1,000	TABLET	9.56	9,560.00		
191	ETOPOSIDE 20MG/ML,5ML AMPULE/VIAL	50	AMPULE/VIAL	429.00	21,450.00		
192	FAMOTIDINE 10 MG/ML,2ML AMPULE	4,000	AMPULE	131.11	524,440.00		

						BIDDER'S OFFER	
NO.	ARTICLES & DESCRIPTION	QTY	UNIT	UNIT COST PHP	ABC (php)	UNIT COST	TOTAL COST
193	FAMOTIDINE 20 MG TABLET	2,000	TABLET	32.08	64,160.00		
194	FELODIPINE 10MG TABLET	1,000	TABLET	19.15	19,150.00		
195	FELODIPINE 5 MG TABLET	500	TABLET	10.05	5,025.00		
196	FENOFIBRATE 160 MG TABLET	4,000	TABLET	34.81	139,240.00		
197	FENOFIBRATE 200 MG CAPSULE	5,000	CAPSULE	18.51	92,550.00		
198	FENTANYL 50MCG/2ML AMPULE	5,000	AMPULE	91.05	455,250.00		
199	FERROUS SALT+FOLIC ACID(60 MG ELEMENTAL IRON+400 MICROGRAM FOLIC ACID) TABLET	6,000	TABLET	0.96	5,760.00		
200	FERROUS SULFATE 60 MG ELEMENTAL IRON TABLET	5,000	TABLET	4.02	20,100.00		
201	FERROUS SULFATE 15MG/0.6ML,15 ML DROPS	200	BOTTLE	24.10	4,820.00		
202	FERROUS SULFATE 30MG/5ML,60 ML SYRUP	200	BOTTLE	28.08	5,616.00		
203	FILGRASTIM 300MG/ML VIAL	100	VIAL	1,642.85	164,285.00		
204	FLUCONAZOLE 150MG TABLET	1,500	TABLET	122.60	183,900.00		
205	FLUCONAZOLE 50 MG TABLET	1,000	TABLET	115.65	115,650.00		
206	FLUCONAZOLE 2MG/ML,100 ML VIAL	500	VIAL	522.20	261,100.00		
207	FLUOROURACIL 50MG/ML , 10 ML VIAL	1,000	VIAL	107.12	107,120.00		
208	FLUTICASONE 125+ SALMETEROL 25MCG 120 DOSES MDI	200	MDI	366.42	73,284.00		

						BIDDER'S OFFER	
NO.	ARTICLES & DESCRIPTION	QTY	UNIT	UNIT COST PHP	ABC (php)	UNIT COST	TOTAL COST
209	FLUTICASONE 250+SALMETEROL 25MCG 120 DOSES MDI	300	MDI	534.26	160,278.00		
210	FLUTICASONE 50 MCG+SALMETEROL 25MCG 120 DOSES MDI	100	MDI	261.11	26,111.00		
211	FLUTICASONE+SALMETEROL 250MCG+50MCG 60 DOSES DPI	300	DPI	851.07	255,321.00		
212	FLUTICASONE+SALMETEROL 500MCG+50MCG 60 DOSES DPI	300	DPI	1,272.50	381,750.00		
213	FOLIC ACID 5 MG TABLET	1,000	TABLET	3.08	3,080.00		
214	FUROSEMIDE 10 MG/ML , 2ML AMPULE	30,000	AMPULE	6.70	201,000.00		
215	FUROSEMIDE 20 MG TABLET	5,000	TABLET	1.40	7,000.00		
216	FUROSEMIDE 40 MG TABLET	5,000	TABLET	2.08	10,400.00		
217	FUSIDATE SODIUM/FUSIDIC ACID 2%,15 G OINTMENT TUBE	500	TUBE	143.27	71,635.00		
218	GABAPENTIN 100 MG CAPSULE	100	CAPSULE	13.39	1,339.00		
219	GABAPENTIN 300 MG CAPSULE	100	CAPSULE	15.41	1,541.00		
220	GADOBUTROL 1.0 MMOL/ML PREFILLED SYRINGE	200	PREFILLED SYRINGE	2,000.00	400,000.00		
221	GENTAMICIN 40 MG/ML ,2 ML (IM/IV)	20,000	AMPULE	4.41	88,200.00		
222	GLICLAZIDE 30MG/MR TABLET	500	TABLET	3.61	1,805.00		
223	GLICLAZIDE 80 MG TABLET	2,000	TABLET	4.02	8,040.00		
224	GLYCEROL 2 GM SUPPOSITORY(RECTAL) SUPPOSITORY	500	SUPPOSITORY	10.00	5,000.00		

						BIDDER'S OFFER	
NO.	ARTICLES & DESCRIPTION	QTY	UNIT	UNIT COST PHP	ABC (php)	UNIT COST	TOTAL COST
225	GLYCERYL TRINITRATE(NITROGLYCERIN) 1MG/ML,10 ML AMPULE	200	AMPULE	507.00	101,400.00		
226	HALOPERIDOL 5 MG TABLET	100	TABLET	3.78	378.00		
227	HALOPERIDOL 5 MG/ML ,1 ML AMPULE	50	AMPULE	158.27	7,913.50		
228	HEPATITIS B 10 MCG/0.5 ML VACCINE VIAL	100	VIAL	227.63	22,763.00		
229	HEPATITIS B 20 MCG/ ML,1 ML VACCINE VIAL	100	VIAL	286.55	28,655.00		
230	HYDRALAZINE 20 MG/ML , 1ML AMP	1,500	AMPULE	219.93	329,895.00		
231	HYDRALAZINE 25 MG TABLET	500	TABLET	25.20	12,600.00		
232	HYDROCORTISONE 100 MG (AS SODIUM SUCCINATE) VIAL	6,000	VIAL	29.32	175,920.00		
233	HYDROCORTISONE 250 MG (AS SODIUM SUCCINATE) VIAL	2,500	VIAL	86.75	216,875.00		
234	HYDROXYETHYL STARCH 6 % , 500 ML BOTTLE	500	BOTTLE	642.06	321,030.00		
235	HYOSCINE 10 MG (AS N-BUTYL BROMIDE) TABLET	5,000	TABLET	2.47	12,350.00		
236	HYOSCINE 20 MG/ML , 1 ML (AS N-BUTYL BROMIDE) AMPULE	10,000	AMPULE	15.11	151,100.00		
237	IBUPROFEN 100 MG/5ML SYRUP ,60ML	200	BOTTLE	45.50	9,100.00		
238	IBUPROFEN 400 MG	2,000	TABLET	1.25	2,500.00		
239	IFOSFAMIDE 2 GM VIAL	50	VIAL	2,634.23	131,711.50		
240	IMMUNOGLOBULIN NORMAL,HUMAN 50 MG /ML,10 ML(IGIV) VIAL	50	VIAL	2,145.00	107,250.00		

						BIDDER'S OFFER	
NO.	ARTICLES & DESCRIPTION	QTY	UNIT	UNIT COST PHP	ABC (php)	UNIT COST	TOTAL COST
241	IMMUNOGLOBULIN NORMAL,HUMAN 50 MG /ML,50 ML(IGIV) VIAL	50	VIAL	7,804.10	390,205.00		
242	INFLUENZA POLYVALENT VACCINE 0.5 ML+PREFILLED SYRINGE	500	AMPULE	468.65	234,325.00		
243	INSULIN,REGULAR 100IU,10 ML VIAL	1,000	VIAL	281.19	281,190.00		
244	INTRAOCULAR IRRIGATING SOLUTION 500 ML(BALANCED SALT SOLN	1,000	BOTTLE	508.82	508,820.00		
245	IOPAMIDOL 612MG/ML EQUIV TO 300 MG IODINE,50ML	1,000	VIAL	935.96	935,960.00		
246	IPRATROPIUM 500MCCG+SALBUTAMOL 2.5MG, 2.5ML	50,000	NEBULE	14.08	704,000.00		
247	IRON SUCROSE 20MG/ML, 5 ML	300	AMPULE	181.35	54,405.00		
248	ISOFLURANE 100ML BOTTLE	100	BOTTLE	2,877.82	287,782.00		
249	ISONIAZID 200MG/ML BOTTLE,120 ml SYRUP	200	BOTTLE	96.34	19,268.00		
250	ISONIAZID 400 MG TABLET	1,000	TABLET	3.00	3,000.00		
251	ISOPHANE HUMAN INSULIN 100 IU/ML , 10 ML VIAL	1,000	VIAL	233.90	233,900.00		
252	ISOSORBIDE 5 MONONITRATE 40 MG TABLET	3,000	TABLET	13.00	39,000.00		
253	ISOSORBIDE 5 MONONITRATE 60 MG TABLET MR	2,000	TABLET	8.71	17,420.00		
254	ISOSORBIDE DINITRATE 1 MG/ML,10 ML AMPULE	1,500	AMPULE	533.99	800,985.00		
255	ISOSORBIDE DINITRATE 10 MG TABLET	3,000	TABLET	13.68	41,040.00		
256	ISOSORBIDE DINITRATE 20 MG TABLET	4,000	TABLET	15.95	63,800.00		

						BIDDER'S OFFER	
NO.	ARTICLES & DESCRIPTION	QTY	UNIT	UNIT COST PHP	ABC (php)	UNIT COST	TOTAL COST
257	ISOSORBIDE DINITRATE 5 MG SUBLINGUAL TABLET	6,000	TABLET	11.31	67,860.00		
258	ISOXSUPRINE HCL 5MG/ML,2 ML AMPULE	2,000	AMPULE	148.43	296,860.00		
259	KETAMINE 50MG/ML,10 ML VIAL	300	VIAL	1,033.70	310,110.00		
260	KETOROLAC 30 MG/ML, 1 ML AMPULE	15,000	AMPULE	31.19	467,850.00		
261	LACTULOSE 3.3 G/5ML SYRUP, 120 ML BOTTLE	1,000	BOTTLE	86.89	86,890.00		
262	LAGUNDI 300MG/5ML SYRUP, 60 ML BOTTLE	100	BOTTLE	80.34	8,034.00		
263	LAGUNDI 600 MG TABLET	500	TABLET	4.02	2,010.00		
264	LETROZOLE 2.5 MG TABLET	500	TABLET	137.80	68,900.00		
265	LEVODOPA+CARBIDOPA 250 MG+25 MG TABLET	200	TABLET	59.71	11,942.00		
266	LEVOFLOXACIN 500 MG TABLET	1,000	TABLET	10.63	10,630.00		
267	LEVOFLOXACIN 5MG/ML, 100 ML VIAL	500	VIAL	334.75	167,375.00		
268	LEVOFLOXACIN 750 MG TABLET	1,000	TABLET	23.95	23,950.00		
269	LEVOTHYROXINE 100 MCG TABLET	1,000	TABLET	11.45	11,450.00		
270	LEVOTHYROXINE 150 MCG TABLET	1,000	TABLET	14.07	14,070.00		
271	LEVOTHYROXINE 50 MCG TABLET	1,000	TABLET	5.02	5,020.00		
272	LIDOCAINE 10%, 50ML SPRAY BOTTLE	10	BOTTLE	2,210.20	22,102.00		

						BIDDER'S OFFER	
NO.	ARTICLES & DESCRIPTION	QTY	UNIT	UNIT COST PHP	ABC (php)	UNIT COST	TOTAL COST
273	LIDOCAINE 2% WITH EPINEPHRINE,1.8ML CAPSULE	10,000	CAPSULE	24.10	241,000.00		
274	LIDOCAINE 2% 5 ML POLYAMPULE	20,000	POLYAMPULE	11.39	227,800.00		
275	LIPIDS 10% 500 ML BOTTLE	300	BOTTLE	1,044.42	313,326.00		
276	LOPERAMIDE 2 MG CAPSULE	2,000	CAPSULE	0.57	1,140.00		
277	LORATADINE 10 MG TABLET	2,000	TABLET	2.95	5,900.00		
278	LORATADINE 5MG/5ML SYRUP, 30 ML BOTTLE	100	BOTTLE	52.22	5,222.00		
279	LOSARTAN 100 MG TABLET	2,000	TABLET	3.77	7,540.00		
280	LOSARTAN+HYDROCHLOROTHIAZIDE 50MG+12.5 MG TABLET	2,000	TABLET	2.50	5,000.00		
281	MAGNESIUM SULFATE 250 MG/ML, 10 ML AMPULE	4,000	AMPULE	19.79	79,160.00		
282	MANNITOL 20% 500 ML BOTTLE	2,000	BOTTLE	119.82	239,640.00		
283	MEBENDAZOLE 100MG/5ML SUSPENSION,60 ML	100	BOTTLE	19.02	1,902.00		
284	MEBENDAZOLE 500 MG TABLET	1,000	TABLET	2.56	2,560.00		
285	MEDROXYPROGESTERONE 150MG/ML,1 ML VIAL	100	VIAL	65.42	6,542.00		
286	MEFENAMIC ACID 250 MG TABLET	2,000	TABLET	0.62	1,240.00		
287	MEFENAMIC ACID 500 MG TABLET	10,000	TABLET	0.61	6,100.00		
288	MERCAPTOPURINE 50 MG TABLET	1,000	TABLET	26.78	26,780.00		

						BIDDER'S OFFER	
NO.	ARTICLES & DESCRIPTION	QTY	UNIT	UNIT COST PHP	ABC (php)	UNIT COST	TOTAL COST
289	MEROPENEM 1 GM VIAL	5,000	VIAL	372.68	1,863,400.00		
290	MEROPENEM 500 MG VIAL	5,000	VIAL	233.65	1,168,250.00		
291	MESNA 100MG/ML, 4 ML AMPULE	100	AMPULE	214.24	21,424.00		
292	METFORMIN HYDROCHLORIDE 850 MG TABLET	2,000	TABLET	9.32	18,640.00		
293	METHOTREXATE 2.5 MG TABLET	1,000	TABLET	14.30	14,300.00		
294	METHOTREXATE 25MG/ML, 2 ML VIAL	200	VIAL	173.56	34,712.00		
295	METHYLDOPA 250 MG TABLET	5,000	TABLET	16.07	80,350.00		
296	METHYLPREDNISOLONE 16 MG TABLET	2,000	TABLET	21.91	43,820.00		
297	METHYLPREDNISOLONE 1GM/16ML+DILUENT POWDER	50	VIAL	3,152.72	157,636.00		
298	METHYLPREDNISOLONE 4 MG TABLET	500	TABLET	8.63	4,315.00		
299	METOCLOPRAMIDE 10 MG TABLET	2,000	TABLET	2.22	4,440.00		
300	METOCLOPRAMIDE 5MG/ML,2 ML AMPULE	5,000	AMPULE	4.00	20,000.00		
301	METOPROLOL 100 MG TABLET	1,000	TABLET	2.03	2,030.00		
302	METOPROLOL 50 MG TABLET	1,000	TABLET	2.02	2,020.00		
303	METRONIDAZOLE 125MG/5MLSUSPENSION, 60 ML BOTTLE	200	BOTTLE	19.75	3,950.00		
304	METRONIDAZOLE 500 MG TABLET	5,000	TABLET	1.29	6,450.00		

						BIDDER'S OFFER	
NO.	ARTICLES & DESCRIPTION	QTY	UNIT	UNIT COST PHP	ABC (php)	UNIT COST	TOTAL COST
305	METRONIDAZOLE 5MG/ML, 100 ML VIAL	5,000	VIAL	16.20	81,000.00		
306	MIDAZOLAM 15 MG TABLET	100	TABLET	31.47	3,147.00		
307	MIDAZOLAM 5MG/ML, 1 ML AMPULE	5,000	AMPULE	104.16	520,800.00		
308	MODIFIED FLUID GELATIN 4 % SOLUTION 500 ML BOTTLE	500	BOTTLE	669.50	334,750.00		
309	MONOBASIC/DIBASIC SODIUM PHOSPATE 19G/7G/133ML, RECTAL	500	BOTTLE	241.02	120,510.00		
310	MONOBASIC/DIBASIC SODIUM PHOSPATE 48G/18G/100ML SOLN,45ML, ORAL	500	BOTTLE	241.02	120,510.00		
311	MONTELUKAST 10 MG TAB	4,000	TABLET	13.39	53,560.00		
312	MONTELUKAST 4 MG ,CHEWABLE	2,000	TABLET	9.27	18,540.00		
313	MONTELUKAST 5 MG ,CHEWABLE	2,000	TABLET	10.54	21,080.00		
314	MORPHINE SULFATE 10 MG	3,000	TABLET	27.31	81,930.00		
315	MORPHINE SULFATE 10MG/ML AMPULE(IM/IV/SC),1ML (HYDROCHLORIDE)	5,000	AMPULE	66.95	334,750.00		
316	MORPHINE SULFATE 30 MG TAB	1,000	TABLET	66.95	66,950.00		
317	MULTIVITAMINS FOR ADULTS CAPSULE	10,000	CAPSULE	1.34	13,400.00		
318	MULTIVITAMINS PER 1ML, 15ML DROPS BOTTLE	500	BOTTLE	29.33	14,665.00		
319	MULTIVITAMINS PER 5ML, 60 ML SYRUP BOTTLE	500	BOTTLE	24.10	12,050.00		
320	MUPIROCIN 2%, 5 GM OINTMENT	1,000	TUBE	78.18	78,180.00		

						BIDDER'S OFFER	
NO.	ARTICLES & DESCRIPTION	QTY	UNIT	UNIT COST PHP	ABC (php)	UNIT COST	TOTAL COST
321	NALBUPHINE 10 MG/ML, 1ML (IM/IV/SC)(AS HYDROCHLORIDE) AMPULE	5,000	AMPULE	83.85	419,250.00		
322	NALOXONE HCL 400MCG/ML,1ML AMPULE	20	AMPULE	509.60	10,192.00		
323	NAPROXEN SODIUM 550 MG TABLET	2,000	TABLET	3.37	6,740.00		
324	NEOSTIGMINE 500 MCG/ML (IM/IV/SC) AMPULE	10	AMPULE	121.84	1,218.40		
325	NICARDIPINE 1MG/ML , 10ML AMPULE	2,000	AMPULE	816.79	1,633,580.00		
326	NICARDIPINE 1MG/ML , 2 ML AMPULE	100	AMPULE	195.49	19,549.00		
327	NIFEDIPINE 10 MG CAPSULE	5,000	CAPSULE	4.55	22,750.00		
328	NIFEDIPINE 30 MG MR TABLET	2,000	TABLET	45.24	90,480.00		
329	NITROFURANTOIN 100 MG CAPSULE	1,000	CAPSULE	5.20	5,200.00		
330	NOREPINEPHRINE 1MG/ML, 2ML AMPULE	3,000	AMPULE	245.56	736,680.00		
331	NOREPINEPHRINE 1MG/ML, 4ML AMPULE	1,000	AMPULE	707.82	707,820.00		
332	NYSTATIN 100,000 U/ML SUSPENSION,30ML	50	BOTTLE	257.76	12,888.00		
333	OFLOXACIN 200 MG TABLET	500	TABLET	5.36	2,680.00		
334	OMEPRAZOLE 20 MG CAPSULE	4,000	CAPSULE	1.31	5,240.00		
335	OMEPRAZOLE 40 MG CAPSULE	6,000	CAPSULE	13.39	80,340.00		
336	OMEPRAZOLE 40 MG POWDER+10ML SOLVENT VIAL	15,000	VIAL	50.87	763,050.00		

						BIDDER'S OFFER	
NO.	ARTICLES & DESCRIPTION	QTY	UNIT	UNIT COST PHP	ABC (php)	UNIT COST	TOTAL COST
337	ONDANSETRON 2MG/ML,4ML AMPULE	600	AMPULE	293.24	175,944.00		
338	ONDANSETRON 8 MG TABLET	200	TABLET	20.00	4,000.00		
339	ORAL REHYDRATION SALTS SACHET(ORS 75 REPLACEMENT) 5.125 GM	5,000	SACHET	3.48	17,400.00		
340	OXACILLIN 500 MG VIAL	10,000	VIAL	27.42	274,200.00		
341	OXALIPLATIN 50 MG VIAL	100	VIAL	4,950.00	495,000.00		
342	OXALIPLATIN 5MG/ML,20 ML VIAL	50	VIAL	10,342.00	517,100.00		
343	OXYCODONE 10 MG TABLET	28	TABLET	165.31	4,628.68		
344	OXYMETAZOLINE 0.025%,15ML,NASAL DROPS(AS HYDROCHLORIDE) BOTTLE	100	BOTTLE	237.00	23,700.00		
345	OXYMETAZOLINE 0.05%,10ML,NASAL SPRAY(AS HYDROCHLORIDE) BOTTLE	100	BOTTLE	276.12	27,612.00		
346	OXYTOCIN 10 IU /ML, 1 ML AMPULE	2,000	AMPULE	12.86	25,720.00		
347	PACLITAXEL 6MG/ML,17ML	200	VIAL	2,379.30	475,860.00		
348	PACLITAXEL 6MG/ML,25	100	VIAL	6,900.00	690,000.00		
349	PARACETAMOL 500 MG TABLET	20,000	TABLET	0.30	6,000.00		
350	PARACETAMOL 100MG/ML DROPS,15ML(ALCOHOL FREE)	500	BOTTLE	15.73	7,865.00		
351	PARACETAMOL 10MG/ML,100 ML VIAL	2,000	VIAL	398.01	796,020.00		
352	PARACETAMOL 125 MG SUPPOSITORY	1,000	SUPPOSITORY	25.77	25,770.00		

						BIDDER'S OFFER	
NO.	ARTICLES & DESCRIPTION	QTY	UNIT	UNIT COST PHP	ABC (php)	UNIT COST	TOTAL COST
353	PARACETAMOL 125MG/ML SYRUP,60ML(125MG/ML)(ALCOHOL FREE)	300	BOTTLE	15.73	4,719.00		
354	PARACETAMOL 150MG/2ML,AMPULE	30,000	AMPULE	7.37	221,100.00		
355	PARACETAMOL 250MG/ML SYRUP, 60ML	300	BOTTLE	16.74	5,022.00		
356	PENICILLIN G BENZATHINE 1,200,000 UNITS VIAL	1,000	VIAL	71.77	71,770.00		
357	PENICILLIN G CRYSTALLINE 1 MILLION UNITS (AS SODIUM SALT) VIAL	20,000	VIAL	6.85	137,000.00		
358	PENICILLIN G CRYSTALLINE 5 MILLION UNITS VIAL	3,000	VIAL	19.98	59,940.00		
359	PETHIDINE 50MG/ML AMPULE(IM/IV/SC),2 ML AMPULE	30	AMPULE	246.81	7,404.30		
360	PETROLEUM JELLY USP GRADE 25 GM JAR	500	JAR	30.00	15,000.00		
361	PHENOBARBITAL 130MG/ML (IM/IV),1ML	500	AMPULE	636.73	318,365.00		
362	PHENOBARBITAL 15 MG TABLET	1,000	TABLET	2.56	2,560.00		
363	PHENOBARBITAL 30 MG TABLET	1,000	TABLET	3.13	3,130.00		
364	PHENOBARBITAL 60 MG TABLET	1,000	TABLET	4.55	4,550.00		
365	PHENOBARBITAL 90 MG TABLET	1,000	TABLET	4.00	4,000.00		
366	PHENYTOIN 100 MG CAPSULE	10,000	CAPSULE	14.87	148,700.00		
367	PHENYTOIN 30MG/5ML SUSPENSION,120 ML	100	BOTTLE	205.74	20,574.00		
368	PHENYTOIN 50MG/ML ,2ML(IM/IV),2ML AMPULE	3,000		274.50	823,500.00		

						BIDDER'S OFFER	
NO.	ARTICLES & DESCRIPTION	QTY	UNIT	UNIT COST PHP	ABC (php)	UNIT COST	TOTAL COST
369	PHENYTOIN 50MG/ML,5 ML AMPULE	100	AMPULE	361.53	36,153.00		
370	PHYTOMENADIONE 10 MG/ML (IM/IV/SC),1 ML AMPULE	8,000	AMPULE	23.95	191,600.00		
371	PIPERACILLIN TAZOBACTAM 2.25 GM VIAL	7,000	VIAL	97.23	680,610.00		
372	PIPERACILLIN TAZOBACTAM 4.5 GM VIAL	6,000	VIAL	136.29	817,740.00		
373	PNEUMOCCOCAL POLYVALENT VACCINE,25MCG/0.5ML PREFILLED	50	VIAL	696.28	34,814.00		
374	POTASSIUM CHLORDE 2 MEQ/ML , 20 ML VIAL	6,000	VIAL	26.78	160,680.00		
375	POTASSIUM CHLORIDE 750 MG DURULES TABLET	6,000	TABLET	31.21	187,260.00		
376	POTASSIUM CITRATE 10 MEQ TABLET	1,000	TABLET	15.41	15,410.00		
377	POVIDONE IODINE 1% ORAL ANTISEPTIC, 60 ML BOTTLE	300	BOTTLE	100.43	30,129.00		
378	POVIDONE IODINE 7.5% SURGICAL CLEANSER, 60 ML BOTTLE	500	BOTTLE	133.10	66,550.00		
379	PREDNISOLONE 0.5%, 5ML EYE DROPS	300	BOTTLE	210.22	63,066.00		
380	PREDNISONE 10 MG TABLET	1,000	TABLET	5.36	5,360.00		
381	PREDNISONE 10 MG/5ML SUSPENSION, 60 ML	100	BOTTLE	120.51	12,051.00		
382	PREDNISONE 5 MG TABLET	1,000	TABLET	1.05	1,050.00		
383	PROPANOLOL 10 MG TABLET	3,000	TABLET	12.99	38,970.00		
384	PROPANOLOL 40 MG TABLET	4,000	TABLET	18.16	72,640.00		

						BIDDER'S OFFER	
NO.	ARTICLES & DESCRIPTION	QTY	UNIT	UNIT COST PHP	ABC (php)	UNIT COST	TOTAL COST
385	PROPOFOL 10MG/ML, 20ML VIAL	1,500	VIAL	144.27	216,405.00		
386	PROPOFOL 10MG/ML, 50ML PREFILLED SYRINGE	10	PREFILLED SYRINGE	1,356.03	13,560.30		
387	PROPYLTHIOURACIL 50 MG TABLET	5,000	TABLET	11.62	58,100.00		
388	PYRAZINAMIDE 250MG/ML SYRUP,120 ML	200	BOTTLE	100.43	20,086.00		
389	RANITIDINE 150 MG TABLET	500	TABLET	1.21	605.00		
390	RANITIDINE 25 MG/ML , 2 ML AMPULE	15,000	AMPULE	4.45	66,750.00		
391	RIFAMPICIN 200 MG/5ML , 120 ML SUSPENSION	200	BOTTLE	210.90	42,180.00		
392	ROCURONIUM 10MG/ML VIAL,5ML	50	VIAL	328.06	16,403.00		
393	ROPIVACAINE 10MG/ML,10 ML	50	AMPULE	456.65	22,832.50		
394	ROSUVASTATIN 10 MG (CALCIUM)	5,000	TABLET	10.95	54,750.00		
395	ROSUVASTATIN 20 MG (CALCIUM)	5,000	TABLET	15.30	76,500.00		
396	SALBUTAMOL 2MG/5ML, 60 ML SYRUP	100	BOTTLE	15.20	1,520.00		
397	SALBUTAMOL 2MG/ML,2.5 ML (AS SULFATE) NEBULE	7,000	NEBULE	8.31	58,170.00		
398	SAMBONG 500 MG TABLET	500	TABLET	7.90	3,950.00		
399	SEVOFLURANE 250 MG BOTTLE	200	BOTTLE	8,344.55	1,668,910.00		
400	SILVER SULFADIAZINE CREAM,25 GMS TUBE	500	TUBE	112.27	56,135.00		

						BIDDER'S OFFER	
NO.	ARTICLES & DESCRIPTION	QTY	UNIT	UNIT COST PHP	ABC (php)	UNIT COST	TOTAL COST
401	SIMVASTATIN 20 MG TABLET	6,000	TABLET	1.07	6,420.00		
402	SIMVASTATIN 40 MG TABLET	5,000	TABLET	5.06	25,300.00		
403	SODIUM BICARBONATE 1 MEQ/ML ,20 ML VIAL	3,000	VIAL	125.00	375,000.00		
404	SODIUM BICARBONATE 1 MEQ/ML ,50 ML VIAL	4,000	VIAL	85.70	342,800.00		
405	SODIUM BICARBONATE 650 MG TABLET	6,000	TABLET	6.50	39,000.00		
406	SODIUM CHLORIDE 2.5 MEQ/ML , 20ML	3,000	VIAL	38.83	116,490.00		
407	SODIUM SULFATE POWDER USP GRADE	1,000	GRAMS	3.00	3,000.00		
408	SOMATOSTATIN 250 MCG	300	AMPULE/VIAL	1,581.80	474,540.00		
409	SOMATOSTATIN 3MG VIAL	50	VIAL	4,830.21	241,510.50		
410	SPIRONOLACTONE 100 MG TAB	3,000	TABLET	31.28	93,840.00		
411	SPIRONOLACTONE 25 MG TAB	3,000	TABLET	12.95	38,850.00		
412	SPIRONOLACTONE 50 MG TAB	3,000	TABLET	33.15	99,450.00		
413	STERILE WATER FOR INJECTION 20 ML	8,000	AMPULE	32.81	262,480.00		
414	STREPTOKINASE 1,500,000 VIAL	50	VIAL	4,305.40	215,270.00		
415	SUXAMETHONIUM (SUCCINYLCHOLINE) 20MG/ML,10 ML VIAL	1,500	VIAL	241.02	361,530.00		
416	TAMOXIFEN 20 MG TABLET	5,000	TABLET	13.12	65,600.00		

						BIDDER'S OFFER	
NO.	ARTICLES & DESCRIPTION	QTY	UNIT	UNIT COST PHP	ABC (php)	UNIT COST	TOTAL COST
417	TAMSOLUSIN 200 MCG CAPSULE	2,000	CAPSULE	67.51	135,020.00		
418	TELMISARTAN 40 MG TABLET	200	TABLET	26.81	5,362.00		
419	TELMISARTAN 80 MG TABLET	200	TABLET	40.04	8,008.00		
420	TERBUTALINE SO4 2.5 MG/ML, 5 ML NEBULE	500	NEBULE	13.00	6,500.00		
421	TETANUS TOXOID 0.5ML AMPULE	7,000	AMPULE	60.26	421,820.00		
422	TETANUS TOXOID IMMUNOGLOBULIN(HUMAN)250IU/ML,1 ML AMPULE	100	AMPULE	977.47	97,747.00		
423	TETRACYCLINE 250 MG CAPSULE	200	CAPSULE	1.95	390.00		
424	TETRACYCLINE 500 MG CAPSULE	200	CAPSULE	2.47	494.00		
425	THEOPHYLLINE 200 MG TABLET	500	TABLET	140.00	70,000.00		
426	TIOTROPIUM 18MCG/DOSE DRY POWDER HANDIHALER	300	DPI	360.00	108,000.00		
427	TOBRAMYCIN 0.3%, 5ML EYEDROPS	300	BOTTLE	411.65	123,495.00		
428	TOBRAMYCIN DEXAMETHASONE 0.3%+0.1%, 5ML EYE DROPS	100	BOTTLE	307.97	30,797.00		
429	TRAMADOL 100 MG MR (AS HYDROCHLORIDE) TABLET	1,000	TABLET	94.48	94,480.00		
430	TRAMADOL 50 MG (AS HYDROCHLORIDE) CAPSULE	5,000	CAPSULE	2.64	13,200.00		
431	TRAMADOL 50 MG/ML, 2ML (IM/IVLSC) AMPULE	5,000	AMPULE	6.55	32,750.00		
432	TRAMADOL 50MG/ML ,1 ML(IM,IV,SC) AMPULE	20,000	AMPULE	11.99	239,800.00		

						BIDDER'S OFFER	
NO.	ARTICLES & DESCRIPTION	QTY	UNIT	UNIT COST PHP	ABC (php)	UNIT COST	TOTAL COST
433	TRANEXAMIC ACID 100 MG/ML ,5ML AMPULE	10,000	AMPULE	16.45	164,500.00		
434	TRANEXAMIC ACID 500 MG CAPSULE	6,000	CAPSULE	6.70	40,200.00		
435	TRIMETAZIDINE 35 MG TAB	1,000	TABLET	12.03	12,030.00		
436	TROPICAMIDE 0.5%, 5 ML EYE DROPS SOLUTION	200	BOTTLE	457.34	91,468.00		
437	URSODEOXYCHOLIC ACID 250 MG CAPSULE	1,000	CAPSULE	45.71	45,710.00		
438	VALPROATE SODIUM 250 MG (AS SODIUM SALT) TABLE	200	TABLET	31.03	6,206.00		
439	VALPROIC ACID 250MG/5ML,120 ML SYRUP	100	BOTTLE	669.50	66,950.00		
440	VALPROIC ACID 500MG/5ML, 5 ML VIAL	100	VIAL	1,927.38	192,738.00		
441	VANCOMYCIN 1 GM VIAL	500	VIAL	1,250.00	625,000.00		
442	VANCOMYCIN 500 MG VIAL	5,000	VIAL	211.56	1,057,800.00		
443	VERAPAMIL 2.5MG/ML,2ML AMPULE	100	AMPULE	169.25	16,925.00		
444	VERAPAMIL 80 MG TABLET	500	TABLET	57.79	28,895.00		
445	VINCRISTINE1MG/ML,2ML VIAL	200	VIAL	461.82	92,364.00		
446	VITAMIN B1B6B12(100MG+5MG+1MG),3ML AMPULE	1,000	AMPULE	82.82	82,820.00		
447	VITAMIN B1B6B12(100MG+5MG+50MCG) TABLET	6,000	TABLET	1.68	10,080.00		
448	WARFARIN 1 MG TABLET	2,000	TABLET	12.52	25,040.00		

						BIDDER'S OFFER	
NO.	ARTICLES & DESCRIPTION	QTY	UNIT	UNIT COST PHP	ABC (php)	UNIT COST	TOTAL COST
449	WARFARIN 2.5 MG TABLET	2,000	TABLET	13.92	27,840.00		
450	WARFARIN 5 MG TABLET	2,000	TABLET	19.28	38,560.00		
451	ZINC 27.5MG/ML,15ML DROPS BOTTLE	200	BOTTLE	50.88	10,176.00		
452	ZINC 55MG/5ML, 60ML SYRUP BOTTLE	200	BOTTLE	54.90	10,980.00		
453	ZOLPIDEM 10 MG TABLET	200	TABLET	65.00	13,000.00		
454	DEXTROSE 10% WATER 500 ML PLASTIC BOTTLE	1,000	BOTTLE	58.50	58,500.00		
455	DEXTROSE 5% BALANCE MULTIPLE MAINTENANCE SOLUTION 500 ML PLASTIC BOTTLE	7,000	BOTTLE	58.50	409,500.00		
456	DEXTROSE 5% LACTATED RINGERS SOLUTION 1 LITER PLASTIC BOTTLE	30,000	BOTTLE	58.50	1,755,000.00		
457	DEXTROSE 5% LACTATED RINGERS SOLUTION 500 ML PLASTIC BOTTLE	3,000	BOTTLE	58.50	175,500.00		
458	DEXTROSE 5%0.3 SODIUM CHLORIDE 1 LITER PLASTIC BOTTLE	5,000	BOTTLE	58.50	292,500.00		
459	DEXTROSE 5% 0.9% SODIUM CHLORIDE 1 LITER PLASTIC BOTTLE	7,000	BOTTLE	58.50	409,500.00		
460	DEXTROSE 5% 0.9% SODIUM CHLORIDE 500 ML PLASTIC BOTTLE	5,000	BOTTLE	58.50	292,500.00		
461	DEXTROSE 5% BALANCE MULTIPLE MAINTENANCE SOLUTION 1 LITER PLASTIC BOTTLE	6,000	BOTTLE	58.50	351,000.00		
462	0.9% SODIUM CHLORIDE 1 LITER PLASTIC BOTTLE	75,000	BOTTLE	58.50	4,387,500.00		
463	0.9% SODIUM CHLORIDE 500 ML PLASTIC BOTTLE	4,000	BOTTLE	58.50	234,000.00		
464	0.9% SODIUM CHLORIDE IRRIGATION SOLUTION 1 LITER PLASTIC BOTTLE	6,000	BOTTLE	58.50	351,000.00		

						BIDDER'S OFFER	
NO.	ARTICLES & DESCRIPTION	QTY	UNIT	UNIT COST PHP	ABC (php)	UNIT COST	TOTAL COST
465	DEXTROSE 5% NORMOSOL RINGERS 1 LITER	300	BOTTLE	58.50	17,550.00		
466	DEXTROSE 5% WATER 1 LITER PLASTIC BOTTLE	3,000	BOTTLE	58.50	175,500.00		
467	DEXTROSE 5% WATER 250 ML GLASS BOTTLE	1,000	BOTTLE	80.00	80,000.00		
468	LACTATED RINGERS SOLUTION 1 LITER PLASTIC BOTTLE	5,000	BOTTLE	58.50	292,500.00		
469	LACTATED RINGERS SOLUTION 500 ML PLASTIC BOTTLE	5,000	BOTTLE	58.50	292,500.00		
470	CHLORPRAZAMINE 100 MG TABLET	2,000	TABLET	1.51	3,020.00		
471	CLOZAPINE 100 MG TABLET	1,000	TABLET	17.06	17,060.00		
472	OLANZEPINE 5 MG TABLET	500	TABLET	75.00	37,500.00		
473	OLANZEPINE 10 MG TABLET	500	TABLET	36.15	18,075.00		
474	RESPERIDONE 1 MG TABLET	2,000	TABLET	20.28	40,560.00		
475	RESPERIDONE 2 MG TABLET	2,000	TABLET	19.28	38,560.00		
476	RESPERIDONE 3 MG TABLET	2,000	TABLET	45.00	90,000.00		
477	ESCITALOPRAM 10 MG TABLET	500	TABLET	196.40	98,200.00		
478	QUETIAPINE 100 MG TABLET	500	TABLET	32.27	16,135.00		
479	QUETIAPINE 300 MG TABLET	500	TABLET	86.76	43,380.00		
480	SERTRALINE 50 MG TABLET	300	TABLET	160.60	48,180.00		

						BIDDER'S OFFER	
NO.	**ARTICLES & DESCRIPTION**	**QTY**	**UNIT**	**UNIT COST PHP**	**ABC (php)**	**UNIT COST**	**TOTAL COST**
481	ALPRAZOLAM 250 MCG TABLET	1,000	TABLET	82.40	82,400.00		
482	ALPRAZOLAM 500 MCG TABLET	1,000	TABLET	195.80	195,800.00		
483	FLUPHENAZINE 25 MG/ML,10ML	50	VIAL	520.87	26,043.50		
484	LITHIUM CARBONATE 450 MG TABLET MR	500	TABLET	216.50	108,250.00		
				TOTAL BID AMOUNT			

Please see attached terms & conditions:

Name and Signature of Company's Representative

ELIZABETH V. PALINES MD, FPPS, FPNA, FCNSP
HBAC Chairman

Bid Form

Date: _____
Invitation to Bid[3] N[o]: _____

To: [name and address of Procuring Entity]

Gentlemen and/or Ladies:

Having examined the Bidding Documents including Bid Bulletin Numbers *[insert numbers]*, the receipt of which is hereby duly acknowledged, we, the undersigned, offer to *[supply/deliver/perform] [description of the Goods]* in conformity with the said Bidding Documents for the sum of *[total Bid amount in words and figures]* or such other sums as may be ascertained in accordance with the Schedule of Prices attached herewith and made part of this Bid.

We undertake, if our Bid is accepted, to deliver the goods in accordance with the delivery schedule specified in the Schedule of Requirements.

If our Bid is accepted, we undertake to provide a performance security in the form, amounts, and within the times specified in the Bidding Documents.

We agree to abide by this Bid for the Bid Validity Period specified in **BDS** provision for **ITB** Clause 18.2 and it shall remain binding upon us and may be accepted at any time before the expiration of that period.

Commissions or gratuities, if any, paid or to be paid by us to agents relating to this Bid, and to contract execution if we are awarded the contract, are listed below:[4]

Name and address of agent	Amount and Currency	Purpose of Commission or gratuity

(if none, state "None")

Until a formal Contract is prepared and executed, this Bid, together with your written acceptance thereof and your Notice of Award, shall be binding upon us.

We understand that you are not bound to accept the Lowest Calculated Bid or any Bid you may receive.

[3] If ADB, JICA and WB funded projects, use IFB.

[4] Applicable only if the Funding Source is the ADB, JICA or WB.

We certify/confirm that we comply with the eligibility requirements as per **ITB** Clause 5 of the Bidding Documents.

We likewise certify/confirm that the undersigned, *[for sole proprietorships, insert:* as the owner and sole proprietor or authorized representative of *Name of Bidder*, has the full power and authority to participate, submit the bid, and to sign and execute the ensuing contract, on the latter's behalf for the *Name of Project* of the *Name of the Procuring Entity] [for partnerships, corporations, cooperatives, or joint ventures, insert:* is granted full power and authority by the *Name of Bidder,* to participate, submit the bid, and to sign and execute the ensuing contract on the latter's behalf for *Name of Project* of the *Name of the Procuring Entity]*.

We acknowledge that failure to sign each and every page of this Bid Form, including the attached Schedule of Prices, shall be a ground for the rejection of our bid.

Dated this _____ day of _____ 20_____.

_____ _____

[signature] *[in the capacity of]*

Duly authorized to sign Bid for and on behalf of _____

For Goods Offered From Abroad

Name of Bidder _____. Invitation to Bid[5] Number ___. Page ____ of _____.

1	2	3	4	5	6	7	8	9
Item	Description	Country of origin	Quantity	Unit price CIF port of entry (specify port) or CIP named place (specify border point or place of destination)	Total CIF or CIP price per item (col. 4 x 5)	Unit Price Delivered Duty Unpaid (DDU)	Unit price Delivered Duty Paid (DDP)	Total Price delivered DDP (col 4 x 8)

_____ _____

[signature] *[in the capacity of]*

Duly authorized to sign Bid for and on behalf of ___ _____

[5] If ADB, JICA and WB funded projects, use IFB.

For Goods Offered From Within the Philippines

Name of Bidder _____. Invitation to Bid[6] Number _. Page . of ___.

1	2	3	4	5	6	7	8	9	10
Item	Description	Country of origin	Quantity	Unit price EXW per item	Transportation and Insurance and all other costs incidental to delivery, per item	Sales and other taxes payable if Contract is awarded, per item	Cost of Incidental Services, if applicable, per item	Total Price, per unit (col 5+6+7+8)	Total Price delivered Final Destination (col 9) x (col 4)

_____ _____

[signature] *[in the capacity of]*

Duly authorized to sign Bid for and on behalf of _____

[6] If ADB, JICA and WB funded projects, use IFB.

Contract Agreement Form

THIS AGREEMENT made the _____ day of _____ 20_____ between *[name of PROCURING ENTITY]* of the Philippines (hereinafter called "the Entity") of the one part and *[name of Supplier]* of *[city and country of Supplier]* (hereinafter called "the Supplier") of the other part:

WHEREAS the Entity invited Bids for certain goods and ancillary services, viz., *[brief description of goods and services]* and has accepted a Bid by the Supplier for the supply of those goods and services in the sum of *[contract price in words and figures]* (hereinafter called "the Contract Price").

NOW THIS AGREEMENT WITNESSETH AS FOLLOWS:

1. In this Agreement words and expressions shall have the same meanings as are respectively assigned to them in the Conditions of Contract referred to.

2. The following documents shall be deemed to form and be read and construed as part of this Agreement, viz.:

(a) the Supplier's Bid, including the Technical and Financial Proposals, and all other documents/statements submitted (*e.g.* bidder's response to clarifications on the bid), including corrections to the bid resulting from the Procuring Entity's bid evaluation;
(b) the Schedule of Requirements;
(c) the Technical Specifications;
(d) the General Conditions of Contract;
(e) the Special Conditions of Contract;
(f) the Performance Security; and
(g) the Entity's Notice of Award.

3. In consideration of the payments to be made by the Entity to the Supplier as hereinafter mentioned, the Supplier hereby covenants with the Entity to provide the goods and services and to remedy defects therein in conformity in all respects with the provisions of the Contract

4. The Entity hereby covenants to pay the Supplier in consideration of the provision of the goods and services and the remedying of defects therein, the Contract Price or such other sum as may become payable under the provisions of the contract at the time and in the manner prescribed by the contract.

IN WITNESS whereof the parties hereto have caused this Agreement to be executed in accordance with the laws of the Republic of the Philippines on the day and year first above written.

Signed, sealed, delivered by _____ the _____ (for the Entity)

Signed, sealed, delivered by _____ the _____ (for the Supplier).

Omnibus Sworn Statement

REPUBLIC OF THE PHILIPPINES)
CITY/MUNICIPALITY OF _____) S.S.

A F F I D A V I T

I, *[Name of Affiant]*, of legal age, *[Civil Status]*, *[Nationality]*, and residing at *[Address of Affiant]*, after having been duly sworn in accordance with law, do hereby depose and state that:

1. ***Select one, delete the other:***

   If a sole proprietorship: I am the sole proprietor or authorized representative of *[Name of Bidder]* with office address at *[address of Bidder]*;

   If a partnership, corporation, cooperative, or joint venture: I am the duly authorized and designated representative of *[Name of Bidder]* with office address at *[address of Bidder]*;

2. ***Select one, delete the other:***

   If a sole proprietorship: As the owner and sole proprietor, or authorized representative of *[Name of Bidder]*, I have full power and authority to do, execute and perform any and all acts necessary to participate, submit the bid, and to sign and execute the ensuing contract for *[Name of the Project]* of the *[Name of the Procuring Entity], as shown in the attached duly notarized Special Power of Attorney*;

   If a partnership, corporation, cooperative, or joint venture: I am granted full power and authority to do, execute and perform any and all acts necessary to participate, submit the bid, and to sign and execute the ensuing contract for *[Name of the Project]* of the *[Name of the Procuring Entity]*, as shown in the attached *[state title of attached document showing proof of authorization (e.g., duly notarized Secretary's Certificate, Board/Partnership Resolution, or Special Power of Attorney, whichever is applicable;)]*;

3. *[Name of Bidder]* is not "blacklisted" or barred from bidding by the Government of the Philippines or any of its agencies, offices, corporations, or Local Government Units, foreign government/foreign or international financing institution whose blacklisting rules have been recognized by the Government Procurement Policy Board;

4. Each of the documents submitted in satisfaction of the bidding requirements is an authentic copy of the original, complete, and all statements and information provided therein are true and correct;

5. *[Name of Bidder]* is authorizing the Head of the Procuring Entity or its duly authorized representative(s) to verify all the documents submitted;

6. ***Select one, delete the rest:***

   If a sole proprietorship: The owner or sole proprietor is not related to the Head of the Procuring Entity, members of the Bids and Awards Committee (BAC), the Technical Working Group, and the BAC Secretariat, the head of the Project Management Office or the end-user unit, and the project consultants by consanguinity or affinity up to the third civil degree;

   If a partnership or cooperative: None of the officers and members of *[Name of Bidder]* is related to the Head of the Procuring Entity, members of the Bids and Awards Committee (BAC), the Technical Working Group, and the BAC Secretariat, the head of the Project Management Office or the end-user unit, and the project consultants by consanguinity or affinity up to the third civil degree;

   If a corporation or joint venture: None of the officers, directors, and controlling stockholders of *[Name of Bidder]* is related to the Head of the Procuring Entity, members of the Bids and Awards Committee (BAC), the Technical Working Group, and the BAC Secretariat, the head of the Project Management Office or the end-user unit, and the project consultants by consanguinity or affinity up to the third civil degree;

7. *[Name of Bidder]* complies with existing labor laws and standards; and

8. *[Name of Bidder]* is aware of and has undertaken the following responsibilities as a Bidder:

   a) Carefully examine all of the Bidding Documents;

   b) Acknowledge all conditions, local or otherwise, affecting the implementation of the Contract;

   c) Made an estimate of the facilities available and needed for the contract to be bid, if any; and

   d) Inquire or secure Supplemental/Bid Bulletin(s) issued for the *[Name of the Project]*.

9. *[Name of Bidder]* did not give or pay directly or indirectly, any commission, amount, fee, or any form of consideration, pecuniary or otherwise, to any person or official, personnel or representative of the government in relation to any procurement project or activity.

IN WITNESS WHEREOF, I have hereunto set my hand this __ day of ___, 20__ at _____, Philippines.

_____
Bidder's Representative/Authorized Signatory

SUBSCRIBED AND SWORN to before me this ___ day of *[month] [year]* at *[place of execution]*, Philippines. Affiant/s is/are personally known to me and was/were identified by me through competent evidence of identity as defined in the 2004 Rules on Notarial Practice (A.M. No. 02-8-13-SC). Affiant/s exhibited to me his/her [insert type of government identification card used], with his/her photograph and signature appearing thereon, with no. _____ and his/her Community Tax Certificate No. _____ issued on ____ at _____.

Witness my hand and seal this ___ day of *[month] [year]*.

NAME OF NOTARY PUBLIC
Serial No. of Commission _____
Notary Public for _____ until _____
Roll of Attorneys No. _____
PTR No. _____ *[date issued], [place issued]*
IBP No. _____ *[date issued], [place issued]*

Doc. No. _____
Page No. _____
Book No. _____
Series of _____

* This form will not apply for WB funded projects.

Bank Guarantee Form for Advance Payment

To: *[name and address of PROCURING ENTITY]*
[name of Contract]

Gentlemen and/or Ladies:

In accordance with the payment provision included in the Special Conditions of Contract, which amends Clause 10 of the General Conditions of Contract to provide for advance payment, *[name and address of Supplier]* (hereinafter called the "Supplier") shall deposit with the PROCURING ENTITY a bank guarantee to guarantee its proper and faithful performance under the said Clause of the Contract in an amount of *[amount of guarantee in figures and words]*.

We, the *[bank or financial institution]*, as instructed by the Supplier, agree unconditionally and irrevocably to guarantee as primary obligator and not as surety merely, the payment to the PROCURING ENTITY on its first demand without whatsoever right of objection on our part and without its first claim to the Supplier, in the amount not exceeding *[amount of guarantee in figures and words]*.

We further agree that no change or addition to or other modification of the terms of the Contract to be performed thereunder or of any of the Contract documents which may be made between the PROCURING ENTITY and the Supplier, shall in any way release us from any liability under this guarantee, and we hereby waive notice of any such change, addition, or modification.

This guarantee shall remain valid and in full effect from the date of the advance payment received by the Supplier under the Contract until *[date]*.

Yours truly,

Signature and seal of the Guarantors

_____
[name of bank or financial institution]

_____
[address]

_____
[date]

BID SECURING DECLARATION FORM

REPUBLIC OF THE PHILIPPINES)
CITY OF _____) S.S.

x----------x

BID SECURING DECLARATION
Invitation to Bid: *[Insert Reference number]*

To: *[Insert name and address of the Procuring Entity]*

I/We[7], the undersigned, declare that:

1. I/We understand that, according to your conditions, bids must be supported by a Bid Security, which may be in the form of a Bid-Securing Declaration.

2. I/We accept that: (a) I/we will be automatically disqualified from bidding for any contract with any procuring entity for a period of two (2) years upon receipt of your Blacklisting order; and, (b) I/we will pay the applicable fine provided under Section 6 of the Guidelines on the Use of Bid Securing Declaration, within fifteen (15) days from receipt of the written demand by the procuring entity for the commission of acts resulting to the enforcement of the bid securing declaration under Sections 23.1(b), 34.2, 40.1 and 69.1, except 69.1(f), of the IRR of RA 9184; without prejudice to other legal action the government may undertake.

3. I/We understand that this Bid Securing Declaration shall cease to be valid on the following circumstances:

    (a) Upon expiration of the bid validity period, or any extension thereof pursuant to your request;

    (b) I am/we are declared ineligible or post-disqualified upon receipt of your notice to such effect, and (i) I/we failed to timely file a request for reconsideration or (ii) I/we filed a waiver to avail of said right;

    (c) I am/we are declared the bidder with the Lowest Calculated Responsive Bid, and I/we have furnished the performance security and signed the Contract.

---

[7] *Select one and delete the other. Adopt the same instruction for similar terms throughout the document.*

IN WITNESS WHEREOF, I/We have hereunto set my/our hand/s this ____ day of *[month] [year]* at *[place of execution]*.

[Insert NAME OF BIDDER'S AUTHORIZED REPRESENTATIVE]
[Insert Signatory's Legal Capacity]
Affiant

SUBSCRIBED AND SWORN to before me this ___ day of *[month] [year]* at *[place of execution]*, Philippines. Affiant/s is/are personally known to me and was/were identified by me through competent evidence of identity as defined in the 2004 Rules on Notarial Practice (A.M. No. 02-8-13-SC). Affiant/s exhibited to me his/her [insert type of government identification card used], with his/her photograph and signature appearing thereon, with no. _____ and his/her Community Tax Certificate No. _____ issued on ____ at _____.

Witness my hand and seal this ___ day of *[month] [year]*.

NAME OF NOTARY PUBLIC
Serial No. of Commission _____
Notary Public for _____ until _____
Roll of Attorneys No. _____
PTR No. _____ *[date issued], [place issued]*
IBP No. _____ *[date issued], [place issued]*

Doc. No. _____
Page No. _____
Book No. _____
Series of _____

Section IX. Foreign-Assisted Projects

Notes on Foreign-Assisted Projects

This Section is intended to assist the Procuring Entity in providing the specific information for foreign-assisted projects of the Asian Development Bank (ADB), the Japan International Cooperation Agency (JICA), and the World Bank.

(a) If the Funding Source is ADB, the Procuring Entity should use the ADB Bid Data Sheet and the ADB Special Conditions of Contract..

(b) If the Funding Source is JICA, the Procuring Entity should use Section III. Bid Data Sheet and Section V. Special Conditions of Contract, both of the GOP.

(c) If the Funding Source is World Bank, the Procuring Entity should use the World Bank Bid Data Sheet and the World Bank Special Conditions of Contract of the GOP.

The Procuring Entity shall use these PBDs with minimum changes as necessary to address project-specific conditions. Any such changes shall be introduced only through the Bid Data Sheet or through the Special Conditions of Contract, and not by introducing changes in the standard wording of the Instructions to Bidders and the General Conditions of Contract.

The Procuring Entity shall allow the Bidders sufficient time to study the Bidding Documents, prepare and complete responsive bids, and submit their bids. A period of at least twenty (20) days for bid preparation shall be required.

Notes on the Invitation to Bid

The Invitation to Bid provides information that enables potential Bidders to decide whether to participate in the procurement at hand. The Invitation to Bid shall be:

(a) Advertised at least once in a newspaper of general nationwide circulation which has been regularly published for at least two (2) years before the date of issue of the advertisement, subject to Sections 21.2.1 (c) of the IRR of R.A. 9184[8];

(b) Posted continuously in the Philippine Government Electronic Procurement System (PhilGEPS) website, the website of the Procuring Entity concerned, if available, and the website prescribed by the foreign government/foreign or international financing institution, if applicable, from the time the Invitation to Bid is advertised until the deadline for the submission and receipt of bids; and

(c) Posted at any conspicuous place reserved for this purpose in the premises of the Procuring Entity concerned from the time the Invitation to Bid is advertised until

[8] Two years after the effectivity of the 2016 Revised IRR of RA 9184, on _____, advertisement in a newspaper of general nationwide circulation shall no longer be required. However, a procuring entity that cannot post its opportunities in the PhillGEPS for justifiable reasons shall continue to publish its advertisements in a newspaper of general circulation.

the deadline for the submission and receipt of bids, as certified by the head of the Bids and Awards Committee (BAC) Secretariat of the Procuring Entity concerned.

Apart from the essential items listed in the Bidding Documents, the Invitation to Bid should also indicate the following:

(a) The date of availability of the Bidding Documents, which shall be from the time the Invitation to Bid is first advertised/posted until the deadline for the submission and receipt of bids.

(b) The place where the Bidding Documents may be acquired or the website where it may be downloaded.

(c) The deadline for the submission and receipt of bids; and

(d) Any important bid evaluation criteria.

The Invitation to Bid should be incorporated into the Bidding Documents. The information contained in the Invitation to Bid must conform to the Bidding Documents and in particular to the relevant information in the BDS.

Notes on the Bid Data Sheet

This Section is intended to assist the Procuring Entity in providing the specific information in relation to the corresponding clauses in the ITB, and has to be prepared for each specific procurement.

The Procuring Entity should specify in the BDS information and requirements specific to the circumstances of the Procuring Entity, the processing of the procurement, the applicable rules regarding Bid price and currency, and the Bid evaluation criteria that will apply to the Bids. In preparing this Section, the following aspects should be checked:

(a) Information that specifies and complements provisions of Section II. Instructions to Bidders must be incorporated.

(b) Amendments and/or supplements, if any, to provisions of Section II. Instructions to Bidders as necessitated by the circumstances of the specific procurement, must also be incorporated.

Notes on the Special Conditions of the Contract

Similar to the Section III. Bid Data Sheet, the clauses in this Section are intended to assist the Procuring Entity in providing contract-specific information in relation to corresponding clauses in the GCC.

The provisions of this Section complement the GCC, specifying contractual requirements linked to the special circumstances of the Procuring Entity, the Procuring Entity's country, the sector, and the Goods procured. In preparing this Section, the following aspects should be checked:

(a) Information that complements provisions of Section IV. General Conditions of

Contract must be incorporated.

(b) Amendments and/or supplements to provisions of Section IV. General Conditions of Contract, as necessitated by the circumstances of the specific project, must also be incorporated.

However, no special condition which defeats or negates the general intent and purpose of the provisions of Section IV. General Conditions of Contract should be incorporated herein.

Table of Contents

[Letterhead of the Procuring Entity]
INVITATION TO BID FOR *[Insert name of Project]*

1. The Government of the Philippines (GOP) *[has received/has applied for/intends to apply for]* a *[Loan/Grant]* from the *[state the foreign government/foreign or international financing institution, (e.g. Asian Development Bank, Japan International Cooperative Agency, or World Bank)]* toward the cost of *[insert name of project]*, and it intends to apply part of the proceeds of this *[Loan/Grant]* to payments under the contract for *[insert name/no. of contract]*.

   Select this for lot-procurement:

   The Government of the Philippines (GOP) *[has received/has applied for/intends to apply for]* a *[Loan/Grant]* from the *[state the foreign government/foreign or international financing institution, (e.g. Asian Development Bank, Japan International Cooperative Agency, or World Bank)]* toward the cost of *[insert name of project]*, and it intends to apply part of the proceeds of this *[Loan/Grant]* to payments under the contract for *[insert name/no. of contract]* for Lot *[insert number and identification of lot]*.

2. The *[insert name of Procuring Entity]* now invites bids for *[insert brief description of Goods to be procured]*.[9] Delivery of the Goods is required *[insert the required delivery date or expected contract duration]*. Bidders should have completed, within *[insert relevant period]* from the date of submission and receipt of bids, a contract similar to the Project. The description of an eligible bidder is contained in the Bidding Documents, particularly, in Sub-section 5, Section II. Instructions to Bidders and the corresponding *{[insert* Asian Development Bank *or* World Bank, *as appropriate]}* Bid Data Sheet.

3. Bidding will be conducted in accordance with relevant procedures for open competitive bidding as specified in the Implementing Rules and Regulations (IRR) of Republic Act (RA) 9184, otherwise known as the "Government Procurement Reform Act", with some amendments, as stated in these Bidding Documents and is open to all Bidders from eligible source countries as defined in the applicable procurement guidelines of the *[state the foreign government/foreign or international financing institution concerned (e.g. Asian Development Bank, Japan International Cooperation Agency, or World Bank)]*. The contract shall be awarded to the Lowest Calculated Responsive Bidder (LCRB) who was determined as such during post-qualification. The approved budget for the contract (ABC) *{in case of lot-procurement, insert: "for Lot [insert number and identification]}* is *[insert here the amount of the ABC]*.

   [If ADB-funded project, ABC may be published, but it shall not be stated or implied that bid prices may not exceed ABC.]

9 A brief description of the type(s) of Goods should be provided, including quantities, location of project, and other information necessary to enable potential bidders to decide whether or not to respond to the invitation.

4. Interested bidders may obtain further information from *[insert name of the Procuring Entity]* and inspect the Bidding Documents at the address given below during *[insert office hours]*.

5. A complete set of Bidding Documents may be acquired by interested Bidders on *[insert date of availability of Bidding Documents]* from the address below *{[Insert if necessary:* and upon payment of the applicable fee for the Bidding Documents, pursuant to the latest Guidelines issued by the GPPB[10], in the amount of *[insert amount in Pesos]*. *Note: For lot procurement, the maximum fee for the Bidding Documents for each lot shall be based on its ABC, in accordance with the Guidelines issues by the GPPB; provided that the total fees for the Bidding Documents of all lots shall not exceed the maximum fee prescribed in the Guidelines for the sum of the ABC of all lots.*}

   It may also be downloaded free of charge from the website of the Philippine Government Electronic Procurement System (PhilGEPS) *{[insert* and the website of the Procuring Entity, *as applicable]}* provided that Bidders shall pay the applicable fee for the Bidding Documents not later than the submission of their bids.

6. The *[insert name of the Procuring Entity]* will hold a Pre-Bid Conference[11] on *[insert time and date]* at *[insert address for Pre-Bid Conference, if applicable]*, which shall be open to prospective bidders.

7. Bids must be duly received by the BAC Secretariat at the address below on or before *[insert time and date]*. All Bids must be accompanied by a bid security in the amount of _____ in [*insert the acceptable form*].

   Bid opening shall be on *[insert time and date]* at *[insert address for Bid opening]*. Bids will be opened in the presence of the Bidders' representatives who choose to attend at the address below. Late bids shall not be accepted.

8. *[Insert such other necessary information deemed relevant by the Procuring Entity]*

9. The *[insert name of the Procuring Entity]* reserves the right to accept or reject any bid, to annul the bidding process, and to reject all bids at any time prior to contract award, in accordance with Section 41 of RA 9184 and its IRR, without thereby incurring any liability to the affected bidder or bidders.

10. For further information, please refer to:

    [Insert name of officer]
    [Insert name of office]

---

[10] For ADB-funded projects, the cost of bidding documents must be nominal, and may not be in accordance with the Guidelines issued by the GPPB. As such, the text ", pursuant to the latest Guidelines issued by the GPPB," shall be deleted.

[11] May be deleted in case the ABC is less than One Million Pesos (PhP 1,000,000.00) where the Procuring Entity may not hold a pre-bid conference.

[Insert postal address] and/or *[Insert street address]*
[Insert telephone number, indicate city code]
[Insert contact's email address]
[Insert facsimile number]
[Insert website address, if applicable]

_____

[Insert Name and Signature of the BAC Chairperson or the Authorized Representative of the BAC Chairperson]

Asian Development Bank Bid Data Sheet

ITB Clause	
1.1	The Procuring Entity is *[insert name of Procuring Entity]*
1.2	The lot*(s)* and reference is/are: *[insert name]*
2	The Funding Source is the Asian Development Bank (ADB) through *[indicate the Loan/Grant/Financing No.]* in the amount of *[insert amount of funds]*. The name of the Project is: *[Insert the name of the project]* Payments by the Foreign Funding Source will be made only at the request of the Procuring Entity and upon approval by the Funding Source in accordance with the terms and conditions of Loan *{[or* Grant, *or* Financing*]}* Agreement No. _____ (hereinafter called the "Financing Agreement"), and will be subject in all respect to the terms and conditions of that Financing Agreement and the applicable law. No party other than the Procuring Entity shall derive any rights from the Financing Agreement or have any claim to the funds.
3.1	ADB's Anticorruption Policy requires Borrowers (including beneficiaries of ADB-financed activity), as well as Bidders, Suppliers, and Contractors under ADB-financed contracts, observe the highest standard of ethics during the procurement and execution of such contracts. In pursuance of this policy, ADB (a) defines, for the purposes of this provision, the terms set forth below as follows: (i) "corrupt practice" means the offering, giving, receiving, or soliciting, directly or indirectly, anything of value to influence improperly the actions of another party; (ii) "fraudulent practice" means any act or omission, including a misrepresentation, that knowingly or recklessly misleads, or attempts to mislead, a party to obtain a financial or other benefit or to avoid an obligation;

	(iii) "coercive practice" means impairing or harming, or threatening to impair or harm, directly or indirectly, any party or the property of the party to influence improperly the actions of a party; (iv) "collusive practice" means an arrangement between two or more parties designed to achieve an improper purpose, including influencing improperly the actions of another party; (v) "obstructive practice" means (a) deliberately destroying, falsifying, altering, or concealing of evidence material to an ADB investigation; (b) making false statements to investigators in order to materially impede an ADB investigation; (c) failing to comply with requests to provide information, documents or records in connection with an Office of Anticorruption and Integrity (OAI) investigation; (d) threatening, harassing, or intimidating any party to prevent it from disclosing its knowledge of matters relevant to the investigation or from pursuing the investigation; or (e) materially impeding ADB's contractual rights of audit or access to information; and (vi) "integrity violation" is any act which violates ADB's Anticorruption Policy, including (i) to (v) above and the following: abuse, conflict of interest, violations of ADB sanctions, retaliation against whistleblowers or witnesses, and other violations of ADB's Anticorruption Policy, including failure to adhere to the highest ethical standard. (b) will reject a proposal for award if it determines that the Bidder recommended for award has, directly or through an agent, engaged in corrupt, fraudulent, collusive, coercive, or obstructive practices or other integrity violations in competing for the Contract; (c) will cancel the portion of the financing allocated to a contract if it determines at any time that representatives of the borrower or of a beneficiary of ADB-financing engaged in corrupt, fraudulent, collusive, coercive, or obstructive practices or other integrity violations during the procurement or the execution of that contract, without the borrower having taken timely and appropriate action satisfactory to ADB to remedy the situation; (d) will impose remedial actions on a firm or an individual, at any time, in accordance with ADB's Anticorruption Policy and Integrity Principles and Guidelines (both as amended from time to time), including declaring ineligible, either indefinitely or for a stated

	period of time, to participate in ADB-financed, administered, or supported activities or to benefit from an ADB-financed, administered, or supported contract, financially or otherwise, if it at any time determines that the firm or individual has, directly or through an agent, engaged in corrupt, fraudulent, collusive, coercive, or obstructive practices or other integrity violations; and (e) will have the right to require that a provision be included in bidding documents and in contracts financed by ADB, requiring Bidders, suppliers and contractors to permit ADB or its representative to inspect their accounts and records and other documents relating to the bid submission and contract performance and to have them audited by auditors appointed by ADB.
5.1	Eligible Bidders are as described in ADB Procurement Guidelines as stated in the Financing Agreement and as described on Asian Development Bank's web page **www.adb.org**. An Eligible Bidder shall be deemed to have the nationality of a country if it is a citizen or constituted or incorporated, and operates in conformity with the provisions of the laws of that country.
5.2	Eligible Bidders are as described in ADB Procurement Guidelines as stated in the Financing Agreement and as described on Asian Development Bank's web page **www.adb.org**.
5.4	Instruction is the same as the GOP Bid Data Sheet
7	Eligible goods and services shall have their origin in eligible source countries as described in ADB Procurement Guidelines as stated in the Financing Agreement and as described on Asian Development Bank's web page **www.adb.org**. For the purpose of this Clause, origin means the country where the goods have been grown in, mined, cultivated, produced, manufactured, or processed; or through manufacture, processing, or assembly, another commercially recognized article results that differs substantially in its basic characteristics from its imported components.
8.1	Instruction is the same as the GOP Bid Data Sheet
8.2	Instruction is the same as the GOP Bid Data Sheet
9.1	Instruction is the same as the GOP Bid Data Sheet

10.1	Instruction is the same as the GOP Bid Data Sheet
12.1	The first envelope shall contain the following eligibility and technical documents: a. Eligibility Requirements i. Registration Certification of the Company; ii. List and copy of relevant contracts that comply to the experience requirement as specified in ITB Clause 5.4; iii. Audited financial statement for the past two years; iv. Committed Line of Credit from a universal or commercial bank, in accordance with ITB Clause 5.5 v. In case of Joint Venture, the JV Agreement, if existing, or a signed Statement from the partner companies that they will enter into a JV in case of award of contract; b. Technical Documents vi. Bid Security or Bid Securing Declaration as required in the ITB 18; vii. Conformity with the technical specifications, as enumerated and specified in Sections VI and VII of the Bidding Documents; viii. Sworn statement in accordance with Section 25.3 of the IRR of RA 9184 and using the form prescribed in Section VIII. Bidding Forms. Foreign bidders may submit the equivalent documents, if any, issued by the country of the foreign bidder.
12.1(a)(ii)	Instruction is the same as the GOP Bid Data Sheet
13.1	Instruction is the same as the GOP Bid Data Sheet
13.1(b)	Domestic preference is not applicable
13.1(c)	Instruction is the same as the GOP Bid Data Sheet
13.2	ABC does not apply as ceiling for bid prices
15.4(a)(iv)	Instruction is the same as the GOP Bid Data Sheet
15.4(b)	Instruction is the same as the GOP Bid Data Sheet
16.1(b)	Instruction is the same as the GOP Bid Data Sheet
16.3	Instruction is the same as the GOP Bid Data Sheet

17.1	Instruction is the same as the GOP Bid Data Sheet
18.1	Instruction is the same as the GOP Bid Data Sheet
18.2	Instruction is the same as the GOP Bid Data Sheet
20.3	Instruction is the same as the GOP Bid Data Sheet
21	Instruction is the same as the GOP Bid Data Sheet
24.1	The BAC shall open the bids in public on *[insert date and time of bid opening]*, at *[insert place of bid opening]*. The time for the bid opening shall be the same as the deadline for receipt of bids or promptly thereafter. Rescheduling the date of the opening of bids shall not be considered except for force majeure, such as natural calamities. In re-scheduling the opening of bids, the BAC shall issue a Notice of Postponement to be posted at the PhilGEPS and the procuring entity's websites.
24.2	During Bid opening, if the first envelope lacks any of the documents listed in the ADB BDS 12.1, the bid shall be declared non-responsive but the documents shall be kept by the Procuring Entity. Only the unopened second envelope shall be returned to the Bidder.
24.3	The BAC shall immediately open the financial proposals in the second envelope of the responsive bids. The bid price shall be read and recorded.
27.1	Domestic preference is not applicable
28.3(a)	Instruction is the same as the GOP Bid Data Sheet
28.3(b)	Instruction is the same as the GOP Bid Data Sheet
28.4	ABC does not apply as ceiling for bid prices
29.2	Instruction is the same as the GOP Bid Data Sheet
32.4(f)	Instruction is the same as the GOP Bid Data Sheet

Asian Development Bank Special Conditions of Contract

The ADB adopts the provisions of the Special Conditions of Contract of the GOP as contained in the Harmonized Philippine Bidding Documents dated _____, except GCC Clause 1.1(j) (Funding Source) and GCC Clause 2.1 (Corrupt, Fraudulent, Collusive, and Coercive Practices) which shall read as follows:

SCC Clause	
1.1(j)	The Funding Source is the Asian Development Bank (ADB) through *[indicate the Loan/Grant/Financing No.]* in the amount of [insert amount of funds].
2.1	ADB's Anticorruption Policy requires Borrowers (including beneficiaries of ADB-financed activity), as well as Bidders, Suppliers, and Contractors under ADB-financed contracts, observe the highest standard of ethics during the procurement and execution of such contracts. In pursuance of this policy, ADB (a) defines, for the purposes of this provision, the terms set forth below as follows: (i) "corrupt practice" means the offering, giving, receiving, or soliciting, directly or indirectly, anything of value to influence improperly the actions of another party; (ii) "fraudulent practice" means any act or omission, including a misrepresentation, that knowingly or recklessly misleads, or attempts to mislead, a party to obtain a financial or other benefit or to avoid an obligation; (iii) "coercive practice" means impairing or harming, or threatening to impair or harm, directly or indirectly, any party or the property of the party to influence improperly the actions of a party; (iv) "collusive practice" means an arrangement between two or more parties designed to achieve an improper purpose, including influencing improperly the actions of another party; (v) "obstructive practice" means (a) deliberately destroying, falsifying, altering, or concealing of evidence material to an ADB investigation; (b) making false statements to investigators in order to materially impede an ADB investigation; (c) failing to comply with

	requests to provide information, documents or records in connection with an Office of Anticorruption and Integrity (OAI) investigation; (d) threatening, harassing, or intimidating any party to prevent it from disclosing its knowledge of matters relevant to the investigation or from pursuing the investigation; or (e) materially impeding ADB's contractual rights of audit or access to information; and (vi) "integrity violation" is any act which violates ADB's Anticorruption Policy, including (i) to (v) above and the following: abuse, conflict of interest, violations of ADB sanctions, retaliation against whistleblowers or witnesses, and other violations of ADB's Anticorruption Policy, including failure to adhere to the highest ethical standard. (b) will reject a proposal for award if it determines that the Bidder recommended for award has, directly or through an agent, engaged in corrupt, fraudulent, collusive, coercive, or obstructive practices or other integrity violations in competing for the Contract; (c) will cancel the portion of the financing allocated to a contract if it determines at any time that representatives of the borrower or of a beneficiary of ADB-financing engaged in corrupt, fraudulent, collusive, coercive, or obstructive practices or other integrity violations during the procurement or the execution of that contract, without the borrower having taken timely and appropriate action satisfactory to ADB to remedy the situation; and (d) will impose remedial actions on a firm or an individual, at any time, in accordance with ADB's Anticorruption Policy and Integrity Principles and Guidelines (both as amended from time to time), including declaring ineligible, either indefinitely or for a stated period of time, to participate in ADB-financed, administered, or supported activities or to benefit from an ADB-financed, administered, or supported contract, financially or otherwise, if it at any time determines that the firm or individual has, directly or through an agent, engaged in corrupt, fraudulent, collusive, coercive, or obstructive practices or other integrity violations.

World Bank Bid Data Sheet

ITB Clause	
1.1	The Procuring Entity is *[insert name of purchasing organization]*
1.2	The lot*(s)* and reference is/are: *[insert name]*
2	The Funding Source is the World Bank through *[indicate the Loan/Grant No.]* in the amount of *[insert amount of funds]*. The name of the Project is: *[Insert the name of the project]*
3.1	The World Bank Guidelines on Anti-Corruption, as stated in the Loan Agreement and as annexed to the World Bank Standard Conditions of Contract, shall be adopted.
5.1	No further instruction.
5.2	The Loan/Grant Agreement provides that procurement shall follow the Bank's Procurement Guidelines and Section 1.8 thereof permits the participation of firm from all countries except for those mentioned in Section 1.10 thereof.".
5.4	Instruction is the same as the GOP Bid Data Sheet
7	Instruction is the same as the GOP Bid Data Sheet
8.1	Instruction is the same as the GOP Bid Data Sheet
8.2	Instruction is the same as the GOP Bid Data Sheet
9.1	Instruction is the same as the GOP Bid Data Sheet
10.1	Instruction is the same as the GOP Bid Data Sheet
12.1	During Bid opening, if the first bid envelope lacks any of the following documents, the bid shall be declared non-responsive. The first envelope shall contain the following eligibility and technical documents: **a. Eligibility Requirements** i. Registration Certification of the Company; ii. List of relevant contracts that comply to experience requirement as

	specified in ITB Clause 5.4; iii. Audited financial statement for the past 2 years; iv. Line of Credit from a universal or commercial bank, in accordance with ITB Clause 5.5; v. In case of Joint Venture, the JV Agreement, if existing, or a signed Statement from the partner companies that they will enter into a JV in case of award of contract. **b. Technical Document** v. Bid Security or bid securing declaration as required in ITB 18; vi. Conformity with the technical specifications, as enumerated and specified in Sections VI and VII of the Bidding Documents; vii. Sworn statement in accordance with Section 25.3 of the IRR of RA 9184 and using the form prescribed in Section VIII. Bidding Forms. Foreign bidders may submit the equivalent documents, if any, issued by the country of the foreign bidder.
12.1(a)(ii)	Instruction is the same as the GOP Bid Data Sheet
13.1	Instruction is the same as the GOP Bid Data Sheet
13.1(b)	Domestic preference is not applicable.
13.2	ABC does not generally apply as a ceiling for bid prices. However, subject to prior concurrence of the World Bank, a ceiling may be applied to bid prices provided the following conditions are met: a) Bidding Documents are obtainable free of charge on a freely accessible website. If payment of Bidding Documents is required by the procuring entity, payment could be made upon the submission of bids. b) The procuring entity has procedures in place to ensure that the ABC is based on recent estimates made by the engineer or the responsible unit of the procuring entity and that the estimates are based on adequate detailed engineering (in the case of works) and reflect the quality, supervision and risk and inflationary factors, as well as prevailing market prices, associated with the types of works or goods to be procured. c) The procuring entity has trained cost estimators on estimating prices and analyzing bid variances. In the case of infrastructure projects, the procuring entity must also have trained quantity surveyors.

	d) The procuring entity has established a system to monitor and report bid prices relative to ABC and engineer's/procuring entity's estimate. e) The procuring entity has established a monitoring and evaluation system for contract implementation to provide a feedback on actual total costs of goods and works.
15.4(a)(iv)	Instruction is the same as the GOP Bid Data Sheet
15.4(b)	Instruction is the same as the GOP Bid Data Sheet
16.1(b)	Instruction is the same as the GOP Bid Data Sheet
16.3	Instruction is the same as the GOP Bid Data Sheet
17.1	Instruction is the same as the GOP Bid Data Sheet
18.1	Instruction is the same as the GOP Bid Data Sheet
18.2	Instruction is the same as the GOP Bid Data Sheet
20.3	Instruction is the same as the GOP Bid Data Sheet
21	Instruction is the same as the GOP Bid Data Sheet
24.1	The BAC shall open the bids in public on *[insert date and time of bid opening]*, at *[insert place of bid opening]*. The time for the bid opening shall be the same as the deadline for receipt of bids or promptly thereafter. Rescheduling the date of the opening of bids shall not be considered except for force majeure, such as natural calamities. In re-scheduling the opening of bids, the BAC shall issue a Notice of Postponement to be posted at the PhilGEPS and the procuring entity's websites.
24.2	During Bid opening, if the first envelope lacks any of the documents listed in World Bank BDS 12.1, the bid shall be declared non-responsive but the documents shall be kept by the Procuring Entity.
24.3	The financial proposals in the second envelope of all the bidders shall be read for record purposes. The first and second envelopes shall not be returned to the bidders.
27.1	No domestic preference is applicable.
28.3(a)	Instruction is the same as the GOP Bid Data Sheet
28.3(b)	Instruction is the same as the GOP Bid Data Sheet
28.4	*Follow Clause ITB No. 13.2 on whether ABC as a price ceiling will apply.*

29.2	Instruction is the same as the GOP Bid Data Sheet
32.4(f)	Instruction is the same as the GOP Bid Data Sheet

World Bank Special Conditions of Contract

The World Bank adopts the provisions of the Special Conditions of Contract of the GOP as contained in the Harmonized Philippine Bidding Documents dated _____, except GCC Clause 2.1 (Corrupt, Fraudulent, Collusive, and Coercive Practices) which shall read as follows:

SCC Clause	
1.1(j)	The World Bank is the Funding Source through Loan Agreement No._____
1.1(k)	Instruction is the same as the GOP SCC
2.1	Adopted is Guidelines on Preventing and Combating Fraud and Corruption in Projects Financed by IBRD Loans and IDA Credits and Grants dated October 15, 2006 and Revised in January 2011, that is Annex to the SCC.
6.2	Instruction is the same as the GOP SCC
10.4	Instruction is the same as the GOP SCC
10.5	Instruction is the same as the GOP SCC
11.3	Instruction is the same as the GOP SCC
13.4(c)	Instruction is the same as the GOP SCC
16.1	Instruction is the same as the GOP SCC
17.3	Instruction is the same as the GOP SCC
17.4	Instruction is the same as the GOP SCC
21.1	Instruction is the same as the GOP SCC


Republic of the Philippines
gppb
Government Procurement Policy Board